{"text_format":"1","workbook":"xlsx","n_sheets":31,"sheets":["CoverSheet","Data","Impact Outcome Indicators_1A","Coverage Indicators_1B","ImpactOutcomeDisaggData","Impactoutcome","Coverage Indicators","CoverageDisaggregationData","WPTM_1C","Intervention By Modules old","Intervention By Modules","PR Cash Reconciliation_2A,B,C","SR_Cash Reconciliation_2D","Budget Variance_2E","Procurement_3","Grant Management_4","PR-LFA Evaluation_5","LFA_Findings&Recommendations_6","PR EFR_7A","LFA EFR_7B","Annual Cash Forecast_8A"," Request and Recommendation_8B","PR Authorization_9A","LFA Authorization_9B","PR_Disbursement Request_7","Modules","EFR Data","Checklist","Memo HIV","Memo TB","Memo Malaria"],"not_rendered":{"charts":0,"images":2,"macros":1,"external_links":11,"defined_names":554,"comments":2,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"CoverSheet","index":0,"n_rows":13,"n_cols":12,"rows_kept":13,"cut":false,"hidden":false,"merged":[[12,3,12,5],[9,0,9,2],[10,0,10,2],[0,0,0,11],[4,0,4,2],[5,0,5,2],[6,0,6,2],[7,0,7,2],[8,0,8,2],[1,0,2,14],[0,12,0,14]]}
["Ongoing Progress Update and Disbursement Request"]
["Cover Sheet: Instructions\n\n• This template is compatible with MS Excel 2013 and later versions. Some drop-downs and formulae may not work with earlier versions and specifically MS Excel 2010. Hence, PRs with earlier MS versions are requested to upgrade to MS Excel 2013 to have the full functionalities of the tool.\n\n• Principal Recipients are first required to complete the Cover Sheet with the General Grant Information listed in the boxes below. They can refer to their Grant Face Sheet/Grant Confirmation to fill part of this information.\n\n• Principal Recipients are required to fill in the information related to the periods covered by the progress update and disbursement request.\n\n• Principal Recipients are required to select the type of submission, i.e. whether they are submitting a Mid-Year (or Quarterly) Progress Update or a Year-End Progress Update/Disbursement Request. This is important as the forms will change depending on the type of submission selected."]
[]
["GENERAL GRANT INFORMATION"]
["Country:",null,null,"Georgia",null,"PROGRESS UPDATE "]
["(Disease) Component",null,null,"HIV/AIDS",null,"Progress Update - Reporting Period:",null,null,"Cycle:","Semester","Number:",5]
["Grant Name/Number:",null,null,"GEO-H-NCDC",null,"Progress Update - Period Covered:",null,null,"Beginning Date:","2016-01-01","End Date:","30-06-2016"]
["Principal Recipient:",null,null,"National Center for Disease Control and Public Health"]
["LFA Name:",null,null,"UNOPS",null,"DISBURSEMENT REQUEST "]
["Program Start Date:",null,null,"2014-04-01",null,"Disbursement Request  - Disbursement Period:",null,null,"Cycle:",null,"Number:","N/A"]
["Currency:",null,null,"EUR",null,"Disbursement Request  - Period Covered:",null,null,"Beginning Date:",null,"End Date:"]
[]
[null,null,null,"Are you submitting:\n•    A Progress Update (PU); or \n•    A Progress Update/Disbursement Request (PU/DR)."]

{"sheet":"Data","index":1,"n_rows":307,"n_cols":19,"rows_kept":307,"cut":false,"hidden":true,"merged":[]}
["Component","Catalog Module Name","Intervention Name","Old Component","Module - Intervention",null,null,null,"Component",null,null,"Component","Catalog Module Name",null,"Component","Impact/Outcome",null,null,"Data Sources "]
["Malaria","Specific prevention interventions (SPI)","Intermittent preventive treatment (IPT) - In pregnancy","Malaria",{"$f":"CONCATENATE(B2,\"  -  \",C2)","v":"Specific prevention interventions (SPI)  -  Intermittent preventive treatment (IPT) - In pregnancy"},null,null,null,"Malaria",null,null,"Malaria","Specific prevention interventions (SPI)","Module1","Malaria","Impact",{"$f":"CONCATENATE(O2,P2)","v":"MalariaImpact"},"Type1","HMIS"]
["Malaria","Specific prevention interventions (SPI)","Intermittent preventive treatment (IPT) - In infancy","Malaria",{"$f":"CONCATENATE(B3,\"  -  \",C3)","v":"Specific prevention interventions (SPI)  -  Intermittent preventive treatment (IPT) - In infancy"},null,null,null,"Tuberculosis",null,null,"Malaria","Vector control","Module2","Tuberculosis","Impact",{"$f":"CONCATENATE(O3,P3)","v":"TuberculosisImpact"},"Type2","Patient records"]
["Malaria","Specific prevention interventions (SPI)","Seasonal malaria chemoprevention","Malaria","Specific prevention interventions (SPI)  -  Seasonal malaria chemoprevention",null,null,null,"HIV/TB",null,null,"Malaria","Case management","Module3","HIV/TB","Impact","HIV/TBImpact","Type3","Training records"]
["Malaria","Specific prevention interventions (SPI)","IEC/BCC","Malaria","Specific prevention interventions (SPI)  -  IEC/BCC",null,null,null,"HIV/AIDS",null,null,"Tuberculosis","TB care and prevention","Module4","HIV/AIDS","Impact","HIV/AIDSImpact","Type4","MICS (Multiple Indicator Cluster Survey)"]
["Malaria","Vector control","Long-lasting insecticidal nets (LLIN) - Mass campaign","Malaria","Vector control  -  Long-lasting insecticidal nets (LLIN) - Mass campaign",null,null,null,"Health Systems Strengthening",null,null,"Tuberculosis","MDR-TB","Module5","Health Systems Strengthening","Impact","Health Systems StrengtheningImpact","Type5","DHS/DHS+ (Demographic and Health\nSurvey)"]
["Malaria","Vector control","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Malaria","Vector control  -  Long-lasting insecticidal nets (LLIN) - Continuous distribution",null,null,null,null,null,null,"HIV/TB","TB care and prevention","Module6","Malaria","Outcome","MalariaOutcome","Type6","AIS (AIDS Indicator Survey)"]
["Malaria","Vector control","Indoor residual spraying (IRS)","Malaria","Vector control  -  Indoor residual spraying (IRS)",null,null,null,null,null,null,"HIV/TB","MDR-TB","Module7","Tuberculosis","Outcome","TuberculosisOutcome","Type7","BSS (Behavioral Surveillance Survey)"]
["Malaria","Vector control","Other vector vontrol measures","Malaria","Vector control  -  Other vector vontrol measures",null,null,null,null,null,null,"HIV/TB","Prevention programs for general population","Module8","HIV/TB","Outcome","HIV/TBOutcome","Type8","Health Facility survey"]
["Malaria","Vector control","Entomological monitoring","Malaria","Vector control  -  Entomological monitoring",null,null,null,null,null,null,"HIV/TB","Prevention programs for MSM and TGs","Module9","HIV/AIDS","Outcome","HIV/AIDSOutcome","Type9","SAMS (Service Availability Mapping\nSurvey)"]
["Malaria","Case management","Facility-based treatment","Malaria","Case management  -  Facility-based treatment",null,null,null,null,null,null,"HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Module10","Health Systems Strengthening","Outcome","Health Systems StrengtheningOutcome","Type10","Households survey"]
["Malaria","Case management","Epidemic preparedness and response","Malaria","Case management  -  Epidemic preparedness and response",null,null,null,null,null,null,"HIV/TB","Prevention programs for other vulnerable populations (please specify)","Module11",null,null,null,null,"Specific surveys and research (specify)"]
["Malaria","Case management","Integrated community case management (ICCM)","Malaria","Case management  -  Integrated community case management (ICCM)",null,null,null,null,null,null,"HIV/TB","Prevention programs for adolescents and youth, in and out of school","Module12",null,null,null,null,"Reports (specify)"]
["Malaria","Case management","Active case detection and investigation (elimination phase)","Malaria","Case management  -  Active case detection and investigation (elimination phase)",null,null,null,null,null,null,"HIV/TB","Prevention programs for sex workers and their clients","Module13",null,null,null,null,"Vital and disease-specific registry"]
["Malaria","Case management","Therapeutic efficacy surveillance","Malaria","Case management  -  Therapeutic efficacy surveillance",null,null,null,null,null,null,"HIV/TB","PMTCT","Module14",null,null,null,null,"Operational Research"]
["Malaria","Case management","Severe malaria","Malaria","Case management  -  Severe malaria",null,null,null,null,null,null,"HIV/TB","Treatment, care and support","Module15",null,null,null,null,"Health Provider survey"]
["Malaria","Case management","Private sector co-payment mechanism","Malaria","Case management  -  Private sector co-payment mechanism",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for general population","Module16",null,null,null,null,"National Health Account"]
["Malaria","Case management","Private sector case management (other)","Malaria","Case management  -  Private sector case management (other)",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for MSM and TGs","Module17",null,null,null,null,"Administrative records"]
["Malaria","Case management","Ensuring drug quality","Malaria","Case management  -  Ensuring drug quality",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Module18",null,null,null,null,"R&R TB system, quarterly reports"]
["Tuberculosis","TB care and prevention","Case detection and diagnosis","Tuberculosis; HIV/TB","TB care and prevention  -  Case detection and diagnosis",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Module19",null,null,null,null,"R&R TB system, yearly management report "]
["Tuberculosis","TB care and prevention","Treatment","Tuberculosis; HIV/TB","TB care and prevention  -  Treatment",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Module20",null,null,null,null,"TB prevalence survey"]
["Tuberculosis","TB care and prevention","Prevention","Tuberculosis; HIV/TB","TB care and prevention  -  Prevention",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for sex workers and their clients","Module21",null,null,null,null,"TB patient register"]
["Tuberculosis","MDR-TB","Case detection and diagnosis: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Case detection and diagnosis: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","PMTCT","Module22",null,null,null,null,"TB laboratory register"]
["Tuberculosis","MDR-TB","Treatment: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Treatment: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","Treatment, care and support","Module23",null,null,null,null,"TB treatment card"]
["Tuberculosis","MDR-TB","Prevention for MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Prevention for MDR-TB",null,null,null,null,null,null,"HIV/AIDS","TB/HIV","Module24",null,null,null,null,"Specify- Reports, Surveys, Questionnaires etc."]
["HIV/TB","TB care and prevention","Case detection and diagnosis","Tuberculosis; HIV/TB","TB care and prevention  -  Case detection and diagnosis",null,null,null,null,null,null,"Tuberculosis","TB/HIV","Module25",null,null,null,null,"MIS (Malaria Indicator Survey)"]
["HIV/TB","TB care and prevention","Treatment","Tuberculosis; HIV/TB","TB care and prevention  -  Treatment",null,null,null,null,null,null,"HIV/TB","TB/HIV","Module26",null,null,null,null,"Situation Analysis"]
["HIV/TB","TB care and prevention","Prevention","Tuberculosis; HIV/TB","TB care and prevention  -  Prevention",null,null,null,null,null,null,"HIV/AIDS","Removing legal barriers to access","Module27",null,null,null,null,"Key informant survey"]
["HIV/TB","MDR-TB","Case detection and diagnosis: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Case detection and diagnosis: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Service delivery","Module28",null,null,null,null,"Surveillance systems"]
["HIV/TB","MDR-TB","Treatment: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Treatment: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Health and community workforce","Module29",null,null,null,null,"Modelled"]
["HIV/TB","MDR-TB","Prevention for MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Prevention for MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Health information systems and M&E","Module30",null,null,null,null,"Other survey, specify"]
["HIV/TB","Prevention programs for general population","RMNCH linkages and gender-based violence (GBV)","HIV/AIDS; HIV/TB","Prevention programs for general population  -  RMNCH linkages and gender-based violence (GBV)",null,null,null,null,null,null,"HIV/AIDS","Program management","Module31",null,null,null,null,"IBBS"]
["HIV/TB","Prevention programs for general population","Other interventions for general population - Please specify","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Other interventions for general population - Please specify",null,null,null,null,null,null,"HIV/AIDS","HSS - Procurement supply chain management (PSCM)","Module32"]
["HIV/TB","Prevention programs for MSM and TGs","Behavioral change as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Behavioral change as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Policy and governance","Module33"]
["HIV/TB","Prevention programs for MSM and TGs","Condoms as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Condoms as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Healthcare financing","Module34"]
["HIV/TB","Prevention programs for MSM and TGs","HIV testing and counseling as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  HIV testing and counseling as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Financial management","Module35"]
["HIV/TB","Prevention programs for MSM and TGs","Diagnosis and treatment of STIs as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of STIs as part of programs for MSM and TGs",null,null,null,null,null,null,"Tuberculosis","Removing legal barriers to access","Module36"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Needle and Syringe programs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Needle and Syringe programs as part of programs for PWID and their partners",null,null,null,null,null,null,"Tuberculosis","HSS - Service delivery","Module37"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","OST and other drug dependence treatment (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  OST and other drug dependence treatment (PWIDs and their partners)",null,null,null,null,null,null,"Tuberculosis","HSS - Health and community workforce","Module38"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Condoms as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Condoms as part of programs for other vulnerable populations",null,null,null,null,null,null,"Tuberculosis","HSS - Health information systems and M&E","Module39"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Behavioral change as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Behavioral change as part of programs for other vulnerable populations",null,null,null,null,null,null,"Tuberculosis","Program management","Module40"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,null,null,null,"Tuberculosis","HSS - Procurement supply chain management (PSCM)","Module41"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Other interventions for other vulnerable populations - Please specify","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Other interventions for other vulnerable populations - Please specify",null,null,null,null,null,null,"Tuberculosis","HSS - Policy and governance","Module42"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Behavioral change as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Behavioral change as part of programs for adolescent and youth",null,null,null,null,null,null,"Tuberculosis","HSS - Healthcare financing","Module43"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Condoms part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Condoms part of programs for adolescent and youth",null,null,null,null,null,null,"Tuberculosis","HSS - Financial management","Module44"]
["HIV/TB","Prevention programs for general population","Behavioral change as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Behavioral change as part of programs for general population",null,null,null,null,null,null,"Malaria","Removing legal barriers to access","Module45"]
["HIV/TB","Prevention programs for general population","Condoms as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Condoms as part of programs for general population",null,null,null,null,null,null,"Malaria","HSS - Service delivery","Module46"]
["HIV/TB","Prevention programs for general population","Male circumcision","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Male circumcision",null,null,null,null,null,null,"Malaria","HSS - Health and community workforce","Module47"]
["HIV/TB","Prevention programs for MSM and TGs","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs",null,null,null,null,null,null,"Malaria","HSS - Health information systems and M&E","Module48"]
["HIV/TB","Prevention programs for MSM and TGs","Other interventions for MSM and TGs - Please specify","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Other interventions for MSM and TGs - Please specify",null,null,null,null,null,null,"Malaria","Program management","Module49"]
["HIV/TB","Prevention programs for sex workers and their clients","Behavioral change as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Behavioral change as part of programs for sex workers and their clients",null,null,null,null,null,null,"Malaria","HSS - Procurement supply chain management (PSCM)","Module50"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of viral hepatitis (PWIDs and their partners)",null,null,null,null,null,null,"Malaria","HSS - Policy and governance","Module51"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Other interventions for IDUs and their partners - Please specify","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Other interventions for IDUs and their partners - Please specify",null,null,null,null,null,null,"Malaria","HSS - Healthcare financing","Module52"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","HIV testing and counseling as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  HIV testing and counseling as part of programs for other vulnerable populations",null,null,null,null,null,null,"Malaria","HSS - Financial management","Module53"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","HIV testing and counseling as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  HIV testing and counseling as part of programs for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","Removing legal barriers to access","Module54"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","RMNCH linkages and GBV as part of programs for adolescent youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  RMNCH linkages and GBV as part of programs for adolescent youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Service delivery","Module55"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Young Key Population interventions as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Young Key Population interventions as part of programs for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Health and community workforce","Module56"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Other interventions for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Other interventions for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Health information systems and M&E","Module57"]
["HIV/TB","Prevention programs for general population","HIV testing and counseling as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  HIV testing and counseling as part of programs for general population",null,null,null,null,null,null,"Health Systems Strengthening","Program management","Module58"]
["HIV/TB","Prevention programs for sex workers and their clients","Condoms as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Condoms as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","Module59"]
["HIV/TB","Prevention programs for sex workers and their clients","HIV testing and counseling as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  HIV testing and counseling as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Policy and governance","Module60"]
["HIV/TB","Prevention programs for sex workers and their clients","Diagnosis and treatment of STIs (sex workers and their clients)","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Diagnosis and treatment of STIs (sex workers and their clients)",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Healthcare financing","Module61"]
["HIV/TB","Prevention programs for sex workers and their clients","Harm reduction as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Harm reduction as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Financial management","Module62"]
["HIV/TB","PMTCT","Prong 1: Primary prevention of HIV infection among women of childbearing age","HIV/AIDS; HIV/TB","PMTCT  -  Prong 1: Primary prevention of HIV infection among women of childbearing age",null,null,null,null,null,null,"HIV/TB","Removing legal barriers to access","Module63"]
["HIV/TB","PMTCT","Prong 2: Preventing unintended pregnancies among women living with HIV","HIV/AIDS; HIV/TB","PMTCT  -  Prong 2: Preventing unintended pregnancies among women living with HIV",null,null,null,null,null,null,"HIV/TB","HSS - Service delivery","Module64"]
["HIV/TB","PMTCT","Prong 3: Preventing vertical HIV transmission","HIV/AIDS; HIV/TB","PMTCT  -  Prong 3: Preventing vertical HIV transmission",null,null,null,null,null,null,"HIV/TB","HSS - Health and community workforce","Module65"]
["HIV/TB","PMTCT","Prong 4: Treatment, care & support to mothers living with HIV, their children &","HIV/AIDS; HIV/TB",{"$f":"CONCATENATE(B67,\"  -  \",C67)","v":"PMTCT  -  Prong 4: Treatment, care & support to mothers living with HIV, their children &"},null,null,null,null,null,null,"HIV/TB","HSS - Health information systems and M&E","Module66"]
["HIV/TB","PMTCT","Other interventions for PMTCT- Please specify","HIV/AIDS; HIV/TB","PMTCT  -  Other interventions for PMTCT- Please specify",null,null,null,null,null,null,"HIV/TB","Program management","Module67"]
["HIV/TB","Prevention programs for sex workers and their clients","Other interventions for sex workers and their clients - Please specify","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Other interventions for sex workers and their clients - Please specify",null,null,null,null,null,null,"HIV/TB","HSS - Procurement supply chain management (PSCM)","Module68"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Behavioural change as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Behavioural change as part of programs for PWID and their partners",null,null,null,null,null,null,"HIV/TB","HSS - Policy and governance","Module69"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Condoms as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Condoms as part of programs for PWID and their partners",null,null,null,null,null,null,"HIV/TB","HSS - Healthcare financing","Module70"]
["HIV/TB","Treatment, care and support","Pre-ART care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Pre-ART care",null,null,null,null,null,null,"HIV/TB","HSS - Financial management","Module71"]
["HIV/TB","Treatment, care and support","Antiretroviral Therapy (ART)","HIV/AIDS; HIV/TB","Treatment, care and support  -  Antiretroviral Therapy (ART)",null,null,null,null,null,null,"HIV/AIDS","Community systems strengthening","Module72"]
["HIV/TB","Treatment, care and support","Treatment monitoring","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment monitoring",null,null,null,null,null,null,"HIV/AIDS","Results based Financing","Module73"]
["HIV/TB","Treatment, care and support","Treatment adherence","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment adherence",null,null,null,null,null,null,"Tuberculosis","Community systems strengthening","Module74"]
["HIV/TB","Treatment, care and support","Prevention, diagnosis and treatment of opportunistic infections","HIV/AIDS; HIV/TB","Treatment, care and support  -  Prevention, diagnosis and treatment of opportunistic infections",null,null,null,null,null,null,"Tuberculosis","Results based Financing","Module75"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of STIs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of STIs as part of programs for PWID and their partners",null,null,null,null,null,null,"Malaria","Community systems strengthening","Module76"]
["HIV/TB","Treatment, care and support","Counseling and psycho-social support","HIV/AIDS; HIV/TB","Treatment, care and support  -  Counseling and psycho-social support",null,null,null,null,null,null,"Malaria","Results based Financing","Module77"]
["HIV/TB","Treatment, care and support","Out-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Out-patient care",null,null,null,null,null,null,"HIV/TB","Community systems strengthening","Module78"]
["HIV/TB","Treatment, care and support","In-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  In-patient care",null,null,null,null,null,null,"HIV/TB","Results based Financing","Module79"]
["HIV/TB","Treatment, care and support","Other interventions for treatment - Please specify","HIV/AIDS; HIV/TB","Treatment, care and support  -  Other interventions for treatment - Please specify"]
["HIV/TB","Prevention programs for general population","Diagnosis and treatment of STIs as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Diagnosis and treatment of STIs as part of programs for general population"]
["HIV/TB","Prevention programs for general population","Blood safety","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Blood safety"]
["HIV/AIDS","Prevention programs for general population","Orphan and vulnerable children (OVC) package","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Orphan and vulnerable children (OVC) package"]
["HIV/AIDS","Prevention programs for general population","RMNCH linkages and gender-based violence (GBV)","HIV/AIDS; HIV/TB","Prevention programs for general population  -  RMNCH linkages and gender-based violence (GBV)"]
["HIV/AIDS","Prevention programs for general population","Other interventions for general population - Please specify","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Other interventions for general population - Please specify"]
["HIV/AIDS","Prevention programs for MSM and TGs","Behavioral change as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Behavioral change as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Condoms as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Condoms as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","HIV testing and counseling as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  HIV testing and counseling as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Diagnosis and treatment of STIs as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of STIs as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Needle and Syringe programs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Needle and Syringe programs as part of programs for PWID and their partners"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","OST and other drug dependence treatment (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  OST and other drug dependence treatment (PWIDs and their partners)"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Condoms as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Condoms as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Behavioral change as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Behavioral change as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Diagnosis and treatment of STIs (other vulnerable populations)"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Other interventions for other vulnerable populations - Please specify","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Other interventions for other vulnerable populations - Please specify"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Behavioral change as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Behavioral change as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Condoms part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Condoms part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for general population","Behavioral change as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Behavioral change as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Condoms as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Condoms as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Male circumcision","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Male circumcision"]
["HIV/AIDS","Prevention programs for MSM and TGs","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Other interventions for MSM and TGs - Please specify","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Other interventions for MSM and TGs - Please specify"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Behavioral change as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Behavioral change as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of viral hepatitis (PWIDs and their partners)"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Other interventions for IDUs and their partners - Please specify","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Other interventions for IDUs and their partners - Please specify"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","HIV testing and counseling as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  HIV testing and counseling as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","HIV testing and counseling as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  HIV testing and counseling as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","RMNCH linkages and GBV as part of programs for adolescent youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  RMNCH linkages and GBV as part of programs for adolescent youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Young Key Population interventions as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Young Key Population interventions as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Other interventions for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Other interventions for adolescent and youth"]
["HIV/AIDS","Prevention programs for general population","HIV testing and counseling as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  HIV testing and counseling as part of programs for general population"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Condoms as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Condoms as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for sex workers and their clients","HIV testing and counseling as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  HIV testing and counseling as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Diagnosis and treatment of STIs (sex workers and their clients)","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Diagnosis and treatment of STIs (sex workers and their clients)"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Harm reduction as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Harm reduction as part of programs for sex workers and their clients"]
["HIV/AIDS","PMTCT","Prong 1: Primary prevention of HIV infection among women of childbearing age","HIV/AIDS; HIV/TB","PMTCT  -  Prong 1: Primary prevention of HIV infection among women of childbearing age"]
["HIV/AIDS","PMTCT","Prong 2: Preventing unintended pregnancies among women living with HIV","HIV/AIDS; HIV/TB","PMTCT  -  Prong 2: Preventing unintended pregnancies among women living with HIV"]
["HIV/AIDS","PMTCT","Prong 3: Preventing vertical HIV transmission","HIV/AIDS; HIV/TB","PMTCT  -  Prong 3: Preventing vertical HIV transmission"]
["HIV/AIDS","PMTCT","Prong 4: Treatment, care & support to mothers living with HIV, their children &","HIV/AIDS; HIV/TB","PMTCT  -  Prong 4: Treatment, care & support to mothers living with HIV, their children &"]
["HIV/AIDS","PMTCT","Other interventions for PMTCT- Please specify","HIV/AIDS; HIV/TB","PMTCT  -  Other interventions for PMTCT- Please specify"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Other interventions for sex workers and their clients - Please specify","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Other interventions for sex workers and their clients - Please specify"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Behavioural change as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Behavioural change as part of programs for PWID and their partners"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Condoms as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Condoms as part of programs for PWID and their partners"]
["HIV/AIDS","Treatment, care and support","Pre-ART care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Pre-ART care"]
["HIV/AIDS","Treatment, care and support","Antiretroviral Therapy (ART)","HIV/AIDS; HIV/TB","Treatment, care and support  -  Antiretroviral Therapy (ART)"]
["HIV/AIDS","Treatment, care and support","Treatment monitoring","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment monitoring"]
["HIV/AIDS","Treatment, care and support","Treatment adherence","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment adherence"]
["HIV/AIDS","Treatment, care and support","Prevention, diagnosis and treatment of opportunistic infections","HIV/AIDS; HIV/TB","Treatment, care and support  -  Prevention, diagnosis and treatment of opportunistic infections"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of STIs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of STIs as part of programs for PWID and their partners"]
["HIV/AIDS","Treatment, care and support","Counseling and psycho-social support","HIV/AIDS; HIV/TB",{"$f":"CONCATENATE(B131,\"  -  \",C131)","v":"Treatment, care and support  -  Counseling and psycho-social support"}]
["HIV/AIDS","Treatment, care and support","Out-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Out-patient care"]
["HIV/AIDS","Treatment, care and support","In-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  In-patient care"]
["HIV/AIDS","Treatment, care and support","Other interventions for treatment - Please specify","HIV/AIDS; HIV/TB","Treatment, care and support  -  Other interventions for treatment - Please specify"]
["HIV/AIDS","Prevention programs for general population","Diagnosis and treatment of STIs as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Diagnosis and treatment of STIs as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Blood safety","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Blood safety"]
["HIV/AIDS","Prevention programs for general population","Orphan and vulnerable children (OVC) package","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Orphan and vulnerable children (OVC) package"]
["HIV/AIDS","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["HIV/AIDS","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["HIV/AIDS","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["HIV/AIDS","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["HIV/AIDS","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["Tuberculosis","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["Tuberculosis","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["Tuberculosis","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["Tuberculosis","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["Tuberculosis","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["HIV/TB","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["HIV/TB","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["HIV/TB","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["HIV/TB","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["HIV/TB","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["HIV/AIDS","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["HIV/AIDS","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["HIV/AIDS","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["HIV/AIDS","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["HIV/AIDS","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["HIV/AIDS","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["HIV/AIDS","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["HIV/AIDS","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["HIV/AIDS","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["HIV/AIDS","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["HIV/AIDS","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["HIV/AIDS","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["HIV/AIDS","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["HIV/AIDS","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["HIV/AIDS","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["HIV/AIDS","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["HIV/AIDS","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["HIV/AIDS","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["HIV/AIDS","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["HIV/AIDS","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["HIV/AIDS","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["HIV/AIDS","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["HIV/AIDS","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["HIV/AIDS","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["HIV/AIDS","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["HIV/AIDS","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["HIV/AIDS","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Tuberculosis","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Tuberculosis","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Tuberculosis","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Tuberculosis","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Tuberculosis","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Tuberculosis","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Tuberculosis","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Tuberculosis","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Tuberculosis","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Tuberculosis","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Tuberculosis","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Tuberculosis","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Tuberculosis","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Tuberculosis","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Tuberculosis","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Tuberculosis","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB",{"$f":"CONCATENATE(B195,\"  -  \",C195)","v":"HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"}]
["Tuberculosis","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Tuberculosis","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Tuberculosis","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Tuberculosis","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Tuberculosis","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Tuberculosis","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Tuberculosis","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Tuberculosis","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Tuberculosis","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Tuberculosis","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["Tuberculosis","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Malaria","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Malaria","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Malaria","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Malaria","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Malaria","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Malaria","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Malaria","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Malaria","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Malaria","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Malaria","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Malaria","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Malaria","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Malaria","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Malaria","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Malaria","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Malaria","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["Malaria","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Malaria","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Malaria","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Malaria","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Malaria","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Malaria","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Malaria","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Malaria","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Malaria","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Malaria","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["Malaria","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Health Systems Strengthening","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Health Systems Strengthening","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Health Systems Strengthening","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Health Systems Strengthening","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Health Systems Strengthening","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Health Systems Strengthening","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Health Systems Strengthening","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Health Systems Strengthening","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Health Systems Strengthening","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Health Systems Strengthening","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Health Systems Strengthening","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Health Systems Strengthening","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Health Systems Strengthening","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Health Systems Strengthening","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Health Systems Strengthening","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Health Systems Strengthening","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Health Systems Strengthening","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Health Systems Strengthening","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Health Systems Strengthening","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB",{"$f":"CONCATENATE(B259,\"  -  \",C259)","v":"Removing legal barriers to access  -  Community-based monitoring of legal rights"}]
["Health Systems Strengthening","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["HIV/TB","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["HIV/TB","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["HIV/TB","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["HIV/TB","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["HIV/TB","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["HIV/TB","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["HIV/TB","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["HIV/TB","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["HIV/TB","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["HIV/TB","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["HIV/TB","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["HIV/TB","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["HIV/TB","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["HIV/TB","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["HIV/TB","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["HIV/TB","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["HIV/TB","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["HIV/TB","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["HIV/TB","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["HIV/TB","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["HIV/TB","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["HIV/TB","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["HIV/TB","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["HIV/TB","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["HIV/TB","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["HIV/TB","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["HIV/TB","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["HIV/AIDS","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["HIV/AIDS","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["HIV/AIDS","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["HIV/AIDS","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["HIV/AIDS","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["Tuberculosis","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["Tuberculosis","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["Tuberculosis","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["Tuberculosis","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["Tuberculosis","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["Malaria","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["Malaria","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["Malaria","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["Malaria","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["Malaria","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["HIV/TB","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["HIV/TB","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["HIV/TB","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["HIV/TB","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["HIV/TB","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]

{"sheet":"Impact Outcome Indicators_1A","index":2,"n_rows":61,"n_cols":32,"rows_kept":61,"cut":false,"hidden":false,"merged":[[0,0,0,5],[23,28,23,33],[52,29,52,33],[53,29,53,33],[54,29,54,33],[55,29,55,33],[56,29,56,33],[57,29,57,33],[58,29,58,33],[24,16,24,17],[24,18,25,18],[24,19,25,19],[24,20,25,20],[23,16,23,27],[57,23,57,27],[58,23,58,27],[24,21,25,21],[24,22,25,22],[24,23,25,27],[6,0,6,1],[6,2,6,5],[4,0,4,1],[4,2,4,5],[5,0,5,1],[24,28,25,28],[24,29,25,33],[26,29,26,33],[27,29,27,33],[28,29,28,33],[29,29,29,33],[30,29,30,33],[31,29,31,33],[32,29,32,33],[60,29,60,33],[33,29,33,33],[34,29,34,33],[35,29,35,33],[36,29,36,33],[37,29,37,33],[38,29,38,33],[39,29,39,33],[40,29,40,33],[51,29,51,33],[59,29,59,33],[59,23,59,27],[60,23,60,27],[26,23,26,27],[52,23,52,27],[53,23,53,27],[54,23,54,27],[55,23,55,27],[56,23,56,27],[37,23,37,27],[38,23,38,27],[39,23,39,27],[40,23,40,27],[51,23,51,27],[32,23,32,27],[33,23,33,27],[34,23,34,27],[35,23,35,27],[36,23,36,27],[27,23,27,27],[28,23,28,27],[29,23,29,27],[30,23,30,27],[31,23,31,27],[5,2,5,5],[7,0,7,1],[7,2,7,5],[8,0,8,1],[8,2,8,5],[9,0,9,1],[9,2,9,5],[13,2,13,5],[17,2,17,5],[19,0,19,15],[23,14,23,15],[24,0,25,0],[24,1,25,5],[24,6,24,7],[24,8,25,8],[24,9,25,9],[24,10,25,10],[24,11,25,11],[24,12,25,12],[24,13,25,15],[26,13,26,15],[28,1,28,5],[28,13,28,15],[29,1,29,5],[29,13,29,15],[27,1,27,5],[27,13,27,15],[26,1,26,5],[30,1,30,5],[30,13,30,15],[31,1,31,5],[31,13,31,15],[32,1,32,5],[32,13,32,15],[33,1,33,5],[33,13,33,15],[34,1,34,5],[34,13,34,15],[35,1,35,5],[35,13,35,15],[36,1,36,5],[36,13,36,15],[37,1,37,5],[37,13,37,15],[38,1,38,5],[38,13,38,15],[39,1,39,5],[39,13,39,15],[40,1,40,5],[40,13,40,15],[51,1,51,5],[51,13,51,15],[60,1,60,5],[60,13,60,15],[56,1,56,5],[56,13,56,15],[57,1,57,5],[57,13,57,15],[58,1,58,5],[58,13,58,15],[52,1,52,5],[52,13,52,15],[53,1,53,5],[53,13,53,15],[54,1,54,5],[54,13,54,15],[55,1,55,5],[55,13,55,15],[59,1,59,5],[59,13,59,15],[41,1,41,5],[41,13,41,15],[41,23,41,27],[41,29,41,33],[42,1,42,5],[42,13,42,15],[42,23,42,27],[42,29,42,33],[43,1,43,5],[43,13,43,15],[43,23,43,27],[43,29,43,33],[44,1,44,5],[44,13,44,15],[44,23,44,27],[44,29,44,33],[45,1,45,5],[45,13,45,15],[45,23,45,27],[45,29,45,33],[46,1,46,5],[46,13,46,15],[46,23,46,27],[46,29,46,33],[50,1,50,5],[50,13,50,15],[50,23,50,27],[50,29,50,33],[47,1,47,5],[47,13,47,15],[47,23,47,27],[47,29,47,33],[48,1,48,5],[48,13,48,15],[48,23,48,27],[48,29,48,33],[49,1,49,5],[49,13,49,15],[49,23,49,27],[49,29,49,33]]}
["On-going Progress Update and Disbursement Request"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"AIS (AIDS Indicator Survey)",null,null,null,null,null,"AIS (AIDS Indicator Survey)"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"BSS (Behavioral and Surveillance Survey)",null,null,null,null,null,"BSS (Behavioral and Surveillance Survey)"]
["GENERAL GRANT INFORMATION",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Census",null,null,null,null,null,"Census"]
["Country:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Clinical cohort follow-up studies",null,null,null,null,null,"Clinical cohort follow-up studies"]
["Disease:",null,"Select",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"DHS/DHS+ (Demographic and Health Survey)",null,null,null,null,null,"DHS/DHS+ (Demographic and Health Survey)"]
["Grant Number:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"MICS (Multiple Indicator Cluster Survey)",null,null,null,null,null,"MICS (Multiple Indicator Cluster Survey)"]
["Principal Recipient:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"MIS (Malaria Indicator Survey)",null,null,null,null,null,"MIS (Malaria Indicator Survey)"]
["Program Start Date:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"WHO Global report/estimates",null,null,null,null,null,"WHO Global report/estimates"]
["Currency:",null,"Select",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Other (type as appropriate)",null,null,null,null,null,"Other (type as appropriate)"]
["PROGRESS UPDATE "]
["Progress Update - Reporting Period:",null,"Cycle:","Select","Number:"]
["Progress Update - Period Covered:",null,"Beginning Date:",null,"End Date:"]
["Progress Update - Number:"]
["DISBURSEMENT REQUEST "]
["Disbursement Request  - Disbursement Period:",null,"Cycle:","Select","Number:"]
["Disbursement Request  - Period Covered:",null,"Beginning Date:",null,"End Date:"]
["Disbursement Request  - Number:"]
[]
[]
[]
["Section 1:  Programmatic Progress"]
["Note: The table below should contain those Impact/Outcome indicators that are (1) due for reporting during the current year of a grant and (2) those reporting on which is overdue from the previous periods."]
["A.  Impact / Outcome Indicators",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Impact / Outcome ","Indicator Description",null,null,null,null,"Baseline \n(if applicable)",null,"Year of Target","Intended Target","Report Due Date","Actual Result","Data Source of Results","Comments on results on Impact/Outcome indicators and data sources, and any other comments",null,null,"Baseline \n(if applicable)",null,"Year of Target","Intended Target","Report Due Date","Verification Method","Verified Result","LFA comments on (a) verified result, (b) source of information used by the PR to report results, including the status of completion of surveys and other methods to measure Impact/Outcome, as applicable,  ",null,null,null,null,"Validated Result","Country Team comments on validated results"]
[null,null,null,null,null,null,"Value","Year",null,null,null,null,null,null,null,null,"Value","Year"]
["Impact","Percentage of men who have sex with men who are living with HIV ",null,null,null,null,0.13,2012,"2015",0.15,"2016-02-15",0.25,"BSS (Behavioral and Surveillance Survey)",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W27","v":0}]
["Impact","Percentage of people who inject drugs who are living with HIV",null,null,null,null,0.03,2012,"2014",0.03,"2015-02-15",2.0199999999999999E-2,"BSS (Behavioral and Surveillance Survey)",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W28","v":0}]
["Impact","Percentage of sex workers who are living with HIV ",null,null,null,null,1.0999999999999999E-2,2012,"2014",2.3E-2,"2015-02-15",7.0000000000000001E-3,"BSS (Behavioral and Surveillance Survey)","The prevalcne of HIV in Tbilisi was 0.6% and 0.8% in Batumi, total number of study participants tested on HIV was 277",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Impact","AIDS related mortality per 100,000 population ",null,null,null,null,2.4,2012,"2014",2.2000000000000002,"2016-02-15",1.9,"HMIS","Preliminary data of the last census is 3.7 million population, the adjustment will be made when the census data will be officially validated by the State. ",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy. ",null,null,null,null,0.85,2013,"HMIS",0.87,"2016-02-15",0.84199999999999997,"HMIS","Nominator+507; denominator+602",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Percentage of men reporting the use of a condom the last time they had anal sex with a male partner",null,null,null,null,0.67300000000000004,2012,"BSS (Behavioral Surveillance Survey)",0.75,"2016-02-15",0.63200000000000001,"BSS (Behavioral and Surveillance Survey)",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Percentage of sex workers reporting the use of a condom with their most recent client",null,null,null,null,0.91100000000000003,2012,"BSS (Behavioral Surveillance Survey)",0.92,"2015-02-15",0.9,"BSS (Behavioral and Surveillance Survey)","The value of the indicator was 94.4% in Tbilisi, but it was only 82.7% in Batumi (total number of respondents was 224",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected ",null,null,null,null,0.83499999999999996,2012,"BSS (Behavioral Surveillance Survey)",0.84,"2015-02-15",0.74299999999999999,"BSS (Behavioral and Surveillance Survey)",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W42","v":0}]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W43","v":0}]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]

{"sheet":"Coverage Indicators_1B","index":3,"n_rows":73,"n_cols":42,"rows_kept":73,"cut":false,"hidden":false,"merged":[[22,33,22,37],[13,33,13,37],[14,33,14,37],[15,33,15,37],[16,33,16,37],[17,33,17,37],[18,33,18,37],[19,33,19,37],[20,33,20,37],[21,33,21,37],[59,2,59,5],[59,19,59,20],[61,2,61,5],[28,2,28,5],[23,33,23,37],[24,33,24,37],[25,33,25,37],[26,33,26,37],[63,33,63,37],[27,33,27,37],[28,33,28,37],[59,33,59,37],[61,33,61,37],[40,2,40,5],[40,19,40,20],[40,33,40,37],[43,2,43,5],[43,19,43,20],[43,33,43,37],[46,2,46,5],[46,19,46,20],[46,33,46,37],[49,2,49,5],[49,19,49,20],[0,0,0,8],[10,30,10,32],[10,33,11,37],[12,33,12,37],[10,19,11,20],[2,0,2,2],[2,3,2,6],[5,3,5,6],[9,0,9,20],[10,0,11,0],[10,1,11,1],[10,2,11,5],[10,6,11,6],[10,7,11,7],[10,8,11,8],[12,2,12,5],[9,21,9,37],[10,16,10,18],[10,21,11,21],[10,22,11,22],[10,27,10,29],[10,9,10,12],[10,23,10,26],[14,2,14,5],[14,19,14,20],[15,2,15,5],[16,2,16,5],[10,13,10,15],[12,19,12,20],[13,2,13,5],[13,19,13,20],[15,19,17,20],[21,2,21,5],[21,19,21,20],[22,2,22,5],[22,19,22,20],[17,2,17,5],[18,2,18,5],[18,19,18,20],[19,2,19,5],[19,19,19,20],[20,19,20,20],[68,2,68,5],[61,19,61,20],[65,2,65,5],[65,19,65,20],[66,2,66,5],[66,19,66,20],[23,2,23,5],[23,19,23,20],[28,19,28,20],[68,19,68,20],[62,2,62,5],[62,19,62,20],[63,2,63,5],[63,19,63,20],[64,2,64,5],[64,19,64,20],[25,2,25,5],[25,19,25,20],[26,2,26,5],[26,19,26,20],[27,2,27,5],[27,19,27,20],[24,2,24,5],[24,19,24,20],[10,38,10,40],[9,38,9,45],[22,41,22,45],[23,41,23,45],[24,41,24,45],[25,41,25,45],[67,0,67,45],[10,41,11,45],[12,41,12,45],[13,41,13,45],[14,41,14,45],[15,41,15,45],[16,41,16,45],[17,41,17,45],[18,41,18,45],[19,41,19,45],[20,41,20,45],[21,41,21,45],[28,41,28,45],[59,41,59,45],[61,41,61,45],[26,41,26,45],[27,41,27,45],[20,2,20,5],[40,41,40,45],[41,2,41,5],[41,19,41,20],[41,33,41,37],[41,41,41,45],[42,2,42,5],[42,19,42,20],[42,33,42,37],[42,41,42,45],[43,41,43,45],[44,2,44,5],[44,19,44,20],[44,33,44,37],[44,41,44,45],[45,2,45,5],[45,19,45,20],[45,33,45,37],[45,41,45,45],[46,41,46,45],[47,2,47,5],[47,19,47,20],[47,33,47,37],[47,41,47,45],[48,2,48,5],[48,19,48,20],[48,33,48,37],[48,41,48,45],[49,33,49,37],[49,41,49,45],[50,2,50,5],[50,19,50,20],[50,33,50,37],[50,41,50,45],[29,2,29,5],[29,19,29,20],[29,33,29,37],[29,41,29,45],[30,2,30,5],[30,19,30,20],[30,33,30,37],[30,41,30,45],[31,2,31,5],[31,19,31,20],[31,33,31,37],[31,41,31,45],[32,2,32,5],[32,19,32,20],[32,33,32,37],[32,41,32,45],[33,2,33,5],[33,19,33,20],[33,33,33,37],[33,41,33,45],[34,2,34,5],[34,19,34,20],[34,33,34,37],[34,41,34,45],[35,2,35,5],[35,19,35,20],[35,33,35,37],[35,41,35,45],[39,2,39,5],[39,19,39,20],[39,33,39,37],[39,41,39,45],[36,2,36,5],[36,19,36,20],[36,33,36,37],[36,41,36,45],[37,2,37,5],[37,19,37,20],[37,33,37,37],[37,41,37,45],[38,2,38,5],[38,19,38,20],[38,33,38,37],[38,41,38,45]]}
["On-going Progress Update and Disbursement Request"]
["PROGRESS UPDATE PERIOD"]
["Grant number:",null,null,{"$f":"IF('[9]PR_Programmatic Progress_1A'!C7=\"\",\"\",'[9]PR_Programmatic Progress_1A'!C7)","v":""}]
["Progress Update - Reporting Period:",null,null,"Cycle:",{"$f":"IF('[9]PR_Programmatic Progress_1A'!D12=\"Select\",\"\",'[9]PR_Programmatic Progress_1A'!D12)","v":""},"Number:",{"$f":"IF('[9]PR_Programmatic Progress_1A'!F12=\"Select\",\"\",'[9]PR_Programmatic Progress_1A'!F12)","v":0}]
["Progress Update - Period Covered:",null,null,"Beginning Date:",{"$f":"IF('[9]PR_Programmatic Progress_1A'!D13=\"\",\"\",'[9]PR_Programmatic Progress_1A'!D13)","v":""},"End Date:",{"$f":"IF('[9]PR_Programmatic Progress_1A'!F13=\"\",\"\",'[9]PR_Programmatic Progress_1A'!F13)","v":""}]
["Progress Update - Number:",null,null,{"$f":"IF('[9]PR_Programmatic Progress_1A'!C14=\"Select\",\"\",'[9]PR_Programmatic Progress_1A'!C14)","v":0}]
[]
["Section 1:  Programmatic Progress"]
["Note: All programmatic indicators contained in the current Performance Framework should be listed, regardless of whether there are targets/results for the period covered by the Progress Update or whether the targets have been met in previous periods.  "]
["B.  Coverage Indicators",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Objective\nNo.","* Indicator No.","Indicator Description",null,null,null,"Tied To","Targets cumulative?\n","Top 10 indicator?","Baseline",null,null,null,"Target",null,null,"Result",null,null,"Reasons for programmatic deviation from intended target and deviations from the related workplan activities",null,"Targets cumulative?\n","Top 10 indicator?","Baseline",null,null,null,"Target",null,null,"Verified Result",null,null,"LFA analysis on progress to date and any variance between targets and results, and any other comments\n(this should not be a “Copy and Paste” of the reasons provided by the PR)",null,null,null,null,"Validated Result",null,null,"Country Team comments on validated results"]
[null,null,null,null,null,null,null,null,null,"Year","N#","D#","%","N#","D#","%","N#","D#","%",null,null,null,null,"Year","N#","D#","%","N#","D#","%","N#","D#","%",null,null,null,null,null,"N#","D#","%"]
[2,1,"Number of MARPs (IDUs, MSM and FSWs) covered with HIV testing and counselling (including provision of results) ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10","2013",9296,"70000",{"$f":"IFERROR(K13/L13,\"\")","v":0.1328},17039,73200,{"$f":"IFERROR(N13/O13,\"\")","v":0.23277322404371584},{"$f":"15348+1057+1124","v":17529},{"$f":"O13","v":73200},{"$f":"IFERROR(Q13/R13,\"\")","v":0.23946721311475411},"Number of PWIDs reached with VCT services during P5 is 15348; Number of 1124 MSM   and number of FSWs 1057 FSW.    Total number 17529                                                                  (source for the data is electronic dabatase of SRs - GHRN and Tanadgoma).",null,"Select","Select",null,null,null,{"$f":"IFERROR(Y13/Z13,\"\")","v":""},null,null,{"$f":"IFERROR(AB13/AC13,\"\")","v":""},null,null,{"$f":"IFERROR(AE13/AF13,\"\")","v":""},null,null,null,null,null,{"$f":"AE13","v":0},{"$f":"AF13","v":0},{"$f":"IFERROR(AM13/AN13,\"\")","v":""}]
[2,"1.1.","Number of prisoners covered with VCT (HIV testing and counselling, including provision of results) ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",2013,1938,null,{"$f":"IFERROR(K14/L14,\"\")","v":""},3675,10000,{"$f":"IFERROR(N14/O14,\"\")","v":0.36749999999999999},3237,10000,{"$f":"IFERROR(Q14/R14,\"\")","v":0.32369999999999999},null,null,"Select","Select",null,null,null,{"$f":"IFERROR(Y14/Z14,\"\")","v":""},null,null,{"$f":"IFERROR(AB14/AC14,\"\")","v":""},null,null,{"$f":"IFERROR(AE14/AF14,\"\")","v":""},null,null,null,null,null,{"$f":"AE14","v":0},{"$f":"AF14","v":0},{"$f":"IFERROR(AM14/AN14,\"\")","v":""}]
[2,1.2,"Proportion of new individuals who test positive for HIV, enrolled in care (pre-ART or ART) services ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10","2013",430,"490",{"$f":"IFERROR(K15/L15,\"\")","v":0.87755102040816324},null,null,"",null,null,"","n/a, the indicator is annual cummulative",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.1,"Number and percentage of MSM reached with HIV prevention programmes - defined package of services",null,null,null,"Current grant","N-not cumulative","Yes - Top 10","2013",765,"17000",4.4999999999999998E-2,2975,17000,0.17499999999999999,2376,17000,0.13976470588235293,"Although, there is underachievement in coverage of MSM, the performance has been considerbly improved during the P5. PR had continious communication with SRs how to further improve the coverage data. PDI methodology proved to be effective among MSM in general. Additional outreach work was organized for FSWs. Procurement of Mobile Ambulatories attributed to increased coverage of PWIDs also. ",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.2000000000000002,"Number and percentage of IDUs reached with HIV prevention programmes - defined package of services ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10","2013",16208,"45000",0.36017777777777776,19830,49700,0.39899396378269619,19389,49700,0.39012072434607648,null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.2999999999999998,"Number and percentage of FSWs reached with HIV prevention programmes - defined package of services ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10","2013",776,"8000",9.7000000000000003E-2,1828,6500,0.28123076923076923,1924,6500,0.29599999999999999,null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.4,"Percentage of individuals receiving OST who received treatment for at least 6 months",null,null,null,"Current grant","N-not cumulative","Yes - Top 10","2013",400,"2450",0.16326530612244897,null,null,0.75,759,968,{"$f":"Q19/R19","v":0.78409090909090906},"759 people from the pool of 968 recruited or transfered patients during the period of July -December, 2015 were receiving OST through GF funding continuously over the period of 6 months . Opening of a new OST center and imrpoved linkadge and possibility of movement between the GF and the State OST programs has contributed to increased results. The tracking of a patient for 6 month in both programs became possible through the e-health OST module.  ",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.5,"Percentage of key affected population screened for TB",null,null,null,"Current grant","N-not cumulative","No",null,"N/A",null,"",10223,17039,0.5999765244439228,{"$f":"SUM(9549+900+832)","v":11281},{"$f":"O20","v":17039},0.66206937026820822,"Ineased VCT coverage influence. Source is electronic database of GNRH and Tanadgoma.",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,3,"Number and percentage of eligible adults and children currently receiving antiretroviral therapy  ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10","2013",2092,"4060",0.51527093596059115,3600,10451,0.34446464453162379,3373,10451,0.32274423500143529,"3373 patients were receiving ART as of July 1, 2016.(Source is electronic database of National AIDS Center). The denominator was updated by the NCDC through Sepctrum in June, 2015, as it was requested in the GF Management letter of May, 2015. New Denominator is 4689 (the previous one was 5080). In July this year AIDS Center has provided new estimates agreed with UNAIDS for number of PLHIV in Georgia which is 10,400 for adults and 51 is for children, as the country has moved to treat all strategy, the denominator was changed accrodingly in the current report. ",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,3.1,"Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)",null,null,null,"Current grant","Y-cumulative annually","No","2013",101,"121",0.83471074380165289,null,null,null,null,null,"","n/a, the indicator is annual cummulative",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,3.2,"Number of patients with HIV Hep C co-infection receiving Hep C treatment ",null,null,null,"Current grant","Y-cumulative annually","No","2013",152,"150",1.0133333333333334,70,70,1,198,70,2.8285714285714287,"Overachivement has resulted from the initiation of the State Hep C Elimination Program that provides free access to highly effective anti-HCV medicine (sofosbovir).  Within the GF program patients have free laboratory monitoring of treatment. ",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,{"$f":"IFERROR(K30/L30,\"\")","v":""},null,null,{"$f":"IFERROR(N30/O30,\"\")","v":""},null,null,{"$f":"IFERROR(Q30/R30,\"\")","v":""},null,null,"Select","Select",null,null,null,{"$f":"IFERROR(Y30/Z30,\"\")","v":""},null,null,{"$f":"IFERROR(AB30/AC30,\"\")","v":""},null,null,{"$f":"IFERROR(AE30/AF30,\"\")","v":""},null,null,null,null,null,{"$f":"AE30","v":0},{"$f":"AF30","v":0},{"$f":"IFERROR(AM30/AN30,\"\")","v":""}]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,{"$f":"IFERROR(K41/L41,\"\")","v":""},null,null,{"$f":"IFERROR(N41/O41,\"\")","v":""},null,null,{"$f":"IFERROR(Q41/R41,\"\")","v":""},null,null,"Select","Select",null,null,null,{"$f":"IFERROR(Y41/Z41,\"\")","v":""},null,null,{"$f":"IFERROR(AB41/AC41,\"\")","v":""},null,null,{"$f":"IFERROR(AE41/AF41,\"\")","v":""},null,null,null,null,null,{"$f":"AE41","v":0},{"$f":"AF41","v":0},{"$f":"IFERROR(AM41/AN41,\"\")","v":""}]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,{"$f":"IFERROR(K52/L52,\"\")","v":""},null,null,{"$f":"IFERROR(N52/O52,\"\")","v":""},null,null,{"$f":"IFERROR(Q52/R52,\"\")","v":""},null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]

{"sheet":"ImpactOutcomeDisaggData","index":4,"n_rows":33,"n_cols":9,"rows_kept":33,"cut":false,"hidden":true,"merged":[[0,1,0,8]]}
[null,"Impact/outcome disaggregation Data "]
[]
[null,"HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HIVI1","Sex",{"$f":"CONCATENATE(C3,D3)","v":"HIVI1Sex"},"Male","Female",null,"Impact"]
[null,"HIV I-2: HIV incidence among 15-49 age group","HIVI2","Sex",{"$f":"CONCATENATE(C4,D4)","v":"HIVI2Sex"},"Male","Female",null,"Impact"]
[null,"HIV I-2: HIV incidence among 15-49 age group","HIVI2","Age",{"$f":"CONCATENATE(C5,D5)","v":"HIVI2Age"},"15-24"]
[null,"HIV I-4: AIDS related mortality per 100,000 population","HIVI4","Sex","HIVI4Sex","Male","Female",null,"Impact"]
[null,"HIV I-4: AIDS related mortality per 100,000 population","HIVI4","Age","HIVI4Age","<15","15+","15-24","Impact"]
[null,"HIV I-9a: Percentage of men who have sex with men who are living with HIV","HIVI9a","Age","HIVI9aAge","<25","25+",null,"Impact"]
[null,"HIV I-9b: Percentage of transgender people who are living with HIV","HIVI9b","Age","HIVI9bAge","<25","25+",null,"Impact"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","MalariaI1","Sex","MalariaI1Sex","Male","Female",null,"Impact"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","MalariaI1","Age","MalariaI1Age","<5","5+",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Sex","MalariaI2Sex","Male","Female",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Age","MalariaI2Age","<5","5+",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Species","MalariaI2Species","P. Vivax","P. Falciparum","Other - specify","Impact"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","MalariaI3","Sex","MalariaI3Sex","Male","Female",null,"Impact"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","MalariaI3","Age","MalariaI3Age","<5","5+",null,"Impact"]
[null,"Malaria I-4: Malaria test positivity rate","MalariaI4","Species","MalariaI4Species","P. Vivax","P. Falciparum","Other - specify","Impact"]
[null,"Malaria I-4: Malaria test positivity rate","MalariaI4","Type of testing",{"$f":"SUBSTITUTE(CONCATENATE(C18,D18),\" \",\"\")","v":"MalariaI4Typeoftesting"},"Microscopy","RDT",null,"Impact"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","MalariaI5","Sex","MalariaI5Sex","Male","Female",null,"Impact"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","MalariaI5","Species","MalariaI5Species","P. Vivax","P. Falciparum","Other - specify"]
[null,"Malaria I-6: All-cause under-5 mortality rate per 1000 live births","MalariaI6","Sex","MalariaI6Sex","Male","Female",null,"Impact"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Sex","HIVO1Sex","Male","Female",null,"Outcome"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Age","HIVO1Age","<15","15+",null,"Outcome"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Duration of treatment",{"$f":"SUBSTITUTE(CONCATENATE(C24,D24),\" \",\"\")","v":"HIVO1Durationoftreatment"},"24 months","36 months",null,"Outcome"]
[null,"HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIVO2","Sex","HIVO2Sex","Male","Female",null,"Outcome"]
[null,"HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIVO2","Age","HIVO2Age","15-19","20-24",null,"Outcome"]
[null,"HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIVO3","Sex","HIVO3Sex","Male","Female",null,"Outcome"]
[null,"HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIVO3","Age","HIVO3Age","15-19","20-24",null,"Outcome"]
[null,"HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client","HIVO5","Sex","HIVO5Sex","Male","Female",null,"Outcome"]
[null,"HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected","HIVO6","Sex","HIVO6Sex","Male","Female",null,"Outcome"]
[null,"HIV O-8: Current school attendance rate among orphans compared to non-orphans","HIVO8","Sex","HIVO8Sex","Male","Female",null,"Outcome"]
[null,"Malaria O-1a: Proportion of population that slept under an insecticide-treated net* the previous night","MalariaO1a","Sex","MalariaO1aSex","Male","Female",null,"Outcome"]
[null,"Malaria O-3: Proportion of population using an insecticide-treated net* among the population with access to an insecticide-treated net","MalariaO3","Sex","MalariaO3Sex","Male","Female",null,"Outcome"]

{"sheet":"Impactoutcome","index":5,"n_rows":28,"n_cols":11,"rows_kept":28,"cut":false,"hidden":true,"merged":[]}
[]
[null,"Type1","Type2","Type3","Type4","Type5","Type6","Type7","Type8","Type9","Type10"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","TB I-1: TB prevalence rate (per 100,000 population)","HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HSS I-1: Under 5 mortality rate per 1000 live births","Malaria O-1a: Proportion of population that slept under an insecticide-treated net* the previous night","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases","HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HSS O-1: Percentage of women attending antenatal care"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","TB I-2: TB incidence rate (per 100,000 population)","HIV I-2: HIV incidence among 15-49 age group","HIV I-2: HIV incidence among 15-49 age group","HSS I-2: Neonatal mortality rate, per 100,000 population","Malaria O-1b: Proportion of children under five years old who slept under an insecticide-treated net* the previous night","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse","HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HSS O-2: Percentage of births attended by skilled health professional"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","TB I-3: TB mortality rate (per 100,000 population)","HIV I-3a: Percentage of antenatal care attendees who were positive for syphilis","HIV I-3a: Percentage of antenatal care attendees who were positive for syphilis","HSS I-3: Maternal mortality ratio, per 100,000 population","Malaria O-1c: Proportion of pregnant women who slept under an insecticide-treated net* the previous night","TB O-2a: Treatment success rate - all forms of TB","HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health"]
[null,"Malaria I-4: Malaria test positivity rate","TB I-4: MDR-TB prevalence among new TB patients","HIV I-3b: Percentage of men who have sex with men with active syphilis","HIV I-3b: Percentage of men who have sex with men with active syphilis","Custom","Malaria O-2: Proportion of population with access to an ITN within their household","TB O-2b: Treatment success rate - bacteriologically confirmed TB cases","HIV O-4a: Percentage of men reporting the use of a condom the last time they had anal sex with a male partner","HIV O-4a: Percentage of men reporting the use of a condom the last time they had anal sex with a male partner","HSS O-4: General service readiness score for health facilities"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","TB I-5: Modelled lives saved based on latest epidemiological data","HIV I-3c: Percentage of sex workers with active syphilis","HIV I-3c: Percentage of sex workers with active syphilis",null,"Malaria O-3: Proportion of population using an insecticide-treated net* among the population with access to an insecticide-treated net","TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases","HIV O-4b: Percentage of transgender people who sell sex reporting the use of a condom with their most recent client","HIV O-4b: Percentage of transgender people who sell sex reporting the use of a condom with their most recent client","Custom"]
[null,"Malaria I-6: All-cause under-5 mortality rate per 1000 live births","TB I-6: Modelled infections averted based on latest epidemiological data","HIV I-4: AIDS related mortality per 100,000 population","HIV I-4: AIDS related mortality per 100,000 population",null,"Malaria O-4: Proportion of households with at least one insecticide-treated net for every two people and/or sprayed by IRS within the last 12 months","TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated","HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client","HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client"]
[null,"Malaria I-7: Modelled lives saved (based on latest epidemiological data)","TB/HIV I-1: TB/HIV mortality rate, per 100,000 population","HIV I-5: New HIV infections among children","HIV I-5: New HIV infections among children",null,"Malaria O-6: Proportion of households with at least one insecticide-treated net* for every two people","HSS O-1: Percentage of women attending antenatal care","HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected","HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected"]
[null,"Malaria I-8: Modelled infections averted (based on latest epidemiological data)","HSS I-1: Under 5 mortality rate per 1000 live births","HIV I-6: Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months","HIV I-6: Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months",null,"HSS O-1: Percentage of women attending antenatal care","HSS O-2: Percentage of births attended by skilled health professional","HIV O-7: Percentage of other vulnerable populations who report the use of a condom at last sexual intercourse","HIV O-7: Percentage of other vulnerable populations who report the use of a condom at last sexual intercourse"]
[null,"HSS I-1: Under 5 mortality rate per 1000 live births","HSS I-2: Neonatal mortality rate, per 100,000 population","HIV I-7: Modelled lives saved based on latest epidemiological data","HIV I-7: Modelled lives saved based on latest epidemiological data",null,"Malaria O-5: Proportion of households with at least one insecticide-treated net","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","HIV O-8: Current school attendance rate among orphans compared to non-orphans","HIV O-8: Current school attendance rate among orphans compared to non-orphans"]
[null,"HSS I-2: Neonatal mortality rate, per 100,000 population","HSS I-3: Maternal mortality ratio, per 100,000 population","HIV I-8: Modelled infections averted based on latest epidemiological data","HIV I-8: Modelled infections averted based on latest epidemiological data",null,"HSS O-2: Percentage of births attended by skilled health professional","HSS O-5: Specific services readiness score for health facilities","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases"]
[null,"HSS I-3: Maternal mortality ratio, per 100,000 population","Custom","HIV I-9a: Percentage of men who have sex with men who are living with HIV","HIV I-9a: Percentage of men who have sex with men who are living with HIV",null,"HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","Custom","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse"]
[null,"Custom",null,"HIV I-9b: Percentage of transgender people who are living with HIV","HIV I-9b: Percentage of transgender people who are living with HIV",null,"HSS O-5: Specific services readiness score for health facilities",null,"TB O-2a: Treatment success rate - all forms of TB","TB O-2a: Treatment success rate - all forms of TB"]
[null,null,null,"HIV I-10: Percentage of sex workers who are living with HIV","HIV I-10: Percentage of sex workers who are living with HIV",null,"Custom",null,"TB O-2b: Treatment success rate - bacteriologically confirmed TB cases","TB O-2b: Treatment success rate - bacteriologically confirmed TB cases"]
[null,null,null,"HIV I-11: Percentage of people who inject drugs who are living with HIV","HIV I-11: Percentage of people who inject drugs who are living with HIV",null,null,null,"TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases","TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases"]
[null,null,null,"HIV I-12: Percentage of other vulnerable populations (specify) who are living with HIV","HIV I-12: Percentage of other vulnerable populations (specify) who are living with HIV",null,null,null,"TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated","TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated"]
[null,null,null,"TB I-1: TB prevalence rate (per 100,000 population)","TB/HIV I-1: TB/HIV mortality rate, per 100,000 population",null,null,null,"HSS O-1: Percentage of women attending antenatal care","HSS O-1: Percentage of women attending antenatal care"]
[null,null,null,"TB I-2: TB incidence rate (per 100,000 population)","HSS I-1: Under 5 mortality rate per 1000 live births",null,null,null,"HSS O-2: Percentage of births attended by skilled health professional","HSS O-2: Percentage of births attended by skilled health professional"]
[null,null,null,"TB I-3: TB mortality rate (per 100,000 population)","HSS I-2: Neonatal mortality rate, per 100,000 population",null,null,null,"HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health"]
[null,null,null,"TB I-4: MDR-TB prevalence among new TB patients","HSS I-3: Maternal mortality ratio, per 100,000 population",null,null,null,"HSS O-5: Specific services readiness score for health facilities","HSS O-5: Specific services readiness score for health facilities"]
[null,null,null,"TB I-5: Modelled lives saved based on latest epidemiological data","Custom",null,null,null,"Custom","Custom"]
[null,null,null,"TB I-6: Modelled infections averted based on latest epidemiological data"]
[null,null,null,"TB/HIV I-1: TB/HIV mortality rate, per 100,000 population"]
[null,null,null,"HSS I-1: Under 5 mortality rate per 1000 live births"]
[null,null,null,"HSS I-2: Neonatal mortality rate, per 100,000 population"]
[null,null,null,"HSS I-3: Maternal mortality ratio, per 100,000 population"]
[null,null,null,"Custom"]

{"sheet":"Coverage Indicators","index":6,"n_rows":20,"n_cols":26,"rows_kept":20,"cut":false,"hidden":true,"merged":[]}
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS"]
[null,null," ",null,null,null,null,null,null,null,null,null,null,null,null,"Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","HIV/AIDS"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"HIV/AIDS","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","HIV/AIDS","Tuberculosis"]
[null,null,null,null,null,"Tuberculosis","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","Tuberculosis","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","HIV/TB","Malaria"]
[null,"Malaria","Malaria","Malaria","Tuberculosis","HIV/TB","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","Malaria","HIV/TB"]
[null,"Specific prevention interventions (SPI)","Vector control","Case management","TB care and prevention","MDR-TB","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","HIV/AIDS","TB/HIV","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Community systems strengthening","Results based Financing"]
[null,"Module1","Module2","Module3","Module4","Module5","Module8","Module9","Module10","Module11","Module12","Module13","Module14","Module15","Module24","Module27","Module28","Module29","Module30","Module31","Module32","Module33","Module34","Module35","Module72","Module73"]
[null,"SPI-1: Proportion of pregnant women attending antenatal clinics who received three or more doses of intermittent preventive treatment (IPTp) for malaria","VC-1: Number of long-lasting insecticidal nets distributed to at-risk populations through mass campaigns","CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)","GP-1: Number of women and men aged 15+ who received an HIV test and know their results","KP-1a: Percentage of MSM reached with HIV prevention programs - defined package of services","KP-1d: Percentage of PWID reached with HIV prevention programs - defined package of services","KP-1e: Percentage of other vulnerable populations reached with HIV prevention programs - defined package of services","YP-1: Percentage of young people aged 10?24 years reached by life skills?based HIV education in schools","KP-1c: Percentage of sex workers reached with HIV prevention programs - defined package of services","PMTCT-1: Percentage of pregnant women who know their HIV status","TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register","Custom ","SD-1: Number of health facilities per 10,000 population","HW-1: Number of health workers per 10,000 population (report on community health workers as applicable)","M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines","Custom","PSM-1: Percentage of health facilities reporting no stock-outs of essential drugs","Custom","HF-1: Government expenditure on health as percentage of general government expenditure","Custom","Custom","Custom"]
[null,"Custom","VC-2: Proportion of population at risk potentially covered by long lasting insecticidal nets distributed","CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses","MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","GP-2: Percentage of individuals from targeted population reached through community outreach with standardized HIV prevention interventions","KP-1b: Percentage of TG reached with HIV prevention programs - defined package of services","KP-2d: Percentage of PWID reached with HIV prevention programs - individual and/or smaller group level interventions","KP-2e: Percentage of other vulnerable populations reached with HIV prevention programs - individual and/or smaller group level interventions","Custom","KP-2c: Percentage of sex workers reached with HIV prevention programs - individual and/or smaller group level interventions","PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission","TCS-2: Percentage of people living with HIV that initiated ART with CD4 count of <200 cells/mm³","TB/HIV-4: Percentage of new HIV-positive patients starting IPT during the reporting period",null,"SD-2: Number of outpatients visits per 10,000 population","HW-2: Distribution of health workers","M&E-2: Proportion of facility reports received over the reports expected during the reporting period",null,"Custom",null,"Custom"]
[null,null,"VC-3: Number of long-lasting insecticidal nets distributed to targeted risk groups through continuous distribution","CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","GP-3: Proportion of new individuals who test positive for HIV, enrolled in care (pre-ART or ART) services","KP-2a: Percentage of MSM reached with HIV prevention programs - individual and/or smaller group level interventions","KP-3d: Percentage of PWID that have received an HIV test during the reporting period and know their results","KP-3e: Percentage of other vulnerable populations that have received an HIV test during the reporting period and know their results",null,"KP-3c: Percentage of sex workers that have received an HIV test during the reporting period and know their results","PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth","TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TB/HIV-3: Percentage of HIV-positive patients who were screened for TB in HIV care or treatment settings",null,"Custom","HW-3: Number of health workers newly recruited at primary health care facilities in the past 12 months, expressed as a percentage of planned recruitment targets","M&E-3: Percentage of deaths registered (as reported by civil or sample registration systems, hospitals, community-based reporting systems) among the total deaths for the same period and geographical region"]
[null,null,"VC-4: Proportion of targeted risk groups receiving long-lasting insecticidal-nets","CM-2a: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at public sector health facilities","DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period","MDR TB-4: Percentage of cases with drug resistant TB (RR-TB and/or MDR-TB) started on treatment for MDR-TB who were lost to follow up at six months","GP-4: Percentage of antenatal care attendees tested for syphilis","KP-2b: Percentage of TG reached with HIV prevention programs - individual and/or smaller group level interventions","KP-4: Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programs","Custom",null,"Custom","Custom","TCS-4: Percentage of health facilities dispensing antiretroviral therapy that experienced a stock-out of at least one required antiretroviral drug in the last 12 month","TB/HIV-2: Percentage of HIV-positive registered TB patients given anti-retroviral therapy during TB treatment",null,null,"HW-4: Annual rate of retention of service providers at primary health care facilities","Custom"]
[null,null,"VC-5: Proportion of households in targeted areas that received Indoor Residual Spraying during the reporting period","CM-2b: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy in the community","DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period","MDR TB-5: Percentage of DST laboratories showing adequate performance on External Quality Assurance","GP-5: Number of male circumcisions performed according to national standards","KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results","KP-5: Percentage of individuals receiving Opioid Substitution Therapy who received treatment for at least 6 months",null,null,null,null,"TCS-5: Proportion of undernourished PLHIV that received therapeutic or supplementary food at any point during the reporting period","Custom",null,null,"Custom"]
[null,null,"VC-6: Proportion of population protected by Indoor Residual Spraying within the last 12 months","CM-2c: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at private sector sites","DOTS-4: Percentage of reporting units reporting no stock-out of first-line anti-TB drugs on the last day of the quarter","Custom","GP-6: Percentage of orphaned and vulnerable children aged 0?17 years whose households received free basic external support in caring for the child according to national guidelines","KP-3b: Percentage of TG that have received an HIV test during the reporting period and know their results","Custom",null,null,null,null,"Custom"]
[null,null,"Custom","CM-3a: Proportion of estimated malaria cases (presumed and confirmed) that received first line antimalarial treatment at public sector health facilities","DOTS-5: Number of children <5 in contact with TB patients who began IPT",null,"Custom","Custom"]
[null,null,null,"CM-3b: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment in the community","DOTS-6: Number of TB cases (all forms) notified among key affected populations/high risk groups"]
[null,null,null,"CM-3c: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment at private sector sites","DOTS-7a: Percentage of notified TB cases, all forms, contributed by non-NTP providers - private/non-governmental facilities"]
[null,null,null,"CM-4: Proportion of health facilities without stock-outs of key commodities during the reporting period","DOTS-7b: Percentage of notified TB cases, all forms, contributed by non-NTP providers - public sector"]
[null,null,null,"CM-5: Percentage of confirmed cases fully investigated (malaria elimination phase)","DOTS-7c: Percentage of notified TB cases, all forms, contributed by non-NTP providers - community referrals"]
[null,null,null,"CM-6: Percentage of foci fully investigated (malaria elimination phase)","Custom"]
[null,null,null,"Custom"]

{"sheet":"CoverageDisaggregationData","index":7,"n_rows":37,"n_cols":10,"rows_kept":37,"cut":false,"hidden":true,"merged":[]}
[null,"Coverage disaggregation Data "]
[null,"Name of Indicator","ShortName","Disaggregation ","Concatenatedcode","Module","Categories"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","Sex",{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(CONCATENATE(C3,D3),\" \",\"\"),\"/\",\"\"),\"-\",\"\")","v":"GP1DSex"},"Prevention programs for general population","Male","Female"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","HIV status","GP1DHIVstatus","Prevention programs for general population","Positive","Negative"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","Age",{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(CONCATENATE(C5,D5),\" \",\"\"),\"/\",\"\"),\"-\",\"\")","v":"GP1DAge"},"Prevention programs for general population","15-24"]
[null,"PMTCT-1: Percentage of pregnant women who know their HIV status","PMTCT1","HIV status-pregnant women","PMTCT1HIVstatuspregnantwomen","PMTCT","Known positive HIV infection at ANC","Newly identified as HIV positive","Testing HIV negative"]
[null,"TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TCS1a","Sex","TCS1aSex","Treatment, care and support","Male","Female"]
[null,"TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TCS1a","Age","TCS1aAge","Treatment, care and support","<15","15+","15-24"]
[null,"TCS-2: Percentage of people living with HIV that initiated ART with CD4 count of <200 cells/mm³","TCS2a","Sex","TCS2aSex","Treatment, care and support","Male","Female"]
[null,"TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TCS3a","Sex","TCS3aSex","Treatment, care and support","Male","Female"]
[null,"TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TCS3a","Age","TCS3aAge","Treatment, care and support","15-24"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","Sex","DOTS1aSex","TB care and prevention","Male","Female"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","HIV test result","DOTS1aHIVtestresult","TB care and prevention","Positive","Negative","Not documented"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","Age","DOTS1aAge","TB care and prevention","<15","15+"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","Sex","DOTS2aSex","TB care and prevention","Male","Female"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","Age","DOTS2aAge","TB care and prevention","<15","15+"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","HIV test result","DOTS2aHIVtestresult","TB care and prevention","Positive","Negative","Not documented"]
[null,"DOTS-6: Number of TB cases (all forms) notified among key affected populations/high risk groups","DOTS6","KAPs/high risk groups","DOTS6KAPshighriskgroups","TB care and prevention","Prisoners","Migrants/ Refugees/ IDPs","Others - specify"]
[null,"MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","MDRTB2","Sex","MDRTB2Sex","MDR-TB","Male","Female"]
[null,"MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","MDRTB2","Age","MDRTB2Age","MDR-TB","<15","15+"]
[null,"MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","MDRTB3","Sex","MDRTB3Sex","MDR-TB","Male","Female"]
[null,"MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","MDRTB3","Age","MDRTB3Age","MDR-TB","<15","15+"]
[null,"VC-3: Number of long-lasting insecticidal nets distributed to targeted risk groups through continuous distribution","VC3a","Targeted risk group","VC3aTargetedriskgroup","Vector control","Pregnant women","Children <5","Migrant workers/ refugees/ IDPs","Others - specify"]
[null,"VC-4: Proportion of targeted risk groups receiving long-lasting insecticidal-nets","VC4a","Targeted risk group","VC4aTargetedriskgroup","Vector control","Pregnant women","Children <5","Migrant workers/ refugees/ IDPs","Others - specify"]
[null,"CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","CM1a","Age","CM1aAge","Case management","<5","5+"]
[null,"CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","CM1a","Type of testing","CM1aTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","CM1b","Age","CM1bAge","Case management","<5","5+"]
[null,"CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","CM1b","Type of testing","CM1bTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","CM1c","Age","CM1cAge","Case management","<5","5+"]
[null,"CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","CM1c","Type of testing","CM1cTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-2a: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at public sector health facilities","CM2a","Age","CM2aAge","Case management","<5","5+"]
[null,"CM-2b: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy in the community","CM2b","Age","CM2bAge","Case management","<5","5+"]
[null,"CM-2c: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at private sector sites","CM2c","Age","CM2cAge","Case management","<5","5+"]
[null,"CM-3a: Proportion of estimated malaria cases (presumed and confirmed) that received first line antimalarial treatment at public sector health facilities","CM3a","Age","CM3aAge","Case management","<5","5+"]
[null,"CM-3b: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment in the community","CM3b","Age","CM3bAge","Case management","<5","5+"]
[null,"CM-3c: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment at private sector sites","CM3c","Age","CM3cAge","Case management","<5","5+"]
[null,"HW-1: Number of health workers per 10,000 population (report on community health workers as applicable)","HW1a","Specialization","HW1aSpecialization","HSS - Health and community workforce","Doctors","Nurses","Lab technicians","Other - specify"]

{"sheet":"WPTM_1C","index":8,"n_rows":53,"n_cols":28,"rows_kept":53,"cut":false,"hidden":false,"merged":[[14,12,14,18],[14,20,14,21],[6,2,6,5],[10,2,10,5],[0,0,0,11],[14,0,14,11]]}
["Ongoing Progress Update and Disbursement Request"]
["Grant number:",null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Component",null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["PROGRESS UPDATE "]
["Progress Update - Reporting Period:",null,"Cycle:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:"]
["DISBURSEMENT REQUEST "]
["Disbursement Request  - Disbursement Period:",null,"Cycle:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:"]
[{"$f":"#REF!","v":{"$error":"#REF!"}}]
[null,null,null,"Section 1:  Programmatic Progress"]
[null,null,null,"Note: Enter only the Workplan Tracking Measures that are due for the reporting period "]
["C- Workplan Tracking Measures ",null,null,null,null,null,null,null,null,null,null,null,"LFA Use Only",null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Module",null,"Intervention","Activity","Activity details- milestones/ targets","Criterion for completion","Milestones/Target for the Current Period ","Country (relevant for multi-country grants)","Target","Progress Status","Score","Reasons for deviation from workplan activities and milestones","Activity details- milestones/ targets","Criterion for completion","Milestones/Target for the Current Period ","Country (relevant for multi-country grants)","Progress Status","Verified Score","LFA analysis of progress and any variance between targets and results, and any other comments\n(this should not be a “Copy and Paste” of the reasons provided by the PR)","Progress Status","Validated Score","Country Team Comments on Validated Score"]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A17,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,null,null,{"$f":"IFERROR(VLOOKUP(J17,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null," "," ",null," ",null,{"$f":"IFERROR(VLOOKUP(Q17,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null,null,{"$f":"IFERROR(VLOOKUP(T17,$AA$19:$AB$22,2,FALSE),\"\")","v":""}]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A18,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,"-",null,{"$f":"IFERROR(VLOOKUP(J18,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null,null,null,null,null,null,{"$f":"IFERROR(VLOOKUP(Q18,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null,null,{"$f":"IFERROR(VLOOKUP(T18,$AA$19:$AB$22,2,FALSE),\"\")","v":""}]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Not Started",0]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Started",1]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Advancing",2]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Completed",3]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A30,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,"-",null,{"$f":"IFERROR(VLOOKUP(J30,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null,null,null,null,null,null,{"$f":"IFERROR(VLOOKUP(Q30,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null,null,{"$f":"IFERROR(VLOOKUP(T30,$AA$19:$AB$22,2,FALSE),\"\")","v":""}]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]

{"sheet":"Intervention By Modules old","index":9,"n_rows":20,"n_cols":80,"rows_kept":20,"cut":false,"hidden":true,"merged":[]}
[]
[null,null," "]
[]
[]
[]
[null,"Specific prevention interventions (SPI)","Vector control","Case management","TBcareandprevention","MDR-TB","TB care and prevention","MDR-TB","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","Treatment, care and support","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","Treatment, care and support","TB/HIV","TB/HIV","TB/HIV","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing"]
[null,"MalariaModule1","MalariaModule2","MalariaModule3","TuberculosisModule4","TuberculosisModule5","HIV/TBModule6","HIV/TBModule7","HIV/TBModule8","HIV/TBModule9","HIV/TBModule10","HIV/TBModule11","HIV/TBModule12","HIV/TBModule13","HIV/TBModule14","HIV/TBModule15","HIV/AIDSModule16","HIV/AIDSModule17","HIV/AIDSModule18","\nHIV/AIDSModule19","HIV/AIDSModule20","HIV/AIDSModule21","HIV/AIDSModule22","\nHIV/AIDSModule23","HIV/AIDSModule24","\nTuberculosisModule25","\nHIV/TBModule26","\nHIV/AIDSModule27","HIV/AIDSModule28","HIV/AIDSModule29","HIV/AIDSModule30","HIV/AIDSModule31","HIV/AIDSModule32","HIV/AIDSModule33","HIV/AIDSModule34","HIV/AIDSModule35","TuberculosisModule36","TuberculosisModule37","TuberculosisModule38","TuberculosisModule39","TuberculosisModule40","TuberculosisModule41","TuberculosisModule42","TuberculosisModule43","TuberculosisModule44","Module45","MalariaModule46","MalariaModule47","MalariaModule48","MalariaModule49","MalariaModule50","MalariaModule51","MalariaModule52","MalariaModule53","Health Systems StrengtheningModule54","Health Systems StrengtheningModule55","Health Systems StrengtheningModule56","Health Systems StrengtheningModule57","Health Systems StrengtheningModule58","Health Systems StrengtheningModule59","Health Systems StrengtheningModule60","Health Systems StrengtheningModule61","Health Systems StrengtheningModule62","HIV/TBModule63","HIV/TBModule64","HIV/TBModule65","HIV/TBModule66","HIV/TBModule67","HIV/TBModule68","HIV/TBModule69","HIV/TBModule70","HIV/TBModule71","HIV/AIDSModule72","HIV/AIDSModule73","TuberculosisModule74","TuberculosisModule75","MalariaModule76","MalariaModule77","HIV/TBModule78","HIV/TBModule79"]
[null,"Intermittent preventive treatment (IPT) - In pregnancy","Long-lasting insecticidal nets (LLIN) - Mass campaign","Facility-based treatment","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","TB/HIV collaborative interventions","TB/HIV collaborative interventions","TB/HIV collaborative interventions","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing"]
[null,"Intermittent preventive treatment (IPT) - In infancy","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Epidemic preparedness and response","Treatment","Treatment: MDR-TB","Treatment","Treatment: MDR-TB","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Engaging all care providers","Engaging all care providers","Engaging all care providers","Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Advocacy for social accountability",null,"Advocacy for social accountability",null,"Advocacy for social accountability",null,"Advocacy for social accountability"]
[null,"Seasonal malaria chemoprevention","Indoor residual spraying (IRS)","Integrated community case management (ICCM)","Prevention","Prevention for MDR-TB","Prevention","Prevention for MDR-TB","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Community TB care delivery","Community TB care delivery","Community TB care delivery","Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination"]
[null,"IEC/BCC","Other vector control measures","Active case detection and investigation (elimination phase)","Other","Other","Other","Other","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Key Affected Populations","Key Affected Populations","Key Affected Populations","Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development"]
[null,"Other","Entomological monitoring","Therapeutic efficacy surveillance",null,null,null,null,"Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Collaborative activities with other programs and sectors","Collaborative activities with other programs and sectors","Collaborative activities with other programs and sectors","Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys"]
[null,null,"Other  ","Severe malaria",null,null,null,null,"HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support","HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support"]
[null,null,null,"Private sector co-payment mechanism",null,null,null,null,"Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care","Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care"]
[null,null,null,"Private sector case management (other)",null,null,null,null,"Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care","Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care"]
[null,null,null,null,null,null,null,null,null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify",null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify"]
[null,null,null,null,null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations",null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations"]
[null,null,null,null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners"]

{"sheet":"Intervention By Modules","index":10,"n_rows":17,"n_cols":26,"rows_kept":17,"cut":false,"hidden":true,"merged":[]}
[]
[]
[null,"SpecificpreventioninterventionsSPI","Vectorcontrol","Casemanagement","TBcareandprevention","MDR-TB","Preventionprogramsforgeneralpopulation","PreventionprogramsforMSMandTGs","PreventionprogramsforpeoplewhoinjectdrugsPWIDandtheirpartners","Preventionprogramsforothervulnerablepopulationspleasespecify","Preventionprogramsforadolescentsandyouthinandoutofschool","Preventionprogramsforsexworkersandtheirclients","PMTCT","Treatmentcareandsupport","TBHIV","Removinglegalbarrierstoaccess","HSSServicedelivery","HSSHealthandcommunityworkforce","HSSHealthinformationsystemsandME","Programmanagement","HSSProcurementsupplychainmanagementPSCM","HSSPolicyandgovernance","HSS-Healthcarefinancing","HSSFinancialmanagement","Communitysystemsstrengthening","Results basedFinancing"]
[null,"Intermittent preventive treatment (IPT) - In pregnancy","Long-lasting insecticidal nets (LLIN) - Mass campaign","Facility-based treatment","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","TB/HIV collaborative interventions","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Community-based monitoring for accountability","Results-based financing"]
[null,"Intermittent preventive treatment (IPT) - In infancy","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Epidemic preparedness and response","Treatment","Treatment: MDR-TB","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Engaging all care providers","Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Advocacy for social accountability"]
[null,"Seasonal malaria chemoprevention","Indoor residual spraying (IRS)","Integrated community case management (ICCM)","Prevention","Prevention for MDR-TB","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Community TB care delivery","Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Social mobilization, building community linkages, collaboration and coordination"]
[null,"IEC/BCC","Other vector control measures","Active case detection and investigation (elimination phase)","Other","Other","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Key Affected Populations","Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Institutional capacity building, planning and leadership development"]
[null,"Other","Entomological monitoring","Therapeutic efficacy surveillance",null,null,"Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Collaborative activities with other programs and sectors","Training on rights for officials, health workers and police",null,null,"Surveys"]
[null,null,"Other  ","Severe malaria",null,null,"HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support"]
[null,null,null,"Private sector co-payment mechanism",null,null,"Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care"]
[null,null,null,"Private sector case management (other)",null,null,"Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care"]
[null,null,null,null,null,null,null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify"]
[null,null,null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations"]
[null,null,null,null,null,null,null,null,"Other interventions for IDUs and their partners - Please specify"]
[null,null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners"]

{"sheet":"PR Cash Reconciliation_2A,B,C","index":11,"n_rows":73,"n_cols":12,"rows_kept":73,"cut":false,"hidden":false,"merged":[[3,0,3,11],[48,1,48,11],[24,1,24,11],[59,5,59,8],[66,5,66,8],[65,1,65,11],[66,2,66,4],[66,9,66,11],[19,0,20,11],[21,0,21,11],[25,2,25,4],[25,5,25,8],[25,9,25,11],[58,1,58,11],[59,1,60,1],[59,2,59,4],[59,9,59,11],[12,6,12,9],[17,6,17,9],[17,1,17,3],[10,1,10,3],[11,1,11,3],[12,1,12,3],[15,1,15,3],[16,1,16,3]]}
[]
[]
[]
["Ongoing Progress Update and Disbursement Request "]
[]
[null,"Grant Name:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"(Disease) Component",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"GA Number",{"$f":"#REF!","v":{"$error":"#REF!"}}]
[]
[null,"PROGRESS UPDATE "]
[null,"Progress Update - Reporting Period:",null,null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Number:"]
[]
[null,"DISBURSEMENT REQUEST "]
[null,"Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Disbursement Request  - Number:"]
[]
["Section 2: Financial Information"]
[]
[]
[]
[]
[null,"A. Principal Recipient Cash Reconciliation Statement in Grant Currency"]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
["Item No.","Description","Cumulative for Previous Periods","Current Reporting Period","Comments","Cumulative for Previous Periods as validated by Global Fund","LFA Adjustments on Current Reporting Period","As verified by LFA","Comments","CT Adjustments (incl. External Audit adjustments)","The Global Fund Validated Figures","Comments"]
[1.1000000000000001,"Cash Balance: Beginning of the Period",0,2351877.6392323477,null,null,0,{"$f":"D28+G28","v":2351877.6392323477},null,0,{"$f":"H28+J28","v":2351877.6392323477}]
[null,"2. Grant Income"]
[null,"Add: "]
[2.1,"Disbursement made to the Principal Recipient ",{"$f":"4418100+438789+3576040.99+550879+1768890.77","v":10752699.76},0,null,0,0,{"$f":"D31+G31","v":0},null,0,{"$f":"H31+J31","v":0}]
[2.2000000000000002,"Disbursement to third parties by the Global Fund on behalf of the Principal Recipient ",{"$f":"193752.19+1021728.79-200-193752.19","v":1021528.79},0,null,0,0,{"$f":"D32+G32","v":0},null,0,{"$f":"H32+J32","v":0}]
[2.2999999999999998,"Interest received on bank accounts",0,0,null,0,0,{"$f":"D33+G33","v":0},null,0,0]
[2.4,"Revenue from income-generating activities (if applicable)",0,0,null,0,0,{"$f":"D34+G34","v":0},null,0,0]
[2.5,"Other income, if applicable (e.g. VAT/Other Tax returns, income from disposal of assets etc.)",{"$f":"15970.48+34589.41+64813/2.6872","v":74679.04748734743},{"$f":"25968.19+(58200.42+42201.28)/2.7206+30084.34/2.533+32345.24/2.3934","v":88263.746978794326},"VAT refund",0,0,{"$f":"D35+G35","v":88263.746978794326},null,0,88263.746978794326]
[2.6,"Total Grant Income",{"$f":"SUM(C31:C35)","v":11848907.597487349},{"$f":"SUM(D31:D35)","v":88263.746978794326},null,{"$f":"SUM(F31:F35)","v":0},{"$f":"SUM(G31:G35)","v":0},{"$f":"SUM(H31:H35)","v":88263.746978794326},null,{"$f":"SUM(J31:J35)","v":0},{"$f":"SUM(K31:K35)","v":88263.746978794326}]
[null,"3. Grant Cash Outflows"]
[null,"Less:"]
[3.1,"Principal Recipient Expenditure (including payments and other advance payments)",3164903.2347427802,603247.17604558531,null,0,0,{"$f":"D39+G39","v":603247.17604558531},null,0,{"$f":"H39+J39","v":603247.17604558531}]
[3.2,"Disbursement to third parties by the Global Fund on behalf of the Principal Recipient ",{"$f":"C32","v":1021528.79},{"$f":"D32","v":0},null,{"$f":"F32","v":0},0,{"$f":"D40+G40","v":0},null,{"$f":"J32","v":0},{"$f":"H40+J40","v":0}]
[3.3,"Principal Recipient disbursement to sub-recipients",5290064.7737255953,1701767.0872921343,null,0,0,{"$f":"D41+G41","v":1701767.0872921343},null,0,{"$f":"H41+J41","v":1701767.0872921343}]
[3.4,"Bank charges on disbursements and payments",300,0,null,0,0,{"$f":"D42+G42","v":0},null,0,0]
[3.5,"Total Grant Cash Outflows",{"$f":"SUM(C39:C42)","v":9476796.7984683756},{"$f":"SUM(D39:D42)","v":2305014.2633377197},null,{"$f":"SUM(F39:F42)","v":0},{"$f":"SUM(G39:G42)","v":0},{"$f":"SUM(H39:H42)","v":2305014.2633377197},null,{"$f":"SUM(J39:J42)","v":0},{"$f":"SUM(K39:K42)","v":2305014.2633377197}]
[null,"4. Reconciling Adjustments"]
[4.0999999999999996,"Other reconciliation adjustments (including for prior periods)",0,0,null,0,0,{"$f":"D45+G45","v":0},null,0,{"$f":"H45+J45","v":0}]
[4.2,"Net exchange gains/losses on translation of balances",-20233.16,87736.680000000008,null,0,0,{"$f":"D46+G46","v":87736.680000000008},null,0,{"$f":"H46+J46","v":87736.680000000008}]
[4.3,"Ineligible transactions from previous periods for which justification was approved by the Global Fund",0,0,null,0,0,{"$f":"D47+G47","v":0},null,0,0]
[4.4000000000000004,"Reimbursement of ineligible transaction from previous periods",0,0,null,0,0,{"$f":"D48+G48","v":0},null,0,0]
[null,"5. Total Cash Balances: End of the reporting period"]
[5.0999999999999996,"Principal Recipient Cash Balance",0,{"$f":"(D28+D36-D43)+D45+D46+D48","v":222863.80287342222},null,null,{"$f":"(G36-G43)+G46+G45","v":0},{"$f":"(H28+H36-H43)+H45+H46-H47","v":222863.80287342222},null,{"$f":"J28+J36-J43+J46+J45","v":0},{"$f":"K28+K36-K43+K46+K45-K47","v":222863.80287342222}]
[5.2,"Sub-Recipient Cash Balance",0,{"$f":"'SR_Cash Reconciliation_2D'!H74","v":0},null,null,{"$f":"'SR_Cash Reconciliation_2D'!K74","v":0},{"$f":"'SR_Cash Reconciliation_2D'!L74","v":0},null,0,{"$f":"+H51+J51","v":0}]
[5.3,"Total Cash Balance",{"$f":"C50+C51","v":0},{"$f":"D50+D51","v":222863.80287342222},null,{"$f":"F50+F51","v":0},{"$f":"G50+G51","v":0},{"$f":"H50+H51","v":222863.80287342222},null,{"$f":"J50+J51","v":0},{"$f":"K50+K51","v":222863.80287342222}]
[null,"6. Commitments & Other Obligations"]
[6.1,"Unpaid invoices, accrued expenditure for severance pay, leave and other liabilities ",0,0,null,0,0,{"$f":"D54+G54","v":0},null,0,{"$f":"H54+J54","v":0}]
[6.2,"Open legal obligations (including signed contracts not yet invoiced) ",0,0,null,0,0,{"$f":"D55+G55","v":0},null,0,{"$f":"H55+J55","v":0}]
[6.3,"Tenders and/or procurement contracts initiated but not yet signed as contracts",0,0,null,0,0,{"$f":"D56+G56","v":0},null,0,{"$f":"H56+J56","v":0}]
[6.4,"Total Commitments & Other Obligations",{"$f":"SUM(C54:C56)","v":0},{"$f":"SUM(D54:D56)","v":0},null,{"$f":"SUM(F54:F56)","v":0},{"$f":"SUM(G54:G56)","v":0},{"$f":"SUM(H54:H56)","v":0},null,{"$f":"SUM(J54:J56)","v":0},{"$f":"SUM(K54:K56)","v":0}]
[]
[null,"B. Principal Recipient Bank Statement Balance & Cash In Transit in Grant Currency"]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
[null,null,null,"As At End of Current Reporting Period","Comments",null,"LFA Adjustments on Current Reporting Period","As verified by LFA","Comments","CT Adjustments","The Global Fund Validated Figures","Comments"]
[7.1,"Principal Recipient Cash Balance as per bank statements (For Information Only):",null,{"$f":"581295.64/2.6083","v":222863.79634244528},"The amount corresponds to GEL 581,295.64 ",null,0,{"$f":"D62+G62","v":222863.79634244528},null,0,{"$f":"H62+J62","v":222863.79634244528}]
[7.2,"Cash in Transit for the reporting period",null,0,null,null,0,{"$f":"D63+G63","v":0},null,0,{"$f":"H63+J63","v":0}]
[7.3,"Cash in Transit after the current reporting period",null,0,null,null,0,{"$f":"D64+G64","v":0},null,0,0]
[]
[null,"C. Principal Recipient Ineligible Transactions in Grant Currency "]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
[null,null,"Cumulative for Previous Periods","Current Reporting Period","Comments","Cumulative for Previous Periods as validated by Global Fund","LFA Adjustments on Current Reporting Period","As verified by LFA","Comments","CT Adjustments","The Global Fund Validated Figures","Comments"]
[8.1,"Ineligible transactions validated for the reporting period",0,0,null,0,{"$f":"G52","v":0},{"$f":"D69+G69","v":0},null,0,{"$f":"H69+J69","v":0}]
[8.1999999999999993,"Ineligible transactions from previous periods for which justification was approved by the Global Fund",{"$f":"C47","v":0},{"$f":"D47","v":0},null,{"$f":"F47","v":0},{"$f":"G47","v":0},{"$f":"D70+G70","v":0},null,{"$f":"J47","v":0},{"$f":"H70+J70","v":0}]
[8.3000000000000007,"Reimbursement of ineligible transactions from previous periods",{"$f":"C48","v":0},{"$f":"D48","v":0},null,{"$f":"F48","v":0},{"$f":"G48","v":0},{"$f":"D71+G71","v":0},null,{"$f":"J48","v":0},0]
[8.4,"Cumulative ineligible transactions for the implementation period",0,{"$f":"D69+C72","v":0},null,0,{"$f":"H69","v":0},{"$f":"F72+G72","v":0},null,0,{"$f":"H72+J72","v":0}]
[8.5,"Open ineligible transactions to be justified and/or reimbursed",{"$f":"C72-C70-C71","v":0},{"$f":"C73+D69-D70-D71","v":0},null,0,null,{"$f":"H72-F70-F71-H70-H71","v":0},null,0,{"$f":"K72-J70-J71-K70-K71","v":0}]

{"sheet":"SR_Cash Reconciliation_2D","index":12,"n_rows":76,"n_cols":16,"rows_kept":76,"cut":false,"hidden":true,"merged":[[21,13,21,15],[16,0,17,11],[19,0,19,15],[6,0,6,2],[7,0,7,2],[8,0,8,2],[11,0,11,2],[12,0,12,2],[8,3,8,6],[13,3,13,6],[13,0,13,2],[21,0,21,9],[21,10,21,12]]}
["Ongoing Progress Update and Disbursement Request "]
[]
["Grant Name:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["(Disease) Component",{"$f":"#REF!","v":{"$error":"#REF!"}}]
[]
["PROGRESS UPDATE "]
["Progress Update - Reporting Period:",null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Progress Update - Number:"]
[]
["DISBURSEMENT REQUEST "]
["Disbursement Request  - Disbursement Period:",null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:"]
[]
[]
["Section 2: Financial Information"]
[]
[]
["D. Principal Recipient Reconciliation of funds provided to Sub-Recipients for the Current Implementation Period"]
[]
["Principal Recipient",null,null,null,null,null,null,null,null,null,"For Local Fund Agent Use Only ",null,null,"For the Global Fund Use Only"]
["(1) \nSub-Recipient Name","(2) \n Cumulative Sub-Recipient expenses for prior periods at Principal Recipient level","(3) \nSub-Recipient Open Advances at Principal Recipient Level","(4) \nDisbursements made by Principal Recipient during the Reporting Period","(5) \nOther Income* during the Reporting Period ","(6) \nExpenditure validated by Principal Recipient during the Reporting Period","(7) \nSub-Recipient Closing Balance at Principal Recipient Level","(8) \nActual Sub-Recipient Cash Balance (if applicable)"," (9)\nVariances on Sub-Recipient Balances","Comments","LFA Adjustments","As verified by LFA","Comments","Country Team Adjustments (incl. External Audit adjustments)","The Global Fund Validated Figures","Comments"]
[null,0,0,0,0,0,{"$f":"+C24+D24+E24-F24","v":0},0,{"$f":"+H24-G24","v":0},null,null,{"$f":"H24+K24","v":0},null,null,{"$f":"L24+N24","v":0}]
[null,0,0,0,0,0,{"$f":"+C25+D25+E25-F25","v":0},0,0,null,null,{"$f":"H25+K25","v":0},null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H38-G38","v":0},null,null,{"$f":"H38+K38","v":0},null,null,{"$f":"L38+N38","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,{"$f":"+C45+D45+E45-F45","v":0},0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H58-G58","v":0},null,null,{"$f":"H58+K58","v":0},null,null,{"$f":"L58+N58","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H71-G71","v":0},null,null,{"$f":"H71+K71","v":0},null,null,{"$f":"L71+N71","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
["Total for the Reporting Period",{"$f":"SUM(B24:B73)","v":0},0,0,0,0,0,0,0,null,null,0,null,null,0]
[]
["* Includes interest income, income generating activites etc."]

{"sheet":"Budget Variance_2E","index":13,"n_rows":43,"n_cols":14,"rows_kept":43,"cut":false,"hidden":false,"merged":[[36,1,36,2],[35,1,35,2],[39,1,39,2],[40,1,40,2],[42,1,42,2],[41,1,41,2],[37,1,37,2],[6,1,6,3],[7,1,7,3],[8,1,8,3],[8,5,8,8],[11,1,11,3],[12,1,12,3],[19,1,19,2],[20,1,20,2],[19,7,19,8],[20,7,20,8],[14,0,14,13],[16,0,16,13],[21,1,21,2],[34,1,34,2],[22,1,22,2],[26,1,26,2],[27,1,27,2],[24,1,24,2],[31,0,31,11],[25,1,25,2],[39,7,39,8],[41,7,41,8],[42,7,42,8],[18,3,18,13],[33,3,33,13],[27,7,27,8],[34,7,34,8],[35,7,35,8],[36,7,36,8],[37,7,37,8],[21,7,21,8],[22,7,22,8],[24,7,24,8],[25,7,25,8],[26,7,26,8]]}
["Ongoing Progress Update and Disbursement Request"]
[]
[null,"Grant Name:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"(Disease) Component",{"$f":"#REF!","v":{"$error":"#REF!"}}]
[]
[null,"PROGRESS UPDATE "]
[null,"Progress Update - Reporting Period:",null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Period Covered:",null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Number:"]
[]
[null,"DISBURSEMENT REQUEST "]
[null,"Disbursement Request  - Disbursement Period:",null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Disbursement Request  - Period Covered:",null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[]
["Section 2: Financial Information"]
[]
["E. Total Principal Recipient Budget Variance and Funding Absorption Analysis"]
[]
[null,null,null,"Principal Recipient"]
[null,null,null,"Budget for Reporting Period","Actual Grant Cash Out-Flow - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","Reasons for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Cash-Outflow - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","Reasons for Variance"]
[null,"1. Total Principal Recipient cash outflow vs. budget",null,{"$f":"SUM(D22:D23)","v":2852884.0446605105},{"$f":"SUM(E22:E23)","v":2305014.2633377197},{"$f":"IF(D21=\"\",IF(E21=\"\",\"\",D21-E21),D21-E21)","v":547869.78132279078},{"$f":"E21/D21","v":0.8079593237067626},null,null,{"$f":"SUM(J22:J23)","v":17581514.506065555},{"$f":"SUM(K22:K23)","v":11781811.061806096},{"$f":"IF(J21=\"\",IF(K21=\"\",\"\",J21-K21),J21-K21)","v":5799703.4442594592},{"$f":"K21/J21","v":0.67012492340983576}]
[null,"    1a. Principal Recipient's total expenditures (including any direct-disbursements to third-parties)",null,1380699.7859671214,{"$f":"'PR Cash Reconciliation_2A,B,C'!D39+'PR Cash Reconciliation_2A,B,C'!D40+'PR Cash Reconciliation_2A,B,C'!D42","v":603247.17604558531},{"$f":"IF(D22=\"\",IF(E22=\"\",0,D22-E22),D22-E22)","v":777452.60992153606},{"$f":"E22/D22","v":0.43691407949559169},"Net variance of EUR 777,453 consists of Positive variance of EUR 1,026,137 and negative variance of EUR 248,684\nPositive variance EUR 1,026,137 consists of the following Savings:\nEUR 12,887 - Actual cost and Quantity (to match the county’s quota for the drug) for Methadone was less than budgeted.\nEUR 798,345 – Commitment for PFSCM order for ARVs placed in 2014 and new order placed in 2015 is transferred to NFM budget. \nEUR 106,688 – Part of IDA commitment was reimbursed by the GF by the end of 2015 and remaining amount was moved to NFM budget.\nEUR 91,604 – Actual cost for HPHE was less than budgeted, also procurement of Saliva Tests was cancelled due to failure of supplier to deliver the tests. \nEUR 338- Actual printing cost was less than budgeted.\nEUR 16,275 – Actual cost for fuel provided to SRs was less than budgeted\n\nNegative Variance EUR 248,684 consists of the following:\nEUR 415– Actual Cost of MPP provided to TG was slightly greater than budgeted. \nEUR 247,740– Actual cost of HPHE was greater than budgeted due to: some activities budgeted in the previous reporting period and increased Quantities of ART monitoring tests and supplies based on the SR’s renewed request. \nEUR 529 – Project management cost (Consultant fee and PR fuel cost) - committed in the Dec 2015 and payment carried out in January 2016.\n",null,10813852.056482488,{"$f":"'PR Cash Reconciliation_2A,B,C'!D39+'PR Cash Reconciliation_2A,B,C'!D40+'PR Cash Reconciliation_2A,B,C'!D42+'PR Cash Reconciliation_2A,B,C'!C39+'PR Cash Reconciliation_2A,B,C'!C40+'PR Cash Reconciliation_2A,B,C'!C42","v":4789979.2007883657},{"$f":"IF(J22=\"\",IF(K22=\"\",0,J22-K22),J22-K22)","v":6023872.8556941226},{"$f":"K22/J22","v":0.44294846792516984},"Net cumulative variance of EUR 6,023,873 consists of Positive variance of EUR 6,404,580 and negative variance of EUR 380,707\nTotal Saving EUR 6,404,580 include: \nEUR 74,081 – Actual cost and quantities for SRs fuel was less than budgeted\nEUR 4,635,799– Savings from  MPP &PSM (ARVs, interferon, methadone, STI medicines, quality control of ARVs) is derived from cancelled activities, actual consumption rates, lower unit prices, including lower unit prices of ARVs offered by PPM and also regimens were simplified. Considerably lower price procurement of interferon through the local tender. Also Procurement of pegylated interferon and ribavirin budgeted at 340,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.  Procurement of methadone was conducted at much lower price than budgeted also (4 EUR vs. 9 EUR). Commitment for PFSCM order for ARVs placed in 2014 and new order placed in 2015 is transferred to NFM budget.\nEUR 1,243,769 – Saving from HPHE procurement (lab supplies, disinfectants, tests systems, Flow cytometer; syringes, condoms) is derived from low unit prices as a result of tenders; revision of the q-ties based on the consumption data and some cancelled activities. In addition instead of one flow cytometer with high technical characteristic, in agreement with GF and AIDS Center, four field equipment – BD Presto, were procured for CD4 count measurement, which has resulted in substantial saving. \nEUR 128,036 - Procurement of office equipment/furniture and printing of materials through tenders resulted in saving. Database development cost budgeted in GHRN is moved to NFM period, the amount is included in the savings.\nEUR 77,978 - Procurement of Vehicles for SRs was cancelled in agreement with GF.\nEUR 244,917 - Saving in Project management costs including International PSM consultant's fee, in HR (HIV M&E specialist , finance specialist, logistics specialist ) ; saving related to renovation of office; procuring furniture (It was handed over from previous PR) ; fuel; tender announcement costs, Technical assistance; late start of media campaign, Audit fee. The FX rate had also impact on savings.\nNegative Variance EUR 380,707 include:\nEUR 370,128 – Overspending in procurement of HPHE including cost of additional 4 mobile ambulatories approved by GF and tests-lab supplies provided to Aids Center\nEUR 1,396 – Actual cost of office equipment/furniture was slightly greater than budgeted.\nEUR 7,580 – Actual need of STI medicines was increased based on the current consumption. \nEUR 1,603– Actual Cost of Printing info materials for TG was greater than budgeted.\n"]
[null,"    1b. Disbursements to sub-recipients",null,1472184.2586933891,{"$f":"'PR Cash Reconciliation_2A,B,C'!D41","v":1701767.0872921343},{"$f":"IF(D23=\"\",IF(E23=\"\",0,D23-E23),D23-E23)","v":-229582.82859874517},1.1559470747245371,"The reporting period relates to activities performed by the SRs for January 2016-June 2016. Within the current period SRs received payment for December 2015 –June 2016, thus all the activities performed by the SRs within the extension period and commitment for December 2015 were reimbursed. All Advance payments were subtracted as their contract service period was until June 30, 2016. Total reimbursement for services equals to EUR 1,701,767 (TG- EUR 250,292; HAPS –EUR 58,257; MHDAC –EUR 345,020; Aids Center EUR 357,134; CIF –EUR 11,526; GHRN- EUR 630,347; Objective 1 - EUR 49,191)\nAs mentioned above the negative variance is derived from differences between the budget period (January 2016-June 2016) and period for which SRs were reimbursed.\n",null,6767662.4495830666,{"$f":"'PR Cash Reconciliation_2A,B,C'!D41+'PR Cash Reconciliation_2A,B,C'!C41","v":6991831.8610177301},{"$f":"IF(J23=\"\",IF(K23=\"\",0,J23-K23),J23-K23)","v":-224169.41143466346},1.0331236099768057,"The cumulative period relates to activities performed by the SRs for April 2014-June 2016 period.\nIn order to allow spending of the large amounts saved during the initial program implementation periods TGF secretariat made a decision to extend the program implementation at no additional cost (within the approved program budget) through June, 2016. Savings from PR and SRs was distributed to SRs thus leading to negative Variance compared to originally approved budget. Main savings in SRs implementation was derived from the following: (a) savings in program implementation (less amounts were spent per activities by SRs for trainings, meetings, M&E visits, for technical service of cars and equipment; less amounts were spent for PDI incentives and for case management and other activities; AIDS Center also procured the international laboratory QC service at a low price). b) differences in the budgeted amounts and the contractual amounts resulted from the service procurement through the tenders; c) late opening of a new OST Center as well as procurement of mobile ambulatories and savings in related expenditures by the GHRN and Narcology Center for HR, T, ME, PA and OVE categories; National AIDS Center had postponed hiring of a new personnel for its administrative and PSM staff; d) canceled activities - Opening of a new ART Treatment Center was canceled; Drug Addiction Prevention Day Conference was canceled due to technical reasons, participation in international conferences were included into ME category, while it was initially budgeted in the OVE in approved GF budget; HAPS had canceled AIDS Victims Day Commemoration Event. ).\nWithin this period SRs received payment for April 2014-June 2016, thus all the activities performed by the Srs within the current grant were reimbursed. Advance payments were subtracted as their contract service period was until June 30, 2016. Total reimbursement for  services equal EUR 6,991,832 ( TG- EUR 1,009,907 ; HAPS –EUR 269,246; MHDAC –EUR 1,301,852; Aids Center EUR 1,360,804; CIF –EUR 335,956 , GHRN- EUR 2,530,242; Objective 1 - EUR 175, 727; BCG Research– EUR 8096 - Stigma Survey among healthcare workers was budgeted under SR HAPS, but through tender another organization was identified as winner). \n"]
[]
[null,"Procurement data for analytical purposes",null,"Budget for Reporting Period","Actual Grant Cash Out-Flow - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","Reasons for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Cash-Outflow - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","Reasons for Variance"]
[null,"2. Total pharmaceutical & non-pharmaceutical incl. equipment expenditures vs.    budget",null,{"$f":"D27+D28","v":1264517.7646596127},{"$f":"E27+E28","v":574770.6509780545},{"$f":"IF(D26=\"\",IF(E26=\"\",\"\",D26-E26),D26-E26)","v":689747.11368155817},{"$f":"E26/D26","v":0.45453742686863186},null,null,{"$f":"J27+J28","v":8705408.0641756002},{"$f":"K27+K28","v":4163229.7402219521},{"$f":"IF(J26=\"\",IF(K26=\"\",\"\",J26-K26),J26-K26)","v":4542178.3239536481},{"$f":"K26/J26","v":0.47823487532473402}]
[null,"    2a.  Health Products- Pharmaceutical Products",null,776937.43153715832,35010.123323565655,{"$f":"IF(D27=\"\",IF(E27=\"\",0,D27-E27),D27-E27)","v":741927.30821359262},{"$f":"E27/D27","v":4.5061702400280401E-2},"The Budget relates to the Medicines and Pharmaceuticals procured locally and through international PSM Agencies to be paid directly by The Global Fund. \nThe variance EUR 741,927 consists of Positive Variance EUR 742,876 and Negative Variance EUR 949\nTotal Saving EUR 742,876 –\nEUR 12,887- Actual cost and Quantity for Methadone was less than budgeted (limited by the county’s quota for drug) ; Commitment for PFSCM order for ARVs placed in 2014 and new order placed in 2015 was transferred to NFM budget.\nOverspending EUR 415 - Actual Cost of MPP provided to TG was slightly greater than budgeted. \nEUR 534 – Procurement of essential drugs performed by Aids Center for palliative care- actual cost is greater than budgeted \n",null,{"$f":"5140297.1056706","v":5140297.1056706002},1438630.7797325263,{"$f":"IF(J27=\"\",IF(K27=\"\",0,J27-K27),J27-K27)","v":3701666.3259380739},{"$f":"K27/J27","v":0.27987307934895006},"The Budget relates to the Medicines and Pharmaceuticals procured locally and through international PSM Agencies to be paid directly by The Global Fund. \nThe variance EUR 3,701,666 consists of Positive Variance EUR 3,710,429 and Negative variance EUR 8,763.\nDriver of saving is available stock at SR: Cheaper unit prices were gained both from the local procurement and through PPM (ARVs). Saving was made due to simplification of ART regimens based on WHO recommendations. \nSaving EUR 3,710,429- \nEUR 181,448 – Volume of Methadone was reduced according to the quota approved for the country and more precise need estimation conducted jointly by Narcology Center and MoH. The actual cost of methadone was less also (4 EUR vs. 9 EUR). \nEUR 15,529 – Actual unit price for vaccines was lower than budgeted.\nEUR 3,139,117– Saving in ARVs resulted from actual PQ signed with PPM and simplification of regimens. Commitment for PFSCM order for ARVs placed in 2014 and new order placed in 2015 is transferred to NFM budget.\nEUR 371,996 - Considerably lower price procurement of interferon through the local tender. Also Procurement of the last portion of the pegylated interferon and ribavirin budgeted at 342,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.\nOverspending EUR 2,339 – Actual Cost of some STI medicines provided to TG was slightly less than budgeted. \nOverspending EUR 8,764 – \nEUR 7,580 – procurement of STI essential drugs – actual cost is greater than budgeted due to updated quantification of the needs by the SR\nEUR 1,184 – procurement of essential drugs for palliative care performed by Aids Center- actual cost is greater than budgeted \n"]
[null,"    2b.  Health Products - Non-Pharmaceuticals & Equipment",null,487580.33312245429,539760.5276544888,{"$f":"IF(D28=\"\",IF(E28=\"\",0,D28-E28),D28-E28)","v":-52180.194532034511},1.1070186613103807,"The Budget relates to the Health product/equipment procured locally and directly by the Global fund. \nThe Negative variance EUR 52,180 consists of Positive Variance EUR 198,293 and Negative Variance EUR 250,474\nTotal Saving EUR 198,293 – \nEUR 106,688 - Part of IDA commitment was reimbursed by the GF by the end of 2015 and remaining amount was moved to NFM budget.\nEUR 12,121 – Actual cost of procurement syringes and needles (other than 1 ml) were less than budgeted.\nEUR 43,283 – Actual cost of procurement lab supplies for Aids Center was less than budgeted.\nEUR 15,787 – Actual cost of procurement Condoms and lubricants was less than budgeted\nEUR 9,256 – Actual cost of procurement disinfectants and lab supplies were less than budgeted.\nEUR 5,613 – Actual cost of procurement tests (rapid tests, tests for STI) were less than budgeted.\nEUR 5,545 – Procurement of Saliva Tests was cancelled (supplier couldn’t deliver the product).\nThe Negative variance EUR 250,474 is related to the following:\nEIR 125,468- Commitment (procurement of Mobile ambulatories) from the previous reporting period and payment carried out in current period\nEUR 3665 – Actual cost or Quantity for 1 ml syringes was greater than budgeted\nEUR 13,480- Actual cost for condoms procured locally was greater than budgeted\nEUR 3,115- Actual cost for some lab supplies and tests was greater than budgeted\nEUR 2,733 - Procurement of tests by CIF committed in Dec 2015 and reimbursed in Jan 2016.\nEUR 102,013 – Actual cost of Procurement of tests for Aids Center was greater than budgeted.\n",null,{"$f":"3565110.958505","v":3565110.958505},2724598.9604894258,{"$f":"IF(J28=\"\",IF(K28=\"\",0,J28-K28),J28-K28)","v":840511.99801557418},0.76423959652351581,"The Budget relates to the Health product/equipment procured locally and directly by the Global fund. \nThe variance EUR 840,512 consists of Positive Variance EUR 1,214,909 and Negative variance EUR 374,397\nLess amounts spent on the procurement (lab supplies, disinfectants, tests systems, Flow cytometer; syringes, condoms) is a result of the low unit prices offered during the tenders; revision of the q-ties based on the consumption data and some cancelled activities.\nSaving EUR 1,214,909 -   \nEUR 63,846 –Instead of one flow cytometer with high technical characteristic, in agreement with GF and AIDS Center, four field equipment – BD Presto, were procured for CD4 count measurement, which has resulted in substantial saving.\nEUR 311,304 – Procurement of syringes through IDA and local tenders for syringes, needles and vain sets resulted in low unit costs. Also quantities were recalculated based on consumption data and stocks at SR level.\nEUR 50,195 – Procurement through IDA and local tenders resulted in lower than budgeted cost for condoms, also quantities were recalculated based on consumption data and stocks at SR level.\nEUR 166,718– Actual costs for procurement of disinfectant and lab supplies/equipment through tenders were less than budgeted also.  \nEUR 16,897 – Based on stocks of Naloxon available at SR level, the less q-ties were procured and cost was lower also. \nEUR 84,545– Actual cost of Procurement of tests (rapid and express tests, tests for STI) was lower than budgeted\nEUR 521,403 – Actual cost for tests and lab supplies for AIDS Center were less than budgeted through local tenders\nOverspending EUR 374,397 -  \nEUR 218,163 – Procurement of tests and lab supplies (HCV real time PCR, Four and two color Flow cytometer) for Aids Center was greater than budgeted.\nEUR 17,935 – Actual cost some of rapid tests was greater than budgeted, including EUR 5,411 – Additional request from TG on procurement of micropipettes approved by GF; \nEUR 9,444 – Actual Q of condoms procured for GHRN was greater than budgeted.\nEUR 3,670 – Actual cost of disinfectants and minor lab supplies was slightly greater than budgeted; \nEUR 120,917 – Cost of procurement of additional 4 mobile ambulatories approved by GF.\nEUR 4,270 -Actual cost of tests under objective 4 was greater than budgeted. (Originally cost was budgeted under PR and was transferred to CIF)\n"]
[]
[]
["For LFA Use Only"]
["E. Total Principal Recipient Budget Variance and Absorption Analysis"]
[]
[null,null,null,"Local Fund Agent (LFA)"]
[null,null,null,"Budget for Reporting Period","Actual Grant Expenditure - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","LFA comments on thePrincipal Recipient's explanation of variances ",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Expenditure - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances "]
[null,"1. Total Principal Recipient cash outflow vs. budget",null,{"$f":"SUM(D37:D38)","v":0},{"$f":"SUM(E37:E38)","v":2305014.2633377197},{"$f":"IF(D36=\"\",IF(E36=\"\",\"\",D36-E36),D36-E36)","v":-2305014.2633377197},{"$f":"E36/D36","v":{"$error":"#DIV/0!"}},null,null,{"$f":"SUM(J37:J38)","v":0},2305014.2633377197,{"$f":"IF(J36=\"\",IF(K36=\"\",\"\",J36-K36),J36-K36)","v":-2305014.2633377197},{"$f":"K36/J36","v":{"$error":"#DIV/0!"}}]
[null,"    1a. Principal Recipient's total expenditures (including any direct-disbursements to third-parties)",null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!H39+'PR Cash Reconciliation_2A,B,C'!H40+'PR Cash Reconciliation_2A,B,C'!H42","v":603247.17604558531},{"$f":"IF(D37=\"\",IF(E37=\"\",0,D37-E37),D37-E37)","v":-603247.17604558531},{"$error":"#DIV/0!"},null,null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!F39+'PR Cash Reconciliation_2A,B,C'!F40+'PR Cash Reconciliation_2A,B,C'!F42+E37","v":603247.17604558531},{"$f":"IF(J37=\"\",IF(K37=\"\",0,J37-K37),J37-K37)","v":-603247.17604558531},{"$f":"K37/J37","v":{"$error":"#DIV/0!"}}]
[null,"    1b. Disbursements to sub-recipients",null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!H41","v":1701767.0872921343},{"$f":"IF(D38=\"\",IF(E38=\"\",0,D38-E38),D38-E38)","v":-1701767.0872921343},{"$error":"#DIV/0!"},null,null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!F41+E38","v":1701767.0872921343},{"$f":"IF(J38=\"\",IF(K38=\"\",0,J38-K38),J38-K38)","v":-1701767.0872921343},{"$error":"#DIV/0!"}]
[]
[null,"Procurement data for analytical purposes",null,"Budget for Reporting Period","Actual Grant Expenditure - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances ",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Expenditure - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances "]
[null,"2. Total pharmaceutical & non-pharmaceutical incl. equipment expenditures vs. budget",null,{"$f":"D42+D43","v":0},{"$f":"E42+E43","v":0},{"$f":"IF(D41=\"\",IF(E41=\"\",\"\",D41-E41),D41-E41)","v":0},{"$f":"E41/D41","v":{"$error":"#DIV/0!"}},null,null,{"$f":"J42+J43","v":0},{"$f":"K42+K43","v":0},{"$f":"IF(J41=\"\",IF(K41=\"\",\"\",J41-K41),J41-K41)","v":0},{"$f":"K41/J41","v":{"$error":"#DIV/0!"}}]
[null,"    2a.  Health Products- Pharmaceutical Products",null,0,0,{"$f":"IF(D42=\"\",IF(E42=\"\",0,D42-E42),D42-E42)","v":0},{"$error":"#DIV/0!"},null,null,0,0,{"$f":"IF(J42=\"\",IF(K42=\"\",0,J42-K42),J42-K42)","v":0},{"$f":"K42/J42","v":{"$error":"#DIV/0!"}}]
[null,"    2b.  Health Products - Non-Pharmaceuticals & Equipment",null,0,0,{"$f":"IF(D43=\"\",IF(E43=\"\",0,D43-E43),D43-E43)","v":0},{"$error":"#DIV/0!"},null,null,0,0,{"$f":"IF(J43=\"\",IF(K43=\"\",0,J43-K43),J43-K43)","v":0},{"$error":"#DIV/0!"}]

{"sheet":"Procurement_3","index":14,"n_rows":63,"n_cols":23,"rows_kept":63,"cut":false,"hidden":false,"merged":[[62,12,62,22],[63,12,63,22],[56,12,56,13],[56,16,56,22],[57,12,57,13],[58,12,58,13],[59,12,59,13],[59,16,59,22],[57,16,57,22],[58,16,58,22],[53,12,53,13],[53,16,53,22],[54,12,54,13],[54,16,54,22],[55,12,55,13],[55,16,55,22],[50,12,50,22],[51,12,51,13],[51,16,51,22],[52,12,52,13],[52,16,52,22],[45,12,45,13],[45,17,45,18],[47,12,47,13],[47,17,47,18],[48,12,48,13],[48,17,48,18],[46,12,46,13],[46,17,46,18],[42,12,42,13],[42,17,42,18],[43,12,43,13],[43,17,43,18],[44,12,44,13],[44,17,44,18],[38,12,38,22],[39,12,39,13],[40,12,40,13],[40,17,40,18],[41,12,41,13],[41,17,41,18],[25,12,25,22],[26,12,26,22],[31,12,31,22],[34,16,34,22],[35,16,35,22],[35,12,35,13],[22,12,22,13],[23,12,23,13],[23,16,23,22],[24,12,24,13],[24,16,24,17],[22,16,22,22],[19,12,19,13],[19,16,19,22],[20,12,20,13],[20,16,20,22],[21,12,21,13],[21,16,21,22],[16,12,16,13],[16,16,16,22],[17,12,17,13],[17,16,17,22],[18,12,18,13],[18,16,18,22],[8,12,8,21],[11,18,11,22],[12,18,12,22],[14,12,14,22],[15,12,15,13],[15,16,15,22],[12,12,12,16],[5,14,5,20],[3,17,3,19],[4,17,4,19],[0,12,0,22],[2,12,2,13],[2,14,2,20],[3,15,3,16],[4,15,4,16]]}
[null,null,null,null,null,null,null,null,null,null,null,null,"Ongoing Progress Review and Disbursement Request"]
[null,null,null,null,null,null,null,null,null,null,null,null,"PROGRESS UPDATE PERIOD"]
[null,null,null,null,null,null,null,null,null,null,null,null,"Grant Name:",null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,null,null,null,null,null,null,null,null,null,null,null,"Progress Update - Reporting Period:",null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},null,"Number:",null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,null,null,null,null,null,null,null,null,null,null,"Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},null,"End Date:",null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,null,null,null,null,null,null,null,null,null,null,null,"Progress Update - Number:"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"Section 3A:  PR - Procurement and Supply Management"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Comments"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1.  Have you updated the Price Quality Reporting (PQR) with the required information on the pharmaceuticals and health products received during the period covered by this PU/DR’ (if applicable)?  If health products procurement information has not been entered into the PQR, please explain why.\n\n!  For further guidance on PQR data entry, please refer to the guidelines.",null,null,null,null,"Select","Prices  and  other  required details  for following  items procured  in   the covered period  was  uploaded to the PQR system:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \n 1.HIV RDT & EIA                                                                                                                                                                                                                                                                                   a) InTec Products Incd( Xiamen, PR China) - Advanced Quality HIV Rapid Test Intec [ITP02121-TC40] 1unit/ Test;   - PO #GF-H-T/ET/G-282                                                                                                                                                                  2.HIV virological testing equipment:\na) Roche  Molecular Systems, Inc. USA - COBAS  Taq Man HIV-1 Test.v2[05923468190];  PO- # GF-H/ET/G-311                               \n3.HIV virological testing consumables/test kits:                                                                                                                                                                                                         a)Nucli SENS EasyMag Magnetic Silica 384 extractions  [280133];  b)Nucli SENS EasyQ HIiv-1v2.0( Automated) 48s/4L   [280130]    - PO# GF-H/ET/G-290                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  4.HIV CD4 testing consumables /test kits: \n a)BD FACSPresto Cartridge Kit, 100s [655495] 1 unit / test-PO#GF-H/ET/G-297                                                                                                                                                                  b) BD FACS, Multi Test CD3/CD8/CD45/CD4 with trucount tubes 50 tests [342447]; BD Callibrite 3 Beads 25 test[340486];BDCalibrite APC Beads for 25tests [340487]-           PO# GF-H/ET/G-295\n4.Male latex condoms procured both through local procurement:                                                                                                                                                                                                a)R&S Consumber Goods ( Germany) PO # GF -H/ET/G-300                                                                                                                                                                                                                                                                                                         \n  5. ARVs procured and imported through  PPM   mechanism in q1 -q2  2016  covered by PQ-16914 and  PE-2093  are not uploaded yet by PFSCM  team.                                                     "]
[]
[null,null,null,null,null,null,null,null,null,null,null,null," 2. Based on the most up-to-date stock situation, are there any risks of stock-outs or expiries for the key pharmaceuticals & health products, listed below, at the central level in the next period of implementation?  If yes, please comment."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Key Pharmaceuticals & Health Products",null,"Risk of Stock-Out","Risk of Expiry","Comment (if yes, please provide information on the specific items that are at risk of stock-out or expiry and the mitigation measures in place or to be implemented)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. In-Vitro Diagnostic Products",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,"Select","Yes","The file for expired ARVs with justification and comments is included in the PUDR package. The ARVs procured during the NCDC PR-ship is included only"]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Lab supplies (e.g. CD4, Viral Load, Cartridges…)",null,"Select","Yes","The lab tests information is provided in separate file included in the PUDR package. "]
[null,null,null,null,null,null,null,null,null,null,null,null,"8. Other (Please specify in the \"Comment\" column)",null,"Select","Select"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"3.  Comment on additional issues related to the procurement and supply management of pharmaceuticals and health products."]
[null,null,null,null,null,null,null,null,null,null,null,null,"With the PR's request National AIDS Center has destoried the expired medicines and reagents procured during the previous PR and some that were expired during the NCDC management of the GF HIV grant. "]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"Section 3B: LFA-Verified Procurement and Supply Management Information"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"PR's response","LFA's response","LFA Comments/Analysis "]
[null,null,null,null,null,null,null,null,null,null,null,null,"1a.  Has the PR updated the Price Quality Reporting (PQR) with the required information on the pharmaceuticals and health products received during the period covered by this PU/DR’ (if applicable)?  (If health products procurement information has not been entered into the PQR, please explain why in comments box)    ",null,{"$f":"R13","v":"Select"},"Select"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"1b.  Value of Pharmaceuticals and Health Products in the PQR "]
[null,null,null,null,null,null,null,null,null,null,null,null,"(!) This table is included in the PU/DR form with the aim to improve completeness of information in the PQR system and not for comparing PQR amounts vis-à-vis expenditure per se. NB: PQR and expenditure amounts on health products may not be equal due to a timelag between payments and delivery of pharmaceuticals/health products.\n(!)  For further guidance on PQR data entry, please refer to the guidelines."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Reporting Currency"]
[null,null,null,null,null,null,null,null,null,null,null,null,"PQR Product Categories",null,"Value of  products received during reporting period","Value of products entered by the PR and verified as correct by the LFA in the PQR during reporting period","Variance","Reason for Variance",null,"Cumulative value of  products received since the start of the grant","Cumulative value of products verified as correct by the LFA in the PQR since the start of the grant","Variance","Reason for Variance"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,null,null,{"$f":"IF(O42=\"\",IF(P42=\"\",\"\",O42-P42),O42-P42)","v":""},null,null,null,null,{"$f":"IF(T42=\"\",IF(U42=\"\",\"\",T42-U42),T42-U42)","v":""}]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. In-Vitro Diagnostic Products",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Indoor Residual Spraying (IRS)",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"Total",null,{"$f":"SUM(O42:O48)","v":0},{"$f":"SUM(P42:P48)","v":0},{"$f":"SUM(Q42:Q48)","v":0},null,null,{"$f":"SUM(T42:T48)","v":0},{"$f":"SUM(U42:U48)","v":0},{"$f":"SUM(V42:V48)","v":0}]
[]
[null,null,null,null,null,null,null,null,null,null,null,null," 2. Based on best information available to the LFA, are there any risks of drug stock-out or expiries at the central level in the next period of implementation?  (If yes, please explain in comments box)\n! This section should be completed by the LFA based on best information on stock at the central level available to the LFA and should not require dedicated visits for on-site checks of stocks."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Key Pharmaceuticals & Health Products",null,"Risk of Stock-Out","Risk of Expiry","Comment (if yes, please provide information on the specific items that are at risk of stock-out or expiry and the mitigation measures in place or to be implemented)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. In-Vitro Diagnostic Products",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Lab supplies (e.g. CD4, Viral Load, Cartridges…)",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"8. Other (Please specify in the \"Comment\" column)",null,"Select","Select"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. LFA analysis of issues related to the procurement and supply management of pharmaceuticals and health products"]

{"sheet":"Grant Management_4","index":15,"n_rows":104,"n_cols":29,"rows_kept":104,"cut":false,"hidden":false,"merged":[[13,7,13,11],[58,7,58,11],[102,24,102,27],[103,24,103,27],[100,23,100,32],[101,28,101,32],[102,28,102,32],[103,28,103,32],[103,15,103,18],[66,24,66,32],[67,24,67,32],[68,24,68,32],[69,24,69,32],[70,24,70,32],[71,24,71,32],[88,24,88,32],[101,24,101,27],[88,14,88,22],[90,14,90,22],[91,14,91,22],[92,14,92,22],[93,14,93,22],[94,14,94,22],[102,15,102,18],[57,24,57,32],[58,24,58,32],[59,24,59,32],[60,24,60,32],[61,24,61,32],[62,24,62,32],[63,24,63,32],[64,24,64,32],[65,24,65,32],[11,23,11,32],[12,24,12,32],[13,24,13,32],[14,24,14,32],[15,24,15,32],[16,24,16,32],[17,24,17,32],[18,24,18,32],[19,24,19,32],[20,24,20,32],[21,24,21,32],[22,24,22,32],[23,24,23,32],[24,24,24,32],[25,24,25,32],[26,24,26,32],[43,24,43,32],[56,23,56,32],[102,13,102,14],[103,13,103,14],[103,1,103,4],[102,1,102,4],[101,1,101,4],[95,5,95,13],[101,7,101,12],[102,7,102,12],[103,7,103,12],[100,13,100,22],[101,13,101,14],[101,19,101,22],[102,19,102,22],[101,15,101,18],[91,1,91,4],[91,5,91,13],[68,14,68,22],[90,1,90,4],[90,5,90,13],[50,7,50,13],[51,1,51,5],[98,1,98,13],[52,1,52,5],[54,1,54,13],[59,1,59,5],[95,1,95,4],[52,7,52,13],[94,1,94,4],[94,5,94,13],[93,1,93,4],[93,5,93,13],[89,1,89,4],[89,5,89,13],[95,14,95,22],[89,14,89,22],[68,1,68,5],[69,1,69,5],[70,1,70,5],[71,1,71,5],[57,1,57,5],[58,1,58,5],[56,13,56,22],[60,14,60,22],[65,14,65,22],[66,14,66,22],[67,14,67,22],[62,14,62,22],[63,14,63,22],[64,1,64,5],[64,7,64,12],[63,7,63,12],[69,14,69,22],[70,14,70,22],[71,14,71,22],[10,1,10,13],[26,1,26,5],[43,1,43,5],[12,7,12,12],[15,7,15,12],[24,7,24,12],[25,7,25,12],[26,7,26,12],[43,7,43,12],[11,1,11,12],[11,13,11,22],[16,1,16,5],[16,7,16,12],[16,14,16,22],[20,1,20,5],[23,14,23,22],[21,14,21,22],[14,14,14,22],[17,1,17,5],[17,7,17,12],[17,14,17,22],[18,14,18,22],[19,1,19,5],[19,7,19,12],[0,1,0,19],[9,1,9,13],[103,19,103,22],[55,1,55,22],[12,14,12,22],[13,14,13,22],[15,14,15,22],[24,14,24,22],[26,14,26,22],[25,14,25,22],[43,14,43,22],[49,1,49,22],[13,1,13,5],[24,1,24,5],[25,1,25,5],[15,1,15,5],[44,1,44,5],[45,1,45,5],[2,1,2,3],[2,4,2,7],[5,4,5,7],[12,1,12,5],[14,1,14,5],[14,7,14,12],[19,14,19,22],[18,1,18,5],[21,1,21,5],[18,7,18,12],[21,7,21,12],[20,7,20,12],[20,14,20,22],[22,1,22,5],[22,7,22,12],[22,14,22,22],[51,14,51,20],[52,14,52,20],[57,14,57,22],[58,14,58,22],[59,14,59,22],[61,14,61,22],[45,7,45,13],[46,1,46,5],[46,14,46,20],[47,14,47,20],[48,14,48,20],[23,1,23,5],[23,7,23,12],[88,1,88,5],[57,7,57,12],[59,7,59,12],[61,7,61,12],[68,7,68,12],[69,7,69,12],[70,7,70,12],[71,7,71,12],[88,7,88,12],[60,1,60,5],[60,7,60,12],[65,1,65,5],[65,7,65,12],[66,1,66,5],[66,7,66,12],[67,1,67,5],[67,7,67,12],[62,1,62,5],[44,7,44,13],[46,7,46,13],[47,1,47,5],[27,1,27,5],[27,7,27,12],[27,14,27,22],[27,24,27,32],[28,1,28,5],[28,7,28,12],[28,14,28,22],[28,24,28,32],[29,1,29,5],[29,7,29,12],[29,14,29,22],[29,24,29,32],[30,1,30,5],[30,7,30,12],[30,14,30,22],[30,24,30,32],[31,1,31,5],[31,7,31,12],[31,14,31,22],[31,24,31,32],[32,1,32,5],[32,7,32,12],[32,14,32,22],[32,24,32,32],[33,1,33,5],[33,7,33,12],[33,14,33,22],[33,24,33,32],[34,1,34,5],[34,7,34,12],[34,14,34,22],[34,24,34,32],[35,1,35,5],[35,7,35,12],[35,14,35,22],[35,24,35,32],[36,1,36,5],[36,7,36,12],[36,14,36,22],[36,24,36,32],[37,1,37,5],[37,7,37,12],[37,14,37,22],[37,24,37,32],[38,1,38,5],[38,7,38,12],[38,14,38,22],[38,24,38,32],[39,1,39,5],[39,7,39,12],[39,14,39,22],[39,24,39,32],[40,1,40,5],[40,7,40,12],[40,14,40,22],[40,24,40,32],[41,1,41,5],[41,7,41,12],[41,14,41,22],[41,24,41,32],[42,1,42,5],[42,7,42,12],[42,14,42,22],[42,24,42,32],[72,1,72,5],[72,7,72,12],[72,14,72,22],[72,24,72,32],[73,1,73,5],[73,7,73,12],[73,14,73,22],[73,24,73,32],[47,7,47,13],[48,1,48,5],[51,7,51,13],[48,7,48,13],[50,1,50,5],[44,14,44,20],[64,14,64,22],[62,7,62,12],[63,1,63,5],[61,1,61,5],[45,14,45,20],[50,14,50,20],[74,1,74,5],[74,7,74,12],[74,14,74,22],[74,24,74,32],[75,1,75,5],[75,7,75,12],[75,14,75,22],[75,24,75,32],[76,1,76,5],[76,7,76,12],[76,14,76,22],[76,24,76,32],[77,1,77,5],[77,7,77,12],[77,14,77,22],[77,24,77,32],[78,1,78,5],[78,7,78,12],[78,14,78,22],[78,24,78,32],[79,1,79,5],[79,7,79,12],[79,14,79,22],[79,24,79,32],[80,1,80,5],[80,7,80,12],[80,14,80,22],[80,24,80,32],[81,1,81,5],[81,7,81,12],[81,14,81,22],[81,24,81,32],[82,1,82,5],[82,7,82,12],[82,14,82,22],[82,24,82,32],[86,1,86,5],[86,7,86,12],[86,14,86,22],[86,24,86,32],[87,1,87,5],[87,7,87,12],[87,14,87,22],[87,24,87,32],[83,1,83,5],[83,7,83,12],[83,14,83,22],[83,24,83,32],[84,1,84,5],[84,7,84,12],[84,14,84,22],[84,24,84,32],[85,1,85,5],[85,7,85,12],[85,14,85,22],[85,24,85,32]]}
[null,"On-going Progress Update and Disbursement Request"]
[null,"PROGRESS UPDATE PERIOD"]
[null,"Grant Name:",null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,"Progress Update - Reporting Period:",null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Period Covered:",null,null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,"Progress Update - Number:"]
[]
[null,"Section 4:  Grant Management"]
[]
[null,"A.  PR and LFA Comments on the Fulfilment of Conditions Precedent and/or Special Conditions Under the Grant Agreement"]
[]
[null,"! Please include in this table the Condition Precedent number as per Grant Agreement and full text of Conditions Precedent and/or other special conditions due for fulfilment during this period or outstanding from previous periods. \n! Some Special Conditions may apply to more than one period of grant implementation.  Their fulfilment during one period does not automatically imply fulfilment in subsequent periods.  The LFA should verify that the status of such conditions is reported by the PR during each period concerned.",null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Conditions Precedent and/or other special conditions\n",null,null,null,null,"Status","PR Comments on Progress of Implementation",null,null,null,null,null,"Status","LFA Analysis\n(this should not be a \"Copy and Paste\" of the comments provided by the PR)",null,null,null,null,null,null,null,null,"Validate Status","Country Team Comments"]
[null,"\nNo later than 30 June 2014, the CCM shall, or the Principal Recipient shall cause the CCM to, submit a Budgeted Sustainability Plan for the gradual governmental take-over of financing, starting in 2015, for activities supported by this Grant. GF agreed to postpone the terminal date of the condition to 31 December, 2015 ",null,null,"Select",null,"Unmet - In Progress","As agreed with the GF the sustainability and transition plan development for HIV and TB grants will be covered from the current TB grant - GEO-T-NCDC. ToR for the plan development is elaborated is shared with the CCM and the GF. The electronic tender was completed during the Q2 and CIF has been selected for this task. Policy and Adviasory Counsil that was selected by the CCM is a technical team of experts that is in charge of supervision and oversight of the STP development process along with the PR. The first phase of the contract has been completed and the STP working plan and main directions is agreed with the CCM. The second phase is ongling which will be ended in September this year when the CIF will present the initial draft  STP without costing; The detailed plan with relevant budget will be developed during the third phase of the service contract (by December 2016).  All national stakeholders are activly engaged in the STP development process. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N14","v":"Select"}]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N15","v":"Select"}]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Met",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N28","v":"Select"}]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[]
[null,"B.  PR & LFA Review of Progress on Implementation of Outstanding Management Actions from Previous Disbursements"]
[null,"! Please list all issues raised in the last Performance Letter from the Global Fund or outstanding from previous Performance Letters, and comment on the progress. Please include the date of the Performance Letter and the item number."]
[null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Global Fund Management Actions",null,null,null,null,"Status","PR Comments on Progress of Implementation",null,null,null,null,null,"Status","LFA Review of PR Progress on Global Fund Management Actions",null,null,null,null,null,null,null,null,"Validate Status","Country Team Comments of PR Progress on Global Fund Management Actions"]
[null,"During the review of the Progress Update as well as of the Audit for the fiscal year 2014, it was noted that the PR is using different accounrding methods to report on the financial positions, namely:  the Progress Updates submitted to the Secretariat semi-annually, are prepared on cash basis, while the statements of financial positions submitted to the MOLHSA quarterly, are prepared according to the local regulations using modified cash basis. Although the PR has sought approval for using modified cash basis for prepareation of the financial statements for fiscal year 2014 during the Audit review process, this was not disclosed to the Secretariat in advance. Due to delay in informing the Secretariat and as a result, delayed approval, the PR was required to prepare the financial statements during the audit review.  Required Actions: During the preparation for the Audit reivew of the financial statements for fiscal year 2015 we recommend the PR:                                                                                                                                                                              a) to bring to the secretarit attendion any specific regulations applied to the PR reorting and preparation of the financial statements, well in advance, The PR is required to disclose these requirements already at the stage of review and approval of the TORs for the Audit of Financial Statements for fiscal year 2015.    b) tofurther develop and refine the process of preparing the financial statements;                                                      c) to ensure that the procedures and related deadlines for all staff involved in preparation of the financial statements are developed in advance and formally documented.                                                                                                Timeline: the PR should submit to the Secretariat the TORs for Audit reeview of the financial statements for fiscal year 2015 addressing the actions outlined by no Later than 31 July 2015. ",null,null,null,null,"Met","\n\nThe required actions were taken/recommendations are considered and followed precisely. ToR was submitted to the TGF for review per indicated deadline. The actual service is provucred and the Audit process for the current reporting period is underway by BDO.\n\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N59","v":"Select"}]
[null,"a) During the review it was noted that the PR's and SR's bookkeeping systems (mostly ORIS) do not contain specific fileds of expenditure categories or individual budget lines, Consequently, the risk or error in classification process exists.                                                                                                                                                      b) Additionally, the PR expenses the Pharmaceuticals, Health Products and Health Equipment as soon as it is transferred to SRs and monitor the use of such assets off balance sheet and perform the record in MS Excel Spreadsheets. There is no other special tool set in place for monitoring the usage neither at PR nor at SR level.  Required Actions: a) The PR is expected to follow up on the integration of the new financial software in existing accounting systems. While this activity should have been implemented during the last reporting period and was postpond, the PR is requested to ensure that the transition is completed before the end of fiscal year 2015. Additionally, the Secretariat requests the PR and SRs to produce semi-annual and monthly reports while reconciling between the financial reports and other accounting data, using MS excel.                                                                                                                                                                b) The PR is requested to ensure that further automation process is taking place, to better facilitate the process of gathering information for preparation of the grant program financail statements. Additionally, the PR should explore options to incorporate the accounting of PP and HPHE in the new financial software during its integration with the existing accounting systems by the end of fiscal year 2015.                                                           Timeline: the PR is requested to report on the progress made concerning the management actions outlined above by no later than 30 June 2015",null,null,null,null,"Unmet - In Progress","\nPR and SR’s have  integrated budget categories and lines in their existing accounting software and reports are reconciled with the accounting data on regular basis.   \nProcess of ERP system development is ongoing. Under GEO-T-NCDC grant PR has procured ERP Licenses - Microsoft Dynamics AX-  and is in the process of procuring System development Service. The latter tender is announced and 2 candidates were participating. At this stage PR is evaluating participants and after identifiing the winner contract will be signed with developer company.  The development process will take up to 7 months. The system will be piloted in the beginning of 2017 and the necessary adjustments will be made during the first semester of 2017. \n\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N60","v":"Select"}]
[null,"During the review of the Enhanced Financial Report (EFR) submitted with the Progress Update 2, inconsistances in reporting were noted:                                                                                                                                    a) The PR has reporting the period from 1 July 2014 to 31 December 2014 for the current period of the EFR, instead of reporting for the annual period 01 April 2014- 31 December 2014;                                                                                                                                                                                                        b) It was noted that the PR has reported in the EFR Table E-Disburcement Breakdown by Implementing Entity the expenditures of the SRs (six HIV SRs) and not PR's disburcements to the SRs.                                                                                                                                                      c) The PR has inserted the expenditure figure of SR HAPS (line #5) of SR CIF (Line #6) in Table E.                                                                                                                                                                                       Required Action and Timelines: The PR is requested to reserve the EFR and to resubmit the document based on the findings outlined above and to submit the revised version to the Secretariat by no later than 31 May 2015. ",null,null,null,null,"Met","The revised EFR document was submitted by the PR by the requested deadline.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue 1: During the review of the progress update, it was noted that the SRs are requested to submit monthly reports, however, the cumulative reports with results covering the 6-months period are not always available. Additionally, it was noted that the disaggregated values for some of the indicators are not produced by the SRs as part of the formally submitted reports. Consequently, the PR is verifying the results for the 6-months periods and performs the final calculation of the results against the targets.                                                                                                                                                              Required Action: While the PR's role is critical in ensuring that the correct data is reported with the Progress Update, it would be beneficial for the SRs to be further involved in reporting and commenting on the progress achieved during the 6-months period. The PR is invited to request for the submission of the semi-annual reports by the SRs with data for all indicators, in addition to the monthly reports submitted.                                                                                                                                                                                   Timeline: The PR is reqeusted to report on the progress made concerning the management action outlines above with the submission of the progress updated, by no later than 14 August 2015. ",null,null,null,null,"Met","All SRs were requested to provide cummulative reports for 6 months (July-December, 2015) and the reports were provided by SRs. PR M&E personnel has validated the reported indicators which are presented in PUDR form.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue #2: While the Secretariat acknowledged the efforts made by the PR and SR to increase the \"number and percentage of IDUs reached with HIV prevention programs\", the PR is expected to provide more details on the results achieved. Furthermore, considering the latest overachivement, the PR should revise and set more ambitious targets for the indicator.                                                                            Required Action: The PR is rquested to submit request for revision of the targets for the indicator 2.2 (for implementation period 1 July 2015 - 31 December 2015).                                                                                                                                                                      Timeline: The PR is requested to send revised Performance Framework to the Secretariat for review by no later than 31 May 2015. ",null,null,null,null,"Met","\nThe issue was resolved with the GHRN . Since April of 2015  we agreed with the SR to not include these secondary clients in the database, as there is no evidence that the 7 digit codes provided by the direct clients for their friend PWIDs is accurate.  The coverage data doesn't include also PDI clients and people who used only hepatitis C testing service. The same time, the coverage of IDUs during the next implementation period with operations of newly procured  mobile ambulatories has been increased and the geographic coverage was improved also. \n\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue #3: During the varification of the indicator 3.1: \"Number and percentage of eligible adults and children currently receiving ART\", it was noted that the results of SPECTRUM analysis were provided by the National AIDS Center to the PR, however the denominator for this indicator wasnot updated to reflect the data.  Required Action: The PR should ensure that the latest verified results of SPECTRUM analysis are used for reporting. Consequently, the demoninator of the idnicator 3.1 shuld be updated to reflect the latest data available. The PR should submit request to the secretariat to for revision of the denimonator for the indiactor 3.1 (implementation periods 1 January 2015 through 31 December 2015). Timeline: The PR is requested to send revised PF to the Secretariat for review by no later than 31 May, 2015",null,null,null,null,"Met","The NCDC has finalized the Spectrum results for the denominator of this indicator and the newly generated figure for the eligible adults and children for 2015 was 4,689. The new estimated figure is 10451 which was applied for P5. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue #4: During the review, it was noted that the number of beneficiares served at the SSR Telavi Health Cabinet (program run by the SR Tanadgoma) remains very low with only 17 beneficiries (FSWs and MSM) served during the last reqporting period.                                                                                                                Required action: While the PR has already initiated discussions on ways to improve the performance in Telavi, the PR should ensure that the coverage of the health cabinet is increased.                                                                                                              Timeline: The PR should demonstrate meassures taken with the next progress update, by no later than 14August, 2015. ",null,null,null,null,"Met","To address the issue, the PDI methodology was succesfully piloted in Telavi and suraunding raions and new FSWs were enrolled in the program. The new clients were given the refferals to healthy cabinet on a regular basis, the same time the number of the outreach rides were increased. All the above has resulted in the increase of the number of FSWs served. A little improvements were observed in using the healthy cabinet services by the FSWs reffered by Tanadgoma to the healthy cabinet. PR, SR and SSR met again to discuss the issue at the begining of Q1. The new strategy that was agreed to be tested was to give the rides to FSWs to the Healthy Cabinets for STI diagnostics and treatment visits by social workers of Tanadgoma's with its car. During the last 6 months 44 clients recieved the STI diagnosit and treatment service (during the previous 6 month the number was 27).  Thus, the P5 data are little bit increased, but not as much, and PR together with the SR Tanadgoma has developed a vaucher system that is piloted in Telavi for STI treatment. Clients are given a free treatment vaucher during the outreach work and are referred to the Health Cabinet. Healthy Cabinet staff reinburcement will partially depend on the number of vaucher holder clients they serve. If the system will be implemented succesfuly PR will consider estalishment of the similer systems in other regions of the country where the coverage with STI treatment is not high. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, issue #5: In the absense of the unified module for the OST program integrated in the health management information system, risk or error and inaccurate calculation of the results achieved under the OST program is high. Required Action: The PR should ensure that the unified OST module is introduced by the ned of the next implementatuin period and is fully functional by the end of the year 2015. Timelien: The PR is expected to report on the results with submission of the next progress update, by no later than 14 August 2015. ",null,null,null,null,"Met","The OST Module has been incorporated in the e-health system since March, 2015 and the GF OST sites were given the individual accesses to the system. Since April, 2015 they started entering the data on OST patients in the system. PR is closely monitoring the data entrance and chacks them against the paper reports during this piloting phase. The Module is available as a final tool for OST patients reporting for the current reporting period.  ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue #6: While we acknowledge the efforts made by the PR to catch up on the implementation of the program, the PR is expected to continue to follow up on the progress and implementation of the activities under Objective 1. Required Action and Timeline: The PR is requested to report on the progress made with respect to implementation of the activities planned under Objective 1 by no later than 30 June 2015. ",null,null,null,null,"Met","The contracts for implementation of Objective 1 were signed during March and Appril of 2015 and SRs are working on the implementation of the following components since April and May.\n\n- Strengthening LGBT Community - SR Tanadgoma, SSRs - NGO Identoba and NGO LGBT Georgia\n- Strengthening HIV COmmunity - SR: NGO Real People, Real Vision,\n- Advocacy component - SR: NGO Real People, Real Vision\n- Training of Health Care Workers for HIV related Stigma Reduction in clinical settings - SR: HIV/AIDS Patients Support Foundation\n\n\nIn July 2015 two additional contracts were signed for implementation of the following interventions:\n\n\n- Media Campaign for Stigma Reduction - SR: McCann Erickson company\n- Survey of health care workers on HIV related stigma and discrimination - SR: BCG Research                                                                                                    All activities outlined in the contracts for the Objaective 1 were completed by the end of 2015.                The contracts were completed successfully.                                                                                                                                                                                                                                         in December 2015 new contract was signed with Tanadgoma for implementation of the LGBT strenghtening component of the Objective 1. SSRs are Identoba and LGBT Georgia. There were some intrnal organizational issues in Identoba due to changes in the leadership and auditing processes, but this didn't have negative impact on the program implementation. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"Other Management Issues: Issue #1                                                                                                                                      During the review of the peer education trainings conducted in October 2014 at the SR Tanadgoma for FSWs and at SSR Kamara for PWIDs, weaknesses in training content and manegement were identified. Required Actions: Following the approval of the training plan for HIV grant for year 2015, the PR should ensure that following recoemndations are addressed while conducting trainings:                                                                                                      a) Establishment of trainings database per SR, which will cintain detailed information on the trainings conducted, including agenda, list of participants at the training and key populations group they are representing, which will allow to count unique participants benefiting from these trainings rather than cumulative number of people trained.                                                                                                                                            b) Training materials should be revised and aligned amongst SRs, per key population group. Clear objectives, content, as well as suitable duration of the training per each key  population group should be established.                                                                                                                                                                                          c c) Pre and post training knwoledge questionnaires should be developed and shared with participants, in order to enhance the learning experience from the trainings, the outcomes from the training shuld be recorded in the electronic database developed by the PR/SR;                                                                                         d) The SRs should report to the PR on the trainings conducted on a quarterly basis.                                            Timeline: The PR is expected to report on the progress with submission of the next progress update, by no later than 14 August 2015. ",null,null,null,null,"Met","The training plan was approved by GF and of April, 2015. The plan was disseminated among SRs and SSRs as a guidance for  planning of respective trainings. The training database tamplate was developed by PR and was provided to SRs in May,2015. They were requsted to start filling out the database from June 1, 2015. All of them have pre and post tests developed and used on regular basis. PR has provided the trianing evaluation form as well that trainees have to fill out for each training.  The SRs were providing the monthly reports using the format provided by the PR. the last 6 moonth summary database was provided by the SRs during January, 2016 which included the total budgeted and total actual costs per training. The same kind report is provided for the first 6 months of 2016 by the SRs.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"OSDV Issue #1:                                                                                                                                                                               Results for indicator \"Number and percentage of IDUs reached with HIV prevention programmes - defined package of services” - SR GHRN clients who are not in direct contact with project staff (secondary reach), but receive service package are considered reached.                                                   Required Actions: While the secondary distribution of commodities ( secondary coverage) might be beneficial for those PWIDs, SSRs should not register beneficiaries with unique identification codes in the database and the SR GHRN should not include these cases within the reported results for this indicator, unless those beneficiaries were already registered in the database and services were provided at least once.\nGiven that there is no mechanism to verify if the clients really received certain number of syringes/needles from their peers, only those who have direct contact with project staff should be counted, and reported.                                                                                                                                                                 Timeline: Immediately\n",null,null,null,null,"Met","See the section H63. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N73","v":"Select"}]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[null,"C.  Comments on Annual Grant Reporting Requirements"]
[]
[null,"! Please indicate a date for the report due for submission.  If a report is overdue, indicate the original due date and explain the reason for delay.",null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Required Documentation",null,null,null,"Due date \n(dd-mmm-yy)","Status","Comments",null,null,null,null,null,"Due date\n(dd-mmm-yy)",null,"Status",null,null,null,"Comments",null,null,null,"Due date\n(dd-mmm-yy)","Validate Status",null,null,null,"Country Team Comments"]
[null,"PR Audit Report",null,null,null,null,"Preparation on track","The report will be sibmitted by the end of September, 2016"]
[null,"Annual Financial Report (AFR) / Enhanced Financial Report (EFR)",null,null,null,null,"Submitted to GF"]

{"sheet":"PR-LFA Evaluation_5","index":16,"n_rows":55,"n_cols":8,"rows_kept":55,"cut":false,"hidden":false,"merged":[[62,0,62,10],[46,0,51,14],[45,0,45,14],[55,0,60,14],[33,15,33,29],[38,0,43,14],[33,0,33,14],[34,0,34,10],[24,0,24,14],[11,0,15,14],[0,0,0,15],[18,0,22,14],[25,0,29,14],[10,0,10,10],[2,0,2,1],[2,2,2,5],[5,2,5,5],[17,0,17,14]]}
["Ongoing Progress Update and Disbursement Request"]
["PROGRESS UPDATE PERIOD"]
["Grant Name:",null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 5: PR and LFA Evaluation of Overall Performance"]
[]
["A.  PR's Overall Self-Evaluation of Grant Performance (including a summary of how financial performance is linked to programmatic achievements)"]
["!  The self-evaluation should be undertaken by taking into account programmatic achievements, financial performance and program issues in various functional areas (M&E, Finance, Procurement, and Program Management, including management of Sub-Recipients).  See Guidelines for more detailed guidance."]
["PR has successfully procured services for all main components of the HIV Extension Grant in December, 2015 and has ensured smooth implementation of the planned activities.\nProgram Indicators:\nFor most of the indicators the PR’s and SRs’ performance within the GEO-H-NCDC program extension period was satisfactory during the P5. In some areas the performance was even exceeding the expectations. For instance, the OST program’s achievement regarding the number of OST patients who utilized the service for 6 month period (78.4% Vs. 75%) Very sound achievement is regarding HCV treatment indicator –283% as the motivation of PLHIV for treatment was increased due to access to the Harvon within the National Hep C Elimination Program. Over the target achievements are reported for VCT of PWIDs and TB screening also which can be attributed to start-up of mobile ambulatory services with increased geographic coverage and increased interest of PWIDs for dual (HIV and Hep C) within the National Hep C Elimination Program. \nThe Initiation of LGBT supporting activities by the SR Tanadgoma contributed to promotion of the HIV prevention service utilization by MSM population. Coverage of MSM with HIV prevention services has been improved but still are slightly behind the targets. PR and SR anticipate further improvement within the LGBT component in the future through continuous support of LGBT resource centers and initiation of hep C testing among this group.  \nThe same time, first time for last few years the coverage of FSWs is overachieved (29.6% Vs. 28.1%). During P5 the PR and SR Tanadgoma has tested new strategies to improve the FSWs’s coverage data. PDI strategy worked well with FSWs in the regions to attract new clients to the Tanadgoma sites. Despite the efforts made, the low STI treatment coverage remained at Telavi and Zugdidi healthy cabinet. PR and SR agreed to use the Tanadgoma’s office car and provide transportation to FSWs referred for the treatment from other districts and villages, thus ensuring they are getting the required services at the healthy cabinet. \nIn order to improve the cost-efficiency of the STI treatment service for FSWs and MSM we started piloting of voucher system from the NFM period in Telavi. Clients are given the vouchers for free of charge diagnostics and treatment that they are presenting at the STI treatment site, the STI clinics will be reimbursed based on the number of the clients served according to the vouchers. \nHigh 66% achievement was detected for screening on TB of key affected populations also (the target was 60%) and facilitated the strengthening of the linkages between the HIV and TB programs. \nProcurement and stock management:\nDuring the reporting period most of the ARV medicines procured within the GF and the State programs were delivered to the country by the PFSCM. Delivery of remained four medicines will be completed by October, 2016.   \nTo ensure that adequate funding is included in the 2016 State Budget, the PR has successful communication with the Ministry of Health which resulted in inclusion of 2,630,000 GEL in the State Budget for procurement of the first line ARVs in 2016 also.  The amount was recalculated based on the latest prices and current projected need of the AIDS Center and the estimated amount that is needed is around 1,5 million GEL for FL ARVs. \nMethadone procurement also was completed on-time with no risk for the program implementation. \nPSM of the program has been improved also, PR and SRs were monitoring of supply consumption data to make reasonable quantifications for the remaining period of the grant + buffer stock. The PSM team had ensured that there was no stock out for any MPP or HP during the reporting period. Just we had to borrow some stock of methadone from the state program before the GF program procured medicine would be delivered in the country. The LMIS of NCDC is still under development, PR has two times provided the NCDC consultants with the stock file of GF programs to be entered in the LMIS module, which didn't happen due to the technical issues, PR has decided to include this in the ERP technical documentation and run independent LMIS for the GF grant programs and same time continue efforts for integration with the NCDC LMIS when completed. \nNo stock outs were reported during the extension period. \nDuring the reporting period PR has requested the SR –National AIDS Center to conduct disposal of expired stocks of medicines and reagents, which was completed in accordance to the state regulations.\nPR has initiated transfer of assets procured by the previous PR within the phase I of the GEO-H-NCDC grant to the current implementing organizations.      \nData Management: \nDespite the fact that SRs are still using the excel based databases, the PR has achieved improved data reporting from SRs based on the continuous oversight and on-site instructions/validations regarding the ways of counting the indicators and the data-base improvement. In parallel, the PR is working on procurement of the service for unified HIV prevention database elaboration. OST module was included in the e-health system of the MoLHSA. PR is regularly validates the paper forms’ data with the e-health OST module data. PR has decided to procure the TA for the sound technical documentation for the HIV prevention database and ensure that the documentation is ready for NFM’s first year (2016). \nSustainability Planning: \nPR has successfully completed the grantmaking process for GAC2 and in May 2016 has received confirmation letter for NFM grant award of 18.268,885 USD. All relevant supporting documents (PF, detailed budget, LoHPHE and Implementation Plan) were provided to the CT on timely manner. \nWithin the ongoing TB grant program CIF is a tender based selected service provider is working on elaboration of the Sustainability and Transition Plan for both, TB and HIV grants. CCM has selected a Policy and Advocacy Council that closely monitors and provides technical oversight to this process. It is anticipated that the Plans will be submitted to the CCM by the end of 2016. \nPR has ensured that budget takeover plan for HIV grant is considered during the preparation of MTEF for 2017-2020 of the Ministry of Labour, Health and Social Affairs.  In addition, PR has sent a detailed reminder letter to the Department of Health of the Ministry indicating the activities and time-frames with relevant budget estimates for the coming years. \nFinancial management\nThe two critical components of this work are a) external to Georgia – reporting to the donor (TGF), and b) internal  – communication and reporting with the Ministries of Health and Finance, with NCDC, state statistics department, tax authorities, state revenue service, suppliers, service providers, etc. Both operations were conducted in a smooth and efficient manner with the stable and robust operations. During the Q1 and Q2 of 2016 PR has timely submitted the regular PUDR report. Also, met all of the donor’s additional ad-hock requests on the provision of financial and/or operational data. This includes PR/SR end-of month balances/receivables/parables etc. As current HIV Grant has ended, all outstanding commitments, including SR activities were reimbursed, the final cash balance was submitted to TGF. Besides the list of assets procured under GPIC for transferring title to existing SRs was agreed with CCM and TGF and relevant permits were obtained.  Also, all remained assets procured within the closing grant will be trasnfered to the NFM grant as agreed with TGF. \nThe PR has successfully procured audit service for the year 2015 through the tender and relevant contract was signed with BDO that includes the audit of the first semester of 2016. The Audit of Consolidated financial statements is ongoing and the report will be submitted by the end of September as agreed with TGF. To improve financial management system PR Under TB Grant has procured ERP Licenses - Microsoft Dynamics AX and is in the process of procuring System development Service. The latter tender is ongoing and contract with developers will be signed in September 2016.  \nTotal payments made to the vendors/providers during the current reporting period is EUR 2,305K. \nPR managed the VAT operations smoothly. Total VAT refund for the reporting period comprised 88K. The surplus of refundable VAT on the State Revenue Service system amounts of EUR 17K as of 30/06/2016 and will be refunded in Q32016.\nIn general, the PR has succesfully completed all interventions within the closing grant and major savings were included into  the NFM grant. Remained unspent amount will be reimbursed to TGF. \n"]
[]
[]
[]
[]
[]
["B.  Planned Changes in the Program, if any"]
[" a) Country is adopting Treat All strategy of WHO which means that PLHIV are offered ART despite the DC4 cell count, thus more HIV positive people are eligible to ART;    The Government has procured first line ARV medicines from PFSCM for 2016, the State budget already has the relevant amount budgted for the same kind procurement for 2017;                          b) Hepatitis C treatment for PLHIV is fully covered by the State Hep C Program, GF program covers costs of hep C diagnostics; from July 2016 all costs of PLHIV hep C treatment will be covered by the State.                                                                                                                                                                                                                                                                                                                             c) piloting of vaucher system for treatment of STIs among FSWs and MSM in Telavi;                                                                                                                                                                                                             d) Dialogue is initiated with the Ministry regarding the take over of the GF OST program from July 2017. "]
[]
[]
[]
[]
[]
["C.  External factors beyond the control of the Principal Recipient that have impacted or may impact the Program"]
["a) Implementation of hepatitis C Elimination Program that started in 2015 in the country had positive impact on HIV program implementation. Especially beneficial the new program was for HIV/HCV co-infected patients who got access to highly effective Direct Antiviral (DAAs) Medicines. In addition, HCV servicies are getting integrated with the HIV services (harm reduction basically) and the HIV and HCV tandem testing was offered to interested people countrywide.                                                                                                                                                              b) Criminalization of drug use creates barriers for implementation of NSP in Georgia. Community mobilization for decriminlization of drug use is getting stronger. The issue gets more attention due to the increasing understanding of the need for engegement of the PWID community in Hep C elimination program.                                                                                                                                                                                                                                                                                                                                      "]
[]
[]
[]
[]
[]
["For LFA Use Only"]
[]
["A. LFA  Overall Evaluation and Rating of Grant Performance (including a summary of how financial performance is linked to programmatic achievements)"]
["!  The evaluation should be undertaken by taking into account programmatic achievements, financial performance and program issues in various functional areas (M&E, Finance, Procurement, and Program Management, including management of sub-recipients).  See Guidelines for more detailed guidance on the completion of this section."]
[]
["Indicator rating","Select",null,"Any major management issues resulting in downgrade?","Select",null,"Overall Grant Rating","Select"]
[]
[]
[]
[]
[]
[]
[]
[]
["B.  LFA comments on PR planned changes in the program, if any"]
[]
[]
[]
[]
[]
[]
[]
[]
["C.  LFA Comments on External Factors Beyond Control of the Principal Recipients that have impacted or may impact program"]

{"sheet":"LFA_Findings&Recommendations_6","index":17,"n_rows":39,"n_cols":10,"rows_kept":39,"cut":false,"hidden":false,"merged":[[21,0,21,1],[22,0,22,1],[18,2,18,4],[19,5,19,8],[20,5,20,8],[21,5,21,8],[22,5,22,8],[19,2,19,4],[20,2,20,4],[21,2,21,4],[22,2,22,4],[18,0,18,1],[19,0,19,1],[20,0,20,1],[26,2,26,4],[26,5,26,8],[25,2,25,4],[25,5,25,8],[23,5,23,8],[24,5,24,8],[23,2,23,4],[24,2,24,4],[17,5,17,8],[12,0,12,1],[13,5,13,8],[14,2,14,4],[14,5,14,8],[13,0,13,1],[16,2,16,4],[12,2,12,4],[16,0,16,1],[17,0,17,1],[14,0,14,1],[15,0,15,1],[0,0,0,9],[2,0,2,1],[2,2,2,5],[5,2,5,5],[26,0,26,1],[24,0,24,1],[13,2,13,4],[25,0,25,1],[17,2,17,4],[23,0,23,1],[15,2,15,4],[15,5,15,8],[18,5,18,8],[16,5,16,8],[10,0,10,9],[12,5,12,8]]}
[" Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST"]
["Grant Name:",null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[]
["For LFA Use Only"]
["Section 6: LFA Findings & Recommendations  "]
[]
["! Based on the information provided in the previous sections and your understanding of the grant, please summarise any important management issues, proposing a recommendation for each.\nNB: an issue is considered as 'important' if it impacts or is likely to impact program implementation and results.                                                                                                                                                                                                          ! Instead of repeating detailed descriptions of issues covered in other sections, it is acceptable to state the issue and reference the section containing the details."]
[]
["Functional Areas",null,"Description of Identified Issues \n(in order of importance)",null,null,"LFA Recommendations \n(in order of importance)",null,null,null,"Country Team Comments"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
[]
[]
["Select"]
["Yes"]
["No"]
[]
["Select"]
["Program management (including SR management)"]
["Financial management and systems"]
["Monitoring and evaluation"]
["Pharmaceutical & health product management"]
["Other management issues, including: PR capacity to develop quality programmatic and financial reports"]

{"sheet":"PR EFR_7A","index":18,"n_rows":206,"n_cols":12,"rows_kept":206,"cut":false,"hidden":false,"merged":[[169,0,169,11],[204,4,204,10],[176,4,176,11],[177,4,177,10],[201,4,201,10],[202,4,202,10],[203,4,203,10],[188,4,188,10],[189,4,189,10],[200,4,200,10],[170,0,174,11],[186,4,186,10],[183,4,183,10],[184,4,184,10],[185,4,185,10],[190,4,190,10],[111,0,113,4],[115,4,115,7],[115,8,115,11],[161,0,163,4],[168,0,168,11],[29,1,29,3],[30,0,30,2],[33,4,33,7],[33,8,33,11],[110,0,110,3],[28,1,28,3],[17,1,17,3],[18,1,18,3],[19,1,19,3],[20,1,20,3],[21,1,21,3],[22,1,22,3],[23,1,23,3],[24,1,24,3],[25,1,25,3],[26,1,26,3],[27,1,27,3],[8,4,9,4],[8,8,9,8],[12,4,14,7],[15,4,15,7],[15,8,15,11],[16,1,16,2],[5,0,5,1],[5,2,5,3],[6,0,6,1],[6,2,6,3],[7,0,7,1],[8,0,8,1],[7,2,7,3],[0,0,0,5],[3,0,3,1],[3,2,3,3],[3,5,4,7],[4,0,4,1],[4,2,4,3],[2,0,2,5],[1,0,1,5],[196,4,196,10],[197,4,197,10],[198,4,198,10],[199,4,199,10],[187,4,187,10],[191,4,191,10],[192,4,192,10],[193,4,193,10],[194,4,194,10],[195,4,195,10],[178,4,178,10],[179,4,179,10],[180,4,180,10],[181,4,181,10],[182,4,182,10]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 7A: PR - Enhanced Financial Reporting"]
[]
["Country",null,{"$f":"CoverSheet!D5","v":"Georgia"},null,null,"PLEASE REFER TO THE \"GUIDANCE FOR COMPLETION OF THE ENHANCED FINANCIAL REPORTING TEMPLATE\" DOCUMENT TO ASSIST YOU IN COMPLETING THE TEMPLATE"]
["Grant No.",null,{"$f":"CoverSheet!D7","v":"GEO-H-NCDC"}]
["PR",null,{"$f":"CoverSheet!D8","v":"National Center for Disease Control and Public Health"},null,null,"TO BE COMPLETED ONLY ONCE A YEAR "]
["Currency",null,{"$f":"CoverSheet!D11","v":"EUR"}]
["Disease(Component)",null,{"$f":"CoverSheet!D6","v":"HIV/AIDS"},null,null,null,"dd-mm-yyyy",null,null,null,"dd-mm-yyyy"]
[null,null,null,null,"Current Reporting Period","Start Date:","2016-01-01",null,"Cumulative Reporting Period","Start Date:","2014-04-01"]
[null,null,null,null,null,"End Date:","2016-06-30",null,null,"End Date:","2016-06-30"]
[null,null,null,null,null,null,null,"The end date for the current reporting period and cumulative reporting period must be the same"]
[null,null,{"$f":"CONCATENATE(\"EFR\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"EFRHIVAIDS"}]
[null,null,{"$f":"CONCATENATE(\"SDA\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"SDAHIVAIDS"},null,"The \"TOTAL\" rows in Table A, B and C will have a RED background if the amounts in each table do not agree. If the Totals for each Table agrees, these rows will have a YELLOW background. "]
[]
[]
["A- BREAKDOWN* BY  EXPENDITURE CATEGORY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Category",null,null," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"Human Resources",null,null,1151898.682920902,1336803.9824213963,{"$f":"E18-F18","v":-184905.29950049426},null,5154744.5533048585,5625304.2754543424,{"$f":"I18-J18","v":-470559.72214948386}]
[2,"Technical Assistance",null,null,40745.842233788353,50545.149097571833,{"$f":"E19-F19","v":-9799.3068637834804},null,367107.72509880585,274126.76838604518,{"$f":"I19-J19","v":92980.956712760672}]
[3,"Training",null,null,20327.136311128226,26934.767905954595,-6607.6315948263691,null,390722.78593186371,243163.74952456294,147559.03640730077]
[4,"Health Products and Health Equipment",null,null,487580.33312245429,539760.5276544888,-52180.194532034511,"The Budget relates to the Health product/equipment procured locally and directly by the Global fund. \nThe Negative variance EUR 52,180 consists of Positive Variance EUR 198,293 and Negative Variance EUR 250,474\nTotal Saving EUR 198,293 – \nEUR 106,688 - Part of IDA commitment was reimbursed by the GF by the end of 2015 and remaining amount was moved to NFM budget.\nEUR 12,121 – Actual cost of procurement syringes and needles (other than 1 ml) were less than budgeted.\nEUR 43,283 – Actual cost of procurement lab supplies for Aids Center was less than budgeted.\nEUR 15,787 – Actual cost of procurement Condoms and lubricants was less than budgeted\nEUR 9,256 – Actual cost of procurement disinfectants and lab supplies were less than budgeted.\nEUR 5,613 – Actual cost of procurement tests (rapid tests, tests for STI) were less than budgeted.\nEUR 5,545 – Procurement of Saliva Tests was cancelled (supplier couldn’t deliver the product).\nThe Negative variance EUR 250,474 is related to the following:\nEIR 125,468- Commitment (procurement of Mobile ambulatories) from the previous reporting period and payment carried out in current period\nEUR 3665 – Actual cost or Quantity for 1 ml syringes was greater than budgeted\nEUR 13,480- Actual cost for condoms procured locally was greater than budgeted\nEUR 3,115- Actual cost for some lab supplies and tests was greater than budgeted\nEUR 2,733 - Procurement of tests by CIF committed in Dec 2015 and reimbursed in Jan 2016.\nEUR 102,013 – Actual cost of Procurement of tests for Aids Center was greater than budgeted.\n",3565110.958505,2724599.3721733922,840511.58633160777,"The Budget relates to the Health product/equipment procured locally and directly by the Global fund. \nThe variance EUR 840,512 consists of Positive Variance EUR 1,214,909 and Negative variance EUR 374,397\nLess amounts spent on the procurement (lab supplies, disinfectants, tests systems, Flow cytometer; syringes, condoms) is a result of the low unit prices offered during the tenders; revision of the q-ties based on the consumption data and some cancelled activities.\nSaving EUR 1,214,909 -   \nEUR 63,846 –Instead of one flow cytometer with high technical characteristic, in agreement with GF and AIDS Center, four field equipment – BD Presto, were procured for CD4 count measurement, which has resulted in substantial saving.\nEUR 311,304 – Procurement of syringes through IDA and local tenders for syringes, needles and vain sets resulted in low unit costs. Also quantities were recalculated based on consumption data and stocks at SR level.\nEUR 50,195 – Procurement through IDA and local tenders resulted in lower than budgeted cost for condoms, also quantities were recalculated based on consumption data and stocks at SR level.\nEUR 166,718– Actual costs for procurement of disinfectant and lab supplies/equipment through tenders were less than budgeted also.  \nEUR 16,897 – Based on stocks of Naloxon available at SR level, the less q-ties were procured and cost was lower also. \nEUR 84,545– Actual cost of Procurement of tests (rapid and express tests, tests for STI) was lower than budgeted\nEUR 521,403 – Actual cost for tests and lab supplies for AIDS Center were less than budgeted through local tenders\nOverspending EUR 374,397 -  \nEUR 218,163 – Procurement of tests and lab supplies (HCV real time PCR, Four and two color Flow cytometer) for Aids Center was greater than budgeted.\nEUR 17,935 – Actual cost some of rapid tests was greater than budgeted, including EUR 5,411 – Additional request from TG on procurement of micropipettes approved by GF; \nEUR 9,444 – Actual Q of condoms procured for GHRN was greater than budgeted.\nEUR 3,670 – Actual cost of disinfectants and minor lab supplies was slightly greater than budgeted; \nEUR 120,917 – Cost of procurement of additional 4 mobile ambulatories approved by GF.\nEUR 4,270 -Actual cost of tests under objective 4 was greater than budgeted. (Originally cost was budgeted under PR and was transferred to CIF)\n"]
[5,"Medicines and Pharmaceutical Products",null,null,776937.43153715832,35010.123323565655,741927.30821359262,"The Budget relates to the Medicines and Pharmaceuticals procured locally and through international PSM Agencies to be paid directly by The Global Fund. \nThe variance EUR 741,927 consists of Positive Variance EUR 742,876 and Negative Variance EUR 949\nTotal Saving EUR 742,876 –\nEUR 12,887- Actual cost and Quantity for Methadone was less than budgeted (limited by the county’s quota for drug) ; Commitment for PFSCM order for ARVs placed in 2014 and new order placed in 2015 was transferred to NFM budget.\nOverspending EUR 415 - Actual Cost of MPP provided to TG was slightly greater than budgeted. \nEUR 534 – Procurement of essential drugs performed by Aids Center for palliative care- actual cost is greater than budgeted \n",5140297.1056705983,1438631.0810251292,3701666.0246454692,"The Budget relates to the Medicines and Pharmaceuticals procured locally and through international PSM Agencies to be paid directly by The Global Fund. \nThe variance EUR 3,701,666 consists of Positive Variance EUR 3,710,429 and Negative variance EUR 8,763.\nDriver of saving is available stock at SR: Cheaper unit prices were gained both from the local procurement and through PPM (ARVs). Saving was made due to simplification of ART regimens based on WHO recommendations. \nSaving EUR 3,710,429- \nEUR 181,448 – Volume of Methadone was reduced according to the quota approved for the country and more precise need estimation conducted jointly by Narcology Center and MoH. The actual cost of methadone was less also (4 EUR vs. 9 EUR). \nEUR 15,529 – Actual unit price for vaccines was lower than budgeted.\nEUR 3,139,117– Saving in ARVs resulted from actual PQ signed with PPM and simplification of regimens. Commitment for PFSCM order for ARVs placed in 2014 and new order placed in 2015 is transferred to NFM budget.\nEUR 371,996 - Considerably lower price procurement of interferon through the local tender. Also Procurement of the last portion of the pegylated interferon and ribavirin budgeted at 342,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.\nOverspending EUR 2,339 – Actual Cost of some STI medicines provided to TG was slightly less than budgeted. \nOverspending EUR 8,764 – \nEUR 7,580 – procurement of STI essential drugs – actual cost is greater than budgeted due to updated quantification of the needs by the SR\nEUR 1,184 – procurement of essential drugs for palliative care performed by Aids Center- actual cost is greater than budgeted "]
[6,"Procurement and Supply Management Costs",null,null,72160.072905506342,4277.3171545229216,67882.755750983415,null,1005976.6506061351,88868.635240060117,917108.01536607498]
[7,"Infrastructure and Other Equipment",null,null,12161.936850211783,13844.272461054577,-1682.3356108427943,null,312463.61911834206,106118.19915189315,206345.41996644891]
[8,"Communication Materials",null,null,2695.4177897574127,2358.0556589184639,337.36213083894881,null,113889.45684870309,49458.734592689711,64430.722256013381]
[9,"Monitoring & Evaluation",null,null,28313.953022718524,35112.707395072997,-6798.7543723544732,null,316614.61813398567,233500.19048330912,83114.427650676545]
[10,"Living Support to Clients/Target Populations",null,null,32961.135155949174,27955.569239858847,5005.5659160903269,null,198639.72607301292,142642.06407749475,55997.661995518167]
[11,"Planning and Administration",null,null,11192.908740854831,11917.691186057315,-724.78244520248336,null,102543.78114972748,66954.005053097135,35589.776096630347]
[12,"Overheads",null,null,209190.67269926838,213048.55025678343,-3857.8775575150503,null,913403.52562451921,774807.91791821131,138595.6077063079]
[13,"Other",null,null,6718.5213708124757,7445.5386111058269,-727.01724029335128,null,0,13636.046250125799,-13636.046250125799,"VAT amount paid for the service provided by TG under objective 1. The amount is refundable to PR by The State"]
[null,null,null,"TOTAL",{"$f":"E18+E19+E20+E21+E22+E23+E24+E25+E27+E26+E28+E29+E30","v":2852884.04466051},{"$f":"F18+F19+F21+F20+F22+F23+F24+F25+F26+F27+F28+F29+F30","v":2305014.2523663514},{"$f":"SUM(G18:G30)","v":547869.79229415848},null,{"$f":"SUM(I18:I30)","v":17581514.506065555},{"$f":"SUM(J18:J30)","v":11781811.03933035},{"$f":"SUM(K18:K30)","v":5799703.4667351972}]
[]
[]
["B- BREAKDOWN* BY PROGRAM ACTIVITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Macro-category","Objectives","Service Delivery Area"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"Supportive Environment","To establish supportive environment for HIV/AIDS prevention, treatment, care and support","Supportive environment: Stigma reduction in all settings",44134.385829803621,49317.412030843181,{"$f":"E36-F36","v":-5183.02620103956},null,253777.92465515155,176541.56158312268,{"$f":"I36-J36","v":77236.363072028878}]
[2,"Prevention","To increase coverage and quality of preventive interventions targeted at MARPs","Prevention: Behavioral Change Communication - community outreach",1407879.8099595688,1531596.2299509638,{"$f":"E37-F37","v":-123716.41999139497},null,6483074.8212125953,6027884.4465663796,{"$f":"I37-J37","v":455190.3746462157}]
[3,"Treatment","To sustain treatment, care and support for PLHIV including Abkhazia frozen conflict area","Treatment, Care and Support",1382537.1573039449,690968.31580454553,{"$f":"E38-F38","v":691568.84149939939},null,9580900.9317652993,4698166.3381672222,{"$f":"I38-J38","v":4882734.5935980771}]
[4,"Health System Strengthening (HSS)","To generate evidences and document HIV program effectiveness","HSS: Information system & Operational research",18332.691567192916,32603.06884737721,-14270.377280184293,null,585224.05268919375,445598.4386031935,139625.61408600025]
[5,"Supportive Environment","PR Management and Administration ","Supportive environment: Program management and administration",0,529.23670398986394,{"$f":"E40-F40","v":-529.23670398986394},"Project management cost was not budgeted under extension period, only ERP Consultant fee and PR fuel cost was reimbursed in January 2016, that committed in the Dec 2015 ",678536.81574331503,433620.2643063963,{"$f":"I40-J40","v":244916.55143691873},"Saving in Project management costs including International PSM consultant's fee, in HR (HIV M&E specialist , finance specialist, logistics specialist ) ; saving related to renovation of office; procuring furniture (It was handed over from previous PR) ; fuel; tender announcement costs, Technical assistance; late start of media campaign, Audit fee. The FX rate had also impact on savings."]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E41-F41","v":0},null,0,0,{"$f":"I41-J41","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E42-F42","v":0},null,0,0,{"$f":"I42-J42","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E45-F45","v":0},null,0,0,{"$f":"I45-J45","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E46-F46","v":0},null,0,0,{"$f":"I46-J46","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E47-F47","v":0},null,0,0,{"$f":"I47-J47","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E52-F52","v":0},null,0,0,{"$f":"I52-J52","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E53-F53","v":0},null,0,0,{"$f":"I53-J53","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E54-F54","v":0},null,0,0,{"$f":"I54-J54","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E59-F59","v":0},null,0,0,{"$f":"I59-J59","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E62-F62","v":0},null,0,0,{"$f":"I62-J62","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E63-F63","v":0},null,0,0,{"$f":"I63-J63","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E64-F64","v":0},null,0,0,{"$f":"I64-J64","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E67-F67","v":0},null,0,0,{"$f":"I67-J67","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E68-F68","v":0},null,0,0,{"$f":"I68-J68","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E69-F69","v":0},null,0,0,{"$f":"I69-J69","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E74-F74","v":0},null,0,0,{"$f":"I74-J74","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E75-F75","v":0},null,0,0,{"$f":"I75-J75","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E76-F76","v":0},null,0,0,{"$f":"I76-J76","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E79-F79","v":0},null,0,0,{"$f":"I79-J79","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E80-F80","v":0},null,0,0,{"$f":"I80-J80","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E81-F81","v":0},null,0,0,{"$f":"I81-J81","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E89-F89","v":0},null,0,0,{"$f":"I89-J89","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E90-F90","v":0},null,0,0,{"$f":"I90-J90","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E91-F91","v":0},null,0,0,{"$f":"I91-J91","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E93-F93","v":0},null,0,0,{"$f":"I93-J93","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E94-F94","v":0},null,0,0,{"$f":"I94-J94","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E95-F95","v":0},null,0,0,{"$f":"I95-J95","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E97-F97","v":0},null,0,0,{"$f":"I97-J97","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E100-F100","v":0},null,0,0,{"$f":"I100-J100","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E101-F101","v":0},null,0,0,{"$f":"I101-J101","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E102-F102","v":0},null,0,0,{"$f":"I102-J102","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E105-F105","v":0},null,0,0,{"$f":"I105-J105","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E106-F106","v":0},null,0,0,{"$f":"I106-J106","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E107-F107","v":0},null,0,0,{"$f":"I107-J107","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
["TOTAL",null,null,null,{"$f":"SUM(E36:E110)","v":2852884.04466051},{"$f":"SUM(F36:F110)","v":2305014.2633377197},{"$f":"SUM(G36:G110)","v":547869.78132279066},null,{"$f":"SUM(I36:I110)","v":17581514.546065558},{"$f":"SUM(J36:J110)","v":11781811.049226314},{"$f":"SUM(K36:K110)","v":5799703.4968392411}]
[]
[]
[]
[]
["C- BREAKDOWN* BY IMPLEMENTING ENTITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","PR/SR","Name","Type of\nImplementing Entity"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"SR","SRS","NGO/CBO/Academic",44046.592221794388,49191.049883234031,{"$f":"E118-F118","v":-5144.4576614396428},null,252856.9246551515,175727.30738182188,{"$f":"I118-J118","v":77129.617273329612}]
[2,"SR","Georgian Harm Reducation Network","NGO/CBO/Academic",552391.76203311514,630346.92854333087,{"$f":"E119-F119","v":-77955.166510215728},null,2358896.3175999722,2530242.0539025776,{"$f":"I119-J119","v":-171345.73630260536}]
[3,"SR","Center of Mental Health and Prevention of Drug Addiction","Other Government",295324.22025413939,345019.99894355854,-49695.778689419152,null,1155943.4956102581,1301852.3457783421,-145908.85016808403]
[4,"SR","Tanadgoma","NGO/CBO/Academic",218314.20870234887,250292.08044502957,-31977.871742680698,null,922860.73667159572,1009907.3704472514,-87046.633775655646]
[5,"SR","Infectious Diseases, AIDS and Clinical Immunology Research Center","Other Government",310838.31876269972,357134.06738547888,-46295.748622779152,null,1409355.0439977241,1360803.9375092797,48551.106488444377]
[6,"SR","HIV/AIDS Patients Support Foundation","NGO/CBO/Academic",51269.156719291495,58257.060082867189,-6987.9033635756932,null,266338.66661352583,277342.3716737603,-11003.705060234468]
[7,"SR","Curatio International Foundation","Private Sector",0,11525.902008635256,{"$f":"E124-F124","v":-11525.902008635256},null,401411.26443483966,335956.4616611604,{"$f":"I124-J124","v":65454.802773679257}]
[8,"PR","National Center for Disease Control and Public Health","Other Government",1380699.7859671214,603247.17604558531,777452.60992153606,"Net variance of EUR 777,453 consists of Positive variance of EUR 1,026,137 and negative variance of EUR 248,684\nPositive variance EUR 1,026,137 consists of the following Savings:\nEUR 12,887 - Actual cost and Quantity (to match the county’s quota for the drug) for Methadone was less than budgeted.\nEUR 798,345 – Commitment for PFSCM order for ARVs placed in 2014 and new order placed in 2015 is transferred to NFM budget. \nEUR 106,688 – Part of IDA commitment was reimbursed by the GF by the end of 2015 and remaining amount was moved to NFM budget.\nEUR 91,604 – Actual cost for HPHE was less than budgeted, also procurement of Saliva Tests was cancelled due to failure of supplier to deliver the tests. \nEUR 338- Actual printing cost was less than budgeted.\nEUR 16,275 – Actual cost for fuel provided to SRs was less than budgeted\n\nNegative Variance EUR 248,684 consists of the following:\nEUR 415– Actual Cost of MPP provided to TG was slightly greater than budgeted. \nEUR 247,740– Actual cost of HPHE was greater than budgeted due to: some activities budgeted in the previous reporting period and increased Quantities of ART monitoring tests and supplies based on the SR’s renewed request. \nEUR 529 – Project management cost (Consultant fee and PR fuel cost) - committed in the Dec 2015 and payment carried out in January 2016.\n",10813852.056482488,4789979.2008721214,6023872.8556103669,"Net cumulative variance of EUR 6,023,873 consists of Positive variance of EUR 6,404,580 and negative variance of EUR 380,707\nTotal Saving EUR 6,404,580 include: \nEUR 74,081 – Actual cost and quantities for SRs fuel was less than budgeted\nEUR 4,635,799– Savings from  MPP &PSM (ARVs, interferon, methadone, STI medicines, quality control of ARVs) is derived from cancelled activities, actual consumption rates, lower unit prices, including lower unit prices of ARVs offered by PPM and also regimens were simplified. Considerably lower price procurement of interferon through the local tender. Also Procurement of pegylated interferon and ribavirin budgeted at 340,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.  Procurement of methadone was conducted at much lower price than budgeted also (4 EUR vs. 9 EUR). Commitment for PFSCM order for ARVs placed in 2014 and new order placed in 2015 is transferred to NFM budget.\nEUR 1,243,769 – Saving from HPHE procurement (lab supplies, disinfectants, tests systems, Flow cytometer; syringes, condoms) is derived from low unit prices as a result of tenders; revision of the q-ties based on the consumption data and some cancelled activities. In addition instead of one flow cytometer with high technical characteristic, in agreement with GF and AIDS Center, four field equipment – BD Presto, were procured for CD4 count measurement, which has resulted in substantial saving. \nEUR 128,036 - Procurement of office equipment/furniture and printing of materials through tenders resulted in saving. Database development cost budgeted in GHRN is moved to NFM period, the amount is included in the savings.\nEUR 77,978 - Procurement of Vehicles for SRs was cancelled in agreement with GF.\nEUR 244,917 - Saving in Project management costs including International PSM consultant's fee, in HR (HIV M&E specialist , finance specialist, logistics specialist ) ; saving related to renovation of office; procuring furniture (It was handed over from previous PR) ; fuel; tender announcement costs, Technical assistance; late start of media campaign, Audit fee. The FX rate had also impact on savings.\nNegative Variance EUR 380,707 include:\nEUR 370,128 – Overspending in procurement of HPHE including cost of additional 4 mobile ambulatories approved by GF and tests-lab supplies provided to Aids Center\nEUR 1,396 – Actual cost of office equipment/furniture was slightly greater than budgeted.\nEUR 7,580 – Actual need of STI medicines was increased based on the current consumption. \nEUR 1,603– Actual Cost of Printing info materials for TG was greater than budgeted.\n"]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E131-F131","v":0},null,0,0,{"$f":"I131-J131","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E134-F134","v":0},null,0,0,{"$f":"I134-J134","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E137-F137","v":0},null,0,0,{"$f":"I137-J137","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E157-F157","v":0},null,0,0,{"$f":"I157-J157","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,null,null,"TOTAL",{"$f":"SUM(E118:E160)","v":2852884.0446605105},{"$f":"SUM(F118:F160)","v":2305014.2633377197},{"$f":"SUM(G118:G160)","v":547869.78132279078},null,{"$f":"SUM(I118:I160)","v":17581514.506065555},{"$f":"SUM(J118:J160)","v":11781811.049226314},{"$f":"SUM(K118:K160)","v":5799703.4568392411}]
[]
[]
[]
[]
["* The sum of all three breakdowns should be equal (A- Budget Line-item, B- Program Activity, C- Implementing Entity)."]
["** For the purposes of this report, the SDA Program management and administration should be included in the Supportive Environment Macro Category."]
[]
["D- ADDITIONAL INFORMATION"]
["Please disclose any relevant information concerning the information in the above tables. Refer to the Guidelines for Completing the Template if required."]
[]
[]
[]
[]
[]
[]
["E- DISBURSEMENTS BREAKDOWN BY IMPLEMENTING ENTITY",null,null,null,"Cumulative Reporting Period"]
["#","Name","Type of\nImplementing Entity","Cumulative Disbursements","Comments"]
[1,"Real People, Real Vision","NGO/CBO/Academic",31130.44,"Activities under Objective 1 had 3 implementers (Srs) -Real people real vision (2 contracts); Tanadgoma( 1 contract) ; HAPS (1 contract)"]
[2,"Tanadgoma","NGO/CBO/Academic",{"$f":"76601.91+49191.05","v":125792.96000000001}]
[3,"HIV/AIDS Patients Support Foundation","NGO/CBO/Academic",18803.830000000002]
[4,"Georgian Harm Reducation Network","NGO/CBO/Academic",2530242.0539025776]
[5,"Center of Mental Health and Prevention of Drug Addiction","Other Government",1301852.3457783421]
[6,"Tanadgoma","NGO/CBO/Academic",1009907.3704472514]
[7,"Infectious Diseases, AIDS and Clinical Immunology Research Center","Other Government",1360803.9375092797]
[8,"HIV/AIDS Patients Support Foundation","NGO/CBO/Academic",269246.37167376]
[9,"BCG Research","Private Sector",8096,"Stigma Survey among healthcare workers was budgeted under SR HAPS, but through tender another organization was identified as winner"]
[10,"Curatio International Foundation","Private Sector",335956.4616611604]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"TOTAL",{"$f":"SUM(D179:D205)","v":6991831.7709723702}]

{"sheet":"LFA EFR_7B","index":19,"n_rows":206,"n_cols":26,"rows_kept":206,"cut":false,"hidden":false,"merged":[[202,4,202,10],[188,4,188,10],[189,4,189,10],[200,4,200,10],[201,4,201,10],[190,4,190,10],[191,4,191,10],[192,4,192,10],[193,4,193,10],[194,4,194,10],[195,4,195,10],[196,4,196,10],[197,4,197,10],[198,4,198,10],[199,4,199,10],[180,4,180,10],[181,4,181,10],[204,4,204,10],[169,0,169,11],[170,0,174,11],[176,4,176,11],[177,4,177,10],[178,4,178,10],[179,4,179,10],[182,4,182,10],[183,4,183,10],[203,4,203,10],[184,4,184,10],[185,4,185,10],[186,4,186,10],[187,4,187,10],[168,0,168,11],[27,1,27,3],[28,1,28,3],[29,1,29,3],[30,0,30,2],[33,4,33,7],[33,8,33,11],[110,0,110,3],[111,0,113,4],[115,4,115,7],[115,8,115,11],[161,0,163,4],[26,1,26,3],[21,1,21,3],[21,15,21,16],[21,20,21,21],[22,1,22,3],[22,15,22,16],[22,20,22,21],[23,1,23,3],[23,15,23,16],[23,20,23,21],[24,1,24,3],[25,1,25,3],[18,1,18,3],[18,15,18,16],[18,20,18,21],[19,1,19,3],[20,1,20,3],[20,15,20,16],[20,20,20,21],[16,1,16,2],[16,15,16,16],[16,20,16,21],[17,1,17,3],[17,15,17,16],[17,20,17,21],[8,8,9,8],[12,4,14,7],[15,4,15,7],[15,8,15,11],[15,20,15,21],[15,15,15,16],[8,0,8,1],[0,0,0,5],[3,0,3,1],[3,2,3,3],[3,5,4,7],[4,0,4,1],[4,2,4,3],[5,0,5,1],[5,2,5,3],[6,0,6,1],[6,2,6,3],[7,0,7,1],[8,4,9,4],[7,2,7,3]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 7B: LFA - Enhanced Financial Reporting"]
[]
["Country",null,{"$f":"CoverSheet!D5","v":"Georgia"},null,null,"PLEASE REFER TO THE \"GUIDANCE FOR COMPLETION OF THE ENHANCED FINANCIAL REPORTING TEMPLATE\" DOCUMENT TO ASSIST YOU IN COMPLETING THE TEMPLATE"]
["Grant No.",null,{"$f":"CoverSheet!D7","v":"GEO-H-NCDC"}]
["PR",null,{"$f":"CoverSheet!D8","v":"National Center for Disease Control and Public Health"},null,null,"TO BE COMPLETED ONLY ONCE A YEAR "]
["Currency",null,{"$f":"CoverSheet!D11","v":"EUR"}]
["Disease(Component)",null,{"$f":"CoverSheet!D6","v":"HIV/AIDS"},null,null,null,"dd-mm-yyyy",null,null,null,"dd-mm-yyyy"]
[null,null,null,null,"Current Reporting Period","Start Date:",null,null,"Cumulative Reporting Period","Start Date:"]
[null,null,null,null,null,"End Date:",null,null,null,"End Date:"]
[null,null,null,null,null,null,null,"The end date for the current reporting period and cumulative reporting period must be the same"]
[null,null,{"$f":"CONCATENATE(\"EFR\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"EFRHIVAIDS"}]
[null,null,{"$f":"CONCATENATE(\"SDA\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"SDAHIVAIDS"},null,"The \"TOTAL\" rows in Table A, B and C will have a RED background if the amounts in each table do not agree. If the Totals for each Table agrees, these rows will have a YELLOW background. "]
[]
[]
["A- BREAKDOWN* BY  EXPENDITURE CATEGORY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period",null,null,null,null,null,null,{"$f":"IF('[3]PR_Programmatic Progress_1A'!R15=\"Select\",\"Please select currency on Page\n 'PR_Programmatic Achievement (1)'\", \"All amounts are in: \"&'[3]PR_Programmatic Progress_1A'!R15)","v":"All amounts are in: "},null,"Budget for Reporting Period","Actual Cash Outflow for Reporting Period","Variance","Reason for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Cash Outflow through period of Progress Update","Variance","Reason for Variance"]
["#","Category",null,null," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance",null,null,null,"1. Total PR cash outflow vs. budget",null,{"$f":"R18+R19","v":0},{"$f":"S18+S19","v":0},{"$f":"IF(R17=\"\",IF(S17=\"\",\"\",R17-S17),R17-S17)","v":0},null,null,{"$f":"W18+W19","v":0},{"$f":"X18+X19","v":0},{"$f":"IF(W17=\"\",IF(X17=\"\",\"\",W17-X17),W17-X17)","v":0}]
[1,"Human Resources",null,null,0,0,{"$f":"E18-F18","v":0},null,0,0,{"$f":"I18-J18","v":0},null,null,null,null,"    1a. PR's total expenditures",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C13","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D13","v":0},{"$f":"IF(R18=\"\",IF(S18=\"\",0,R18-S18),R18-S18)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H13","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I13","v":0},{"$f":"IF(W18=\"\",IF(X18=\"\",0,W18-X18),W18-X18)","v":0}]
[2,"Technical Assistance",null,null,0,0,{"$f":"E19-F19","v":0},null,0,0,{"$f":"I19-J19","v":0},null,null,null,null,"    1b. Disbursements to sub-recipients",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C14","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D14","v":0},{"$f":"IF(R19=\"\",IF(S19=\"\",0,R19-S19),R19-S19)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H14","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I14","v":0},{"$f":"IF(W19=\"\",IF(X19=\"\",0,W19-X19),W19-X19)","v":0}]
[3,"Training",null,null,0,0,0,null,0,0,0]
[4,"Health Products and Health Equipment",null,null,0,0,0,null,0,0,0,null,null,null,null,null,null,"Budget for Reporting Period*","Actual Cash Outflow for Reporting Period","Variance","Reason for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Cash Outflow through period of Progress Update","Variance","Reason for Variance"]
[5,"Medicines and Pharmaceutical Products",null,null,0,0,0,null,0,0,0,null,null,null,null,"2. Total pharmaceutical & health product expenditures vs. budget",null,{"$f":"R23+R24","v":0},{"$f":"S23+S24","v":0},{"$f":"IF(R22=\"\",IF(S22=\"\",\"\",R22-S22),R22-S22)","v":0},null,null,{"$f":"W23+W24","v":0},{"$f":"X23+X24","v":0},{"$f":"IF(W22=\"\",IF(X22=\"\",\"\",W22-X22),W22-X22)","v":0}]
[6,"Procurement and Supply Management Costs",null,null,0,0,0,null,0,0,0,null,null,null,null,"    2a.  Medicines and pharmaceutical products",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C18","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D18","v":0},{"$f":"IF(R23=\"\",IF(S23=\"\",0,R23-S23),R23-S23)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H18","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I18","v":0},{"$f":"IF(W23=\"\",IF(X23=\"\",0,W23-X23),W23-X23)","v":0}]
[7,"Infrastructure and Other Equipment",null,null,0,0,0,null,0,0,0,null,null,null,null,"    2b.  Health products and health equipment",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C19","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D19","v":0},{"$f":"IF(R24=\"\",IF(S24=\"\",0,R24-S24),R24-S24)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H19","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I19","v":0},{"$f":"IF(W24=\"\",IF(X24=\"\",0,W24-X24),W24-X24)","v":0}]
[8,"Communication Materials",null,null,0,0,0,null,0,0,0]
[9,"Monitoring & Evaluation",null,null,0,0,0,null,0,0,0]
[10,"Living Support to Clients/Target Populations",null,null,0,0,0,null,0,0,0]
[11,"Planning and Administration",null,null,0,0,0,null,0,0,0]
[12,"Overheads",null,null,0,0,0,null,0,0,0]
[13,"Other",null,null,0,0,0,null,0,0,0]
[null,null,null,"TOTAL",{"$f":"SUM(E18:E30)","v":0},{"$f":"SUM(F18:F30)","v":0},{"$f":"SUM(G18:G30)","v":0},null,{"$f":"SUM(I18:I30)","v":0},{"$f":"SUM(J18:J30)","v":0},0]
[]
[]
["B- BREAKDOWN* BY PROGRAM ACTIVITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Macro-category","Objectives","Service Delivery Area"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E36-F36","v":0},null,0,0,{"$f":"I36-J36","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E37-F37","v":0},null,0,0,{"$f":"I37-J37","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E51-F51","v":0},null,0,0,{"$f":"I51-J51","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E73-F73","v":0},null,0,0,{"$f":"I73-J73","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E83-F83","v":0},null,0,0,{"$f":"I83-J83","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E97-F97","v":0},null,0,0,{"$f":"I97-J97","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E104-F104","v":0},null,0,0,{"$f":"I104-J104","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E107-F107","v":0},null,0,0,{"$f":"I107-J107","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
["TOTAL",null,null,null,{"$f":"SUM(E36:E110)","v":0},{"$f":"SUM(F36:F110)","v":0},{"$f":"SUM(G36:G110)","v":0},null,{"$f":"SUM(I36:I110)","v":0},{"$f":"SUM(J36:J110)","v":0},{"$f":"SUM(K36:K110)","v":0}]
[]
[]
[]
[]
["C- BREAKDOWN* BY IMPLEMENTING ENTITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","PR/SR","Name","Type of\nImplementing Entity"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E118-F118","v":0},null,0,0,{"$f":"I118-J118","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E119-F119","v":0},null,0,0,{"$f":"I119-J119","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E122-F122","v":0},null,0,0,{"$f":"I122-J122","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E127-F127","v":0},null,0,0,{"$f":"I127-J127","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E131-F131","v":0},null,0,0,{"$f":"I131-J131","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E147-F147","v":0},null,0,0,{"$f":"I147-J147","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,null,null,"TOTAL",{"$f":"SUM(E118:E160)","v":0},{"$f":"SUM(F118:F160)","v":0},{"$f":"SUM(G118:G160)","v":0},null,{"$f":"SUM(I118:I160)","v":0},{"$f":"SUM(J118:J160)","v":0},{"$f":"SUM(K118:K160)","v":0}]
[]
[]
[]
[]
["* The sum of all three breakdowns should be equal (A- Budget Line-item, B- Program Activity, C- Implementing Entity)."]
["** For the purposes of this report, the SDA Program management and administration should be included in the Supportive Environment Macro Category."]
[]
["D- ADDITIONAL INFORMATION"]
["Please disclose any relevant information concerning the information in the above tables. Refer to the Guidelines for Completing the Template if required."]
[]
[]
[]
[]
[]
[]
["E- DISBURSEMENTS BREAKDOWN BY IMPLEMENTING ENTITY",null,null,null,"Cumulative Reporting Period"]
["#","Name","Type of\nImplementing Entity","Cumulative Disbursements","Comments"]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"TOTAL",{"$f":"SUM(D179:D205)","v":0}]

{"sheet":"Annual Cash Forecast_8A","index":20,"n_rows":36,"n_cols":16,"rows_kept":36,"cut":false,"hidden":false,"merged":[[9,1,9,2],[10,1,10,2],[0,0,0,7],[3,1,3,2],[4,1,4,2],[5,1,5,2],[6,1,6,2],[7,1,7,2],[8,1,8,2]]}
["Ongoing Progress Update and Disbursement Request"]
[]
["Section 8A: The Global Fund Annual Forecast Template"]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[]
["Reporting Cycle","From","To"]
["Current reporting period","2015-01-01","2015-12-31"]
["Cumulative Reporting period","2015-01-01","2015-12-31"]
[]
[]
[]
[]
["Summary Breakdown by Cost Grouping"]
[]
["Costing Dimension (Cost Grouping)","Budget for Forecast Period","Unspent from previous periods","Budget for the Buffer Period","Total Budget available (including the buffer)","Adjustment for the  Forecast Period (based on implementable activities)","Adjustment for the Buffer Period","Total Principal Recipient Forecast (including Buffer)","Comments",null,"Local Fund Agent Adjustment on PR Budget","Local Fund Agent Adjustment on Budget for the Buffer Period","Local Fund Agent Adjustment on the Forecast","Local Fund Agent Adjustment on the Buffer Forecast","Local Fund Agent - Adjusted Forecast (including the buffer)","Comments"]
["Human Resources (HR)",0,{"$f":"'PR EFR_7A'!K18","v":-470559.72214948386},0,{"$f":"B23+C23+D23","v":-470559.72214948386},471327.52261257602,0,{"$f":"E23+F23+G23","v":767.80046309216414},null,null,null,null,null,null,{"$f":"K23+L23+H23+M23+N23","v":767.80046309216414}]
["Technical Assistance",0,{"$f":"'PR EFR_7A'!K19","v":92980.956712760672},0,{"$f":"B24+C24+D24","v":92980.956712760672},-92973.858465181998,0,{"$f":"E24+F24+G24","v":7.0982475786731811},null,null,null,null,null,null,{"$f":"K24+L24+H24+M24+N24","v":7.0982475786731811}]
["Training",0,{"$f":"'PR EFR_7A'!K20","v":147559.03640730077},0,147559.03640730077,-147528.01286727301,0,31.023540027759736,null,null,null,null,null,null,31.023540027759736]
["Health Products and Health Equipment",0,{"$f":"'PR EFR_7A'!K21","v":840511.58633160777},0,840511.58633160777,-840511.58633160801,0,-2.3283064365386963E-10,null,null,null,null,null,null,-2.3283064365386963E-10]
["Medicines and Pharmaceutical Products",0,{"$f":"'PR EFR_7A'!K22","v":3701666.0246454692},0,3701666.0246454692,-3701666.0246454701,0,-9.3132257461547852E-10,null,null,null,null,null,null,-9.3132257461547852E-10]
["Procurement and Supply Management Costs",0,{"$f":"'PR EFR_7A'!K23","v":917108.01536607498},0,917108.01536607498,-917101.37760824698,0,6.6377578279934824,null,null,null,null,null,null,6.6377578279934824]
["Infrastructure and Other Equipment",0,{"$f":"'PR EFR_7A'!K24","v":206345.41996644891},0,206345.41996644891,-206331.81734995899,0,13.602616489923093,null,null,null,null,null,null,13.602616489923093]
["Communication Materials",0,{"$f":"'PR EFR_7A'!K25","v":64430.722256013381},0,64430.722256013381,-64430.722256013403,0,-2.1827872842550278E-11,null,null,null,null,null,null,-2.1827872842550278E-11]
["Monitoring & Evaluation",0,{"$f":"'PR EFR_7A'!K26","v":83114.427650676545},0,83114.427650676545,-83101.312953141605,0,13.114697534940206,null,null,null,null,null,null,13.114697534940206]
["Living Support to Clients/Target Populations",0,{"$f":"'PR EFR_7A'!K27","v":55997.661995518167},0,55997.661995518167,-55975.424229549499,0,22.2377659686681,null,null,null,null,null,null,22.2377659686681]
["Planning and Administration",0,{"$f":"'PR EFR_7A'!K28","v":35589.776096630347},0,35589.776096630347,-35576.870730231298,0,12.905366399048944,null,null,null,null,null,null,12.905366399048944]
["Overheads",0,{"$f":"'PR EFR_7A'!K29","v":138595.6077063079},0,138595.6077063079,-138451.31077214601,0,144.2969341618882,null,null,null,null,null,null,144.2969341618882]
["Other",0,{"$f":"'PR EFR_7A'!K30","v":-13636.046250125799},0,-13636.046250125799,12617.322933113101,0,-1018.7233170126983,null,null,null,null,null,null,-1018.7233170126983]
["Grand Total",{"$f":"SUM(B23:B35)","v":0},{"$f":"SUM(C23:C35)","v":5799703.4667351972},{"$f":"SUM(D23:D35)","v":0},{"$f":"SUM(E23:E35)","v":5799703.4667351972},{"$f":"SUM(F23:F35)","v":-5799703.4726631315},0,-5.9279328252159758E-3,null,null,{"$f":"SUM(K23:K35)","v":0},{"$f":"SUM(L23:L35)","v":0},0,0,-5.9279328252159758E-3]

{"sheet":" Request and Recommendation_8B","index":21,"n_rows":56,"n_cols":18,"rows_kept":56,"cut":false,"hidden":false,"merged":[[58,9,62,14],[36,1,37,8],[32,7,33,17],[55,9,55,14],[32,0,33,6],[36,0,39,0],[39,1,39,8],[48,9,48,12],[50,9,50,12],[52,9,52,12],[41,0,41,8],[52,1,52,4],[39,13,39,17],[41,13,41,17],[41,11,41,12],[39,11,39,12],[40,11,40,12],[40,13,40,17],[42,0,42,8],[9,0,9,17],[38,1,38,8],[30,0,31,6],[27,0,27,16],[28,0,28,16],[20,1,20,3],[30,7,31,17],[36,11,36,12],[36,13,36,17],[37,13,37,17],[38,11,38,12],[37,11,37,12],[38,13,38,17],[6,0,6,4],[6,5,6,9],[0,0,0,14],[2,0,2,4],[2,5,2,9],[5,5,5,9]]}
["Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant Name:",null,null,null,null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 8B.  Disbursement Request and Recommendation"]
[]
["Total forecasted net cash expenditures by the Principal Recipient for the period immediately following the period covered by the Progress Update:"]
[" "]
["1.  Period beginning date:",null,null,null,null,{"$f":"IF(CoverSheet!J11=\"\",\"\",CoverSheet!J11)","v":""},null,"end date:",{"$f":"IF(CoverSheet!L11=\"\",\"\",CoverSheet!L11)","v":""},null,"Approved budget amount (PR):",null,{"$f":"'Annual Cash Forecast_8A'!B36","v":0},null,"Forecasted amount  (PR)",{"$f":"'Annual Cash Forecast_8A'!B36+'Annual Cash Forecast_8A'!C36+'Annual Cash Forecast_8A'!F36","v":-5.9279343113303185E-3}]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,{"$f":"'Annual Cash Forecast_8A'!B36+'Annual Cash Forecast_8A'!K36","v":0},null,"LFA-adjusted forecasted amount:",{"$f":"P13+'Annual Cash Forecast_8A'!M36","v":-5.9279343113303185E-3}]
["2a. Cash buffer period (by default)"]
["  (cash \"buffer\") beginning date:",null,null,null,null,{"$f":"IF(I13=\"\",\"\",I13+1)","v":""},null,"end date:",{"$f":"IF(F17=\"\",\"\",DATE(YEAR(F17),MONTH(F17)+3,DAY(F17)-1))","v":""},null,"Approved budget amount (PR):",null,{"$f":"'Annual Cash Forecast_8A'!D36","v":0},null,"Forecasted amount  (PR):",{"$f":"'Annual Cash Forecast_8A'!D36+'Annual Cash Forecast_8A'!G36","v":0}]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,{"$f":"'Annual Cash Forecast_8A'!D36+'Annual Cash Forecast_8A'!L36","v":0},null,"LFA-adjusted forecasted amount:",{"$f":"P17+'Annual Cash Forecast_8A'!N36","v":0},null,"PR Total Forecast"]
["2b.  Additional \"buffer\" (discretionary, select only if there is a prior agreement with the FPM) (1)",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"P13+P17+P24","v":-5.9279343113303185E-3}]
[null,"Cash \"buffer\" agreed with FPM (2)",null,null,null,"Select ",null,null,null,null,null,null,null,null,null,null,null,"LFA Total Forecast"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"P15+P19+P26","v":-5.9279343113303185E-3}]
[]
["(cash \"buffer\") beginning date",null,null,null,null,{"$f":"IF(I17=\"\",\"\",I17+1)","v":""},null,"end date:",{"$f":"IF(F21=\"\",\"\",IF(F21=\"1M\",DATE(YEAR(I17),MONTH(I17)+1,DAY(I17)-1),IF(F21=\"2M\",DATE(YEAR(I17),MONTH(I17)+2,DAY(I17)-1),IF(F21=\"3M\",DATE(YEAR(I17),MONTH(I17)+3,DAY(I17)-1),\"\"))))","v":""},null,"Approved budget amount:",null,0,null,"Forecasted amount:",0]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,null,null,"LFA-adjusted forecasted amount:"]
[]
["(1) Upon agreement with the FPM, additional Cash buffer can be requested if the PU/DR report contains a completed AFR or EFR report or if there is a request from the Secretariat for the PR to complete the report on SR Cash Reconciliation contained in the “SR Cash Reconciliation 2D”, or if there are any additional Global Fund-specific requirements that cannot be delivered within 60 days.  However such requests may or may not be satisfied based on the review of the current PU/DR."]
["(2) When the additional (cash \"buffer\" ) period is 1 or 2 months, the approved budget and forecasted amounts should be calculated as prorated values for the period following the regular buffer period."]
[]
["PR's explanation of any significant variance between forecasted amounts and amounts as originally budgeted.  Please explain any significant variance (based on your judgment) between the forecasted amounts and the amounts as per approved budgets.  Please specify the main factors and related amounts that are the major drivers of the variance. \nNB. Consider the following items when providing the analysis. \n  - Expected timing of payments for any significant budgetary items,\n  - Impact of existing cash balance at SR levels\n  - Current confirmed commitments to be paid during disbursement request period \n  - Current/expected unit prices compared to those in the budget \n  - Change in quantities compared to budget\n  - Exchange rates and inflation\n  - Linkage between budget absorption and programmatic performance to-date.\n\n! The forecast should include any existing commitments (eligible under this grant) as of the end of the reporting period and which are likely to be paid during the disbursement period"]
[]
["LFA comments on PR's explanation of any significant variance between forecasted amounts and amounts as originally budgeted."]
[]
[]
[]
["Less:","3. Cash Balance: End of period covered by Progress Update (Item 5.1 in PRLFA Cash Reconciliation):",null,null,null,null,null,null,null,"PR-reported amounts","PR Comments","LFA-verified amounts",null,"LFA Comments"]
[null,null,null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D52","v":222863.80287342222},"The remaining cash balance includes USD 193,278 - commited to NFM Budget",{"$f":"'PR Cash Reconciliation_2A,B,C'!H52","v":222863.80287342222}]
[null,"4. Cash in Transit for the reporting period (Disbursements to PR & third party disbursements):",null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D63","v":0},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H63","v":0}]
[null,"5.Cash in Transit after the current reporting period (Disbursements to PR & third party disbursements) :",null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D64","v":0},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H64","v":0}]
[null,null,null,null,null,null,null,null,null,"PR-requested amount","PR Comments","LFA-verified amounts",null,"LFA Comments"]
["6. Disbursement Request to the Global Fund for the period immediately following the period covered by the Progress Update, plus additional period (cash buffer):",null,null,null,null,null,null,null,null,{"$f":"IF(R20=0,0,IF(R20-J38-J39-J40<0,0,R20-J38-J39-J40))","v":0},null,{"$f":"IF(R22=0,0,IF(R22-L38-L39-L40<0,0,R22-L38-L39-L40))","v":0},{"$f":"IF(T22=0,0,IF(T22-M38-M39-M40<0,0,T22-M38-M39-M40))","v":0}]
[]
["7.  Does the PR's Disbursement Request include funds for health product procurement?",null,null,null,null,null,null,null,null,"N/A"]
["8.  Exchange Rate (used to translate local currency into grant currency)",null,null,null,null,null,null,null,null,"Yes"]
[]
[null,null,null,null,null,"Rates used by the PR",null,"LFA-verified rates",null,"Name of local currency, date and source of the exchange rate, and other comments (if appropriate) "]
[]
[null,"- used to convert Opening Cash Balance",null,null,null,2.6168999999999998,null,0,null,"Exchange rate at the closing date of the previous reporting period (source: www.nbg.gov.ge)"]
[]
[null,"- used to convert Closing Cash Balance",null,null,null,2.6082999999999998,null,0,null,"Exchange rate as of 31/07/2016 (source: www.nbg.gov.ge)"]
[]
[null,"- used to convert Total PR Cash Outflow for the Progress Update Period",null,null,null,"N/A",null,0,null,"Exchange rate at the date of transaction  (source: www.nbg.gov.ge)"]
[]
[]
[null,null,null,null,null,null,null,null,null,"LFA comments on the exchange rates used by the PR"]

{"sheet":"PR Authorization_9A","index":22,"n_rows":14,"n_cols":10,"rows_kept":14,"cut":false,"hidden":false,"merged":[[8,0,8,14],[16,0,16,14],[10,0,10,4],[0,0,0,14],[2,0,2,4],[2,5,2,9],[5,5,5,9],[6,0,6,4],[6,5,6,9],[10,5,10,9],[11,5,11,9],[12,5,12,9],[13,5,13,9]]}
["Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant Name:",null,null,null,null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Section 9A.  PR Authorization"]
["The undersigned acknowledges that: (i) all the information (programmatic, financial, or otherwise) provided in this Progress Update and Disbursement Request is complete and accurate; (ii) funds disbursed in accordance with this request shall be deposited in the bank account specified in the Facesheet; and (iii) funds disbursed under the Grant Agreement shall be used in accordance with the Grant Agreement."]
[]
["Signed on behalf of the Principal Recipient:\n(signature of Authorized Designated Representative)"]
["Name:",null,null,null,null,"Paata Imnadze (on behalf of Program Director Irma Khonelidze)"]
["Title:",null,null,null,null,"Deputy Director, NCDC "]
["Date and Place:",null,null,null,null,"31 August 2016      Tbilisi, Georgia"]

{"sheet":"LFA Authorization_9B","index":23,"n_rows":19,"n_cols":10,"rows_kept":19,"cut":false,"hidden":false,"merged":[[13,0,13,14],[21,0,21,14],[0,0,0,14],[2,0,2,4],[2,5,2,9],[5,5,5,9],[6,0,6,4],[6,5,6,9],[10,0,10,14],[12,0,12,14],[11,0,11,14],[15,3,15,5],[16,3,16,5],[17,3,17,5],[18,3,18,5]]}
["Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant Name:",null,null,null,null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["For LFA Use Only"]
["Section 9B.  LFA Authorization"]
["Summary of the LFA's approach used for verification of financial, programmatic and procurement data and Quality Assurance undertaken by the LFA"]
["In this section the LFA should indicate, as applicable, what percentage of expenditures was verified at PR level, if any expenditures were verified at SR level, how many site visits were made, what tender documentation was verified, and any other material parts of verification procedures in line with the verification approach agreed upfront between the LFA and the Global Fund's Secretariat based on country/grant risks.  As a good practice, the verification approach needs to be reviewed jointly by the LFA and the Secretariat annually."]
[]
[]
["The LFA should sign a printed version of the verified PU/DR and send it to the Secretariat as a pdf file by email, or include an electronic signature in the Excel file to be submitted to the Global Fund."]
[]
["Signed on behalf of the LFA:"]
["Name:"]
["Title:"]
["Date and Place:"]

{"sheet":"PR_Disbursement Request_7","index":24,"n_rows":45,"n_cols":19,"rows_kept":45,"cut":false,"hidden":true,"merged":[[33,7,33,12],[40,8,40,11],[42,8,42,11],[44,1,44,4],[44,8,44,11],[30,0,32,0],[0,0,0,9],[2,0,2,4],[2,5,2,8],[5,5,5,8],[6,3,6,8],[10,0,10,18],[11,0,11,18],[23,0,23,19],[24,0,24,19],[26,0,27,7],[26,8,27,18]]}
["On-going Progress Update and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,null,null,null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,null,null,null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 5: Cash Reconciliation and Disbursement Request"]
[]
["B: DISBURSEMENT REQUEST"]
[]
[]
["Total forecasted net cash expenditures by the Principal Recipient for the period immediately following the period covered"]
[" by the Progress Update:"]
["1.  Period beginning date:",null,null,null,{"$f":"IF(CoverSheet!J11=\"\",\"\",CoverSheet!J11)","v":""},null,"end date:",{"$f":"IF(CoverSheet!L11=\"\",\"\",CoverSheet!L11)","v":""},null,"approved budget amount:",null,"forecasted amount:"]
["2a. Cash buffer period (by default)"]
["  (cash \"buffer\") beginning date:",null,null,null,{"$f":"IF(H16=\"\",\"\",H16+1)","v":""},null,"end date:",{"$f":"IF(E18=\"\",\"\",DATE(YEAR(E18),MONTH(E18)+3,DAY(E18)-1))","v":""},null,"approved budget amount:",null,"forecasted amount:"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"PR Total Forecast"]
["2b.  Additional \"buffer\" (discretionary, select only if there is a prior agreement with the FPM) (1)",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"N16+N18+N22","v":0}]
["cash \"buffer\" agreed with FPM (2)",null,"Select "]
["(cash \"buffer\") beginning date",null,null,null,{"$f":"IF(H18=\"\",\"\",H18+1)","v":""},null,"end date:",{"$f":"IF(C21=\"\",\"\",IF(C21=\"1M\",DATE(YEAR(E22),MONTH(E22)+1,DAY(E22)-1),IF(C21=\"2M\",DATE(YEAR(E22),MONTH(E22)+2,DAY(E22)-1),IF(C21=\"3M\",DATE(YEAR(E22),MONTH(E22)+3,DAY(E22)-1),\"\"))))","v":""},null,"approved budget amount:",null,"forecasted amount:"]
[]
["(1) Additional Cash buffer can be requested if the next PU/DR report will contain a completed EFR report or a completed Annex on SR financials, requested by the Secretariat, or if there are any additional GF-specific requirements that cannot be delivered within 45 days. An agreement in principal from the FPM should be obtained prior to requesting an additional cash buffer."]
["(2) When the additional (cash \"buffer\" ) period is 1 or 2 months, the approved budget and forecasted amounts should be calculated as prorated values for the period following the regular buffer period."]
[]
["Please explain any significant variance (based on your judgment) between the forecasted amounts and the amounts as per approved budgets.  Please specify the main factors and related amounts that are the major drivers of the variance. \nNB. Consider the following items when providing the analysis. \n  - Expected timing of payments for any significant budgetary items,\n  - Impact of existing cash balance at SR levels\n  - Current confirmed commitments to be paid during disbursement request period \n  - Current/expected unit prices compared to those in the budget \n  - Change in quantities compared to budget\n  - Exchange rates and inflation\n  - Linkage between budget absorption and programmatic performance to-date.\n\n! The forecast should include any existing commitments (eligible under this grant) as of the end of the reporting period and which are likely to be paid during the disbursement period"]
[]
[]
[]
["Less:","3. Cash Balance: End of period covered by Progress Update (number 10 from PR Cash Reconciliation sheet):",null,null,null,null,null,null,null,null,null,null,null,{"$f":"+'PR Cash Reconciliation_2A,B,C'!#REF!","v":{"$error":"#REF!"}}]
[]
[null,"4.  Cash \"in transit\" disbursed to the PR:"]
[null,"5. Cash \"in transit\" disbursed to third parties by the Global Fund on behalf of the PR",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"+N31+N33+N34","v":{"$error":"#REF!"}}]
[]
["6.  PR's Disbursement Request to the Global Fund for the period immediately following the period covered by the Progress Update, plus additional period (cash buffer):",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"IF(S20=0,0,IF(S20-S34<0,0,S20-S34))","v":0}]
[]
["7.  Does the PR's Disbursement Request include funds for health product procurement?",null,null,null,null,null,null,null,"Select"]
[]
["8. Exchange Rate (used to translate local currency into grant currency)",null,null,null,null,null,null,null,"Name of local currency, date and source of the exchange rate, and other comments (if appropriate) "]
[null,"- used to convert Opening Cash Balance"]
[]
[null,"- used to convert Closing Cash Balance"]
[]
[null,"- used to convert Total Cash Outflow for the Progress Update Period"]

{"sheet":"Modules","index":25,"n_rows":24,"n_cols":6,"rows_kept":24,"cut":false,"hidden":true,"merged":[]}
[]
[null,"HIVAIDS_Module","HIVTB","Tuberculosis","Malaria","Health Systems Strengthening"]
[null,"Prevention programs for general population","Prevention programs for general population","TB care and prevention","Vector control","HSS - Procurement supply chain management (PSCM)"]
[null,"Prevention programs for MSM and TGs","Prevention programs for MSM and TGs","TB/HIV","Case management","HSS - Health information systems and M&E"]
[null,"Prevention programs for sex workers and their clients","Prevention programs for sex workers and their clients","MDR-TB","Specific prevention interventions (SPI)","HSS - Health and community workforce"]
[null,"Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for people who inject drugs (PWID) and their partners","HSS - Procurement supply chain management (PSCM)","HSS - Procurement supply chain management (PSCM)","HSS - Service delivery"]
[null,"Prevention programs for other vulnerable populations (please specify)","Prevention programs for other vulnerable populations (please specify)","HSS - Health information systems and M&E","HSS - Health information systems and M&E","HSS - Financial management"]
[null,"Prevention programs for adolescents and youth, in and out of school","Prevention programs for adolescents and youth, in and out of school","HSS - Health and community workforce","HSS - Health and community workforce","HSS - Policy and governance"]
[null,"PMTCT","PMTCT","HSS - Service delivery","HSS - Service delivery","HSS - Healthcare financing"]
[null,"Treatment, care and support","Treatment, care and support","HSS - Financial management","HSS - Financial management","Removing legal barriers to access"]
[null,"TB/HIV","TB care and prevention","HSS - Policy and governance","HSS - Policy and governance","Program management"]
[null,"HSS - Procurement supply chain management (PSCM)","TB/HIV","HSS - Healthcare financing","HSS - Healthcare financing"]
[null,"HSS - Health information systems and M&E","MDR-TB","Removing legal barriers to access","Removing legal barriers to access"]
[null,"HSS - Health and community workforce","HSS - Procurement supply chain management (PSCM)","Community systems strengthening","Community systems strengthening"]
[null,"HSS - Service delivery","HSS - Health information systems and M&E","Program management","Program management"]
[null,"HSS - Financial management","HSS - Health and community workforce","Results-based Financing","Results based Financing"]
[null,"HSS - Policy and governance","HSS - Service delivery"]
[null,"HSS - Healthcare financing","HSS - Financial management"]
[null,"Removing legal barriers to access","HSS - Policy and governance"]
[null,"Community systems strengthening","HSS - Healthcare financing"]
[null,"Program management","Removing legal barriers to access"]
[null,"Results-based Financing","Community systems strengthening"]
[null,null,"Program management"]
[null,null,"Results-based Financing"]

{"sheet":"EFR Data","index":26,"n_rows":48,"n_cols":12,"rows_kept":48,"cut":false,"hidden":true,"merged":[]}
["EFRHIVAIDS",null,null,null,null,"SDAMalaria",null,"SDATuberculosis",null,"SDAHIVAIDS",null,"SDAHealthSystemsStrengthening"]
["Please Select…",null,null,null,null,"please select…",null,"please select…",null,"Please select…",null,"Please select…"]
["Prevention",null,null,null,null,"Prevention:  Behavioral Change Communication - Mass media",null,"Improving diagnosis",null,"Prevention: Behavioral Change Communication - Mass media",null,"HSS: Service delivery"]
["Treatment",null,null,null,null,"Prevention:  Behavioral Change Communication - community outreach",null,"Standardized treatment, patient support and patient charter",null,"Prevention: Behavioral Change Communication - community outreach",null,"HSS: Human resources"]
["Care and Support",null,null,null,null,"Prevention: Insecticide-treated nets (ITNs)",null,"Procurement and supply management",null,"Prevention: Condom distribution",null,"HSS: Community Systems Strengthening"]
["TB/HIV Collaborative Activities",null,null,null,null,"Prevention: Malaria prevention during pregnancy",null,"M&E",null,"Prevention: Counseling and Testing ",null,"HSS: Information system & Operational research"]
["Supportive Environment",null,null,null,null,"Prevention: Vector control (other than ITNs)",null,"TB/HIV",null,"Prevention: PMTCT",null,"HSS: Infrastructure"]
["Health System Strengthening (HSS)",null,null,null,null,"Prevention: other - specify",null,"MDR-TB",null,"Prevention: Post-exposure prophylaxis (PEP)",null,"HSS: Procurement and Supply management"]
[null,null,null,null,null,"Treatment: Prompt, effective anti-malarial treatment",null,"High-risk groups ",null,"Prevention: STI diagnosis and treatment",null,"HSS: other - specify"]
[null,null,null,null,null,"Treatment: Home based management of malaria",null,"HSS (beyond TB)",null,"Prevention: Blood safety and universal precaution",null,"Supportive environment: Program management and administration"]
["EFRMalaria",null,null,null,null,"Treatment: Diagnosis",null,"PAL (Practical Approach to Lung Health)",null,"Treatment: Antiretroviral treatment (ARV) and monitoring"]
["Please Select…",null,null,null,null,"Treatment: other - specify",null,"PPM / ISTC (Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)",null,"Treatment: Prophylaxis and treatment for opportunistic infections"]
["Prevention",null,null,null,null,"Supportive environment: Monitoring drug resistance",null,"ACSM (Advocacy, communication and social mobilization) ",null,"Care and support: Care and support for the chronically ill"]
["Treatment",null,null,null,null,"Supportive environment: Monitoring insecticide resistance",null,"Community TB care",null,"Care and support: Support for orphans and vulnerable children"]
["Supportive Environment",null,null,null,null,"Supportive environment: Coordination and partnership development (national, community, public-private)",null,"Programme-based operational research",null,"TB/HIV collaborative activities: HIV care and support for HIV-positive TB patients "]
["Health System Strengthening (HSS)",null,null,null,null,"Supportive environment: other - specify",null,"Other:Specify",null,"Supportive environment: Policy development including workplace policy"]
[null,null,null,null,null,"Supportive environment: Program management and administration",null,"Supportive environment: Program management and administration",null,"Supportive environment: Strengthening of civil society and institutional capacity building "]
[null,null,null,null,null,"HSS: Service delivery",null,null,null,"Supportive environment: Stigma reduction in all settings"]
["EFRHealthSystemsStrengthening",null,null,null,null,"HSS: Human resources",null,null,null,"Supportive environment: Program management and administration"]
["Please Select…",null,null,null,null,"HSS: Community Systems Strengthening",null,null,null,"HSS: Service delivery"]
["Health System Strengthening (HSS)",null,null,null,null,"HSS: Information system & Operational research",null,null,null,"HSS: Human resources"]
["Supportive Environment",null,null,null,null,"HSS: Infrastructure",null,null,null,"HSS: Community Systems Strengthening"]
[null,null,null,null,null,"HSS: Procurement and Supply management",null,null,null,"HSS: Information system & Operational research"]
[null,null,null,null,null,"HSS: other - specify",null,null,null,"HSS: Infrastructure"]
[null,null,null,null,null,null,null,null,null,"HSS: Procurement and Supply management"]
[null,null,null,null,null,null,null,null,null,"HSS: Other, specify"]
[]
[]
["EFRTuberculosis"]
["Please Select…"]
["TB Detection"]
["TB Treatment"]
["TB/HIV Collaborative Activities"]
["Supportive Environment"]
["Health System Strengthening"]
[]
[]
[]
[]
["IE"]
["Please Select…"]
["FBO"]
["NGO/CBO/Academic"]
["Private Sector"]
["Ministry Health (MoH)"]
["Other Government"]
["UNDP"]
["Other Multilateral Organization"]

{"sheet":"Checklist","index":27,"n_rows":30,"n_cols":4,"rows_kept":30,"cut":false,"hidden":false,"merged":[[5,0,5,3],[12,0,12,3],[18,0,18,3],[27,0,27,3]]}
["List of supporting documents for PU/DR review"]
[]
["This checklist is included for information and not for completion."]
[]
["List of Latest Approved Documents by functional area","To be made available to the LFA by the PR  ","To be submitted by the LFA to the Secretariat","Comments"]
["M&E"]
["Performance Framework","x"]
["M&E Plan","x"]
["Survey results","x",null,"For Impact/Outcome indicators"]
["M&E Systems Strengthening Assessment","x",null,"If newly available during the reporting period."]
["Other M&E assessments done by partners to assess data quality and M&E system issues.","x",null,"If newly available during the reporting period."]
[]
["Procurement"]
["Consumption reports for pharmaceuticals and health products","x"]
["Supplier invoices","x"]
["Procurement Plan","x"]
["Stock level reports","x"]
[]
["Finance"]
["Approved budgets","x",null,"For the periods covered by Progress Update and Disbursement Request, including the buffer period."]
["Cash books","x"]
["General Ledger ","x"]
["Cash forecasts ","x"]
["Bank statements","x"]
["Bank Reconciliations","x"]
["Annual PR Audit Report, Financial Statements, Management Letters and Responses (if Due)","x"]
["Annual SR Audit Report, Financial Statements, Management Letters and Responses (if Due)","x"]
["General Management"]
["Grant Agreement (including implementation letters)","x"]
["Workplan","x"]

{"sheet":"Memo HIV","index":28,"n_rows":26,"n_cols":10,"rows_kept":26,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["Please select…","Please select…","Please select…","Please select…","Please select…",null,null,null,null,"Please select…"]
["Prevention: Behavioral Change Communication - Mass media","% of young women and men aged 15-24 who are HIV infected ","impact","% of young people aged 15-24 who had sex with more than one partner in the last year ","National Health Accounts","Please enter a corresponding indicator here…",null,null,null,"Please select disease and Impact/Outcome first"]
["Prevention: Behavioral Change Communication - community outreach","% of adults aged 15-49 who are HIV infected ","outcome","% of young people aged 15-19 who have never had sex ","DHS/DHS+ (Demographic and Health Survey)","Please enter a data source here…"]
["Prevention: Condom distribution","% of adults and children with HIV still alive 12 months after initiation of antiretroviral therapy (extend to 2, 3, 5 years as program matures) ",null,"% of young people aged 15-24 who never had sex in the last year of those who ever had sex","MICS (Multiple Indicator Cluster Survey)","Please enter a SDA here…"]
["Prevention: Counseling and Testing ","% of infants born to HIV infected mothers who are infected ",null,"% of young people aged 15-24 reporting the consistent use of a condom with non-regular sexual partners in the last year ","AIS (AIDS Indicator Survey)"]
["Prevention: PMTCT","% of most-at-risk population(s) (sex workers, clients of sex workers, men who have sex with men, injecting drug users) who are HIV infected ",null,"% of young women and men who had sex before the age of 15 ","SAMS (Service Availibility Mapping Survey)"]
["Prevention: Post-exposure prophylaxis (PEP)","% of HIV seroprevalence among all newly registered TB patients",null,"% of adults and children who are still on treatment after 6 months, 1, 2, 3, 5 years from the initiation of treatment ","BSS (Behavioral and Surveillance Survey)"]
["Prevention: STI diagnosis and treatment",null,null,"% of injecting drug users who have adopted behaviors that reduce transmission of HIV. ","Sentinel surveillance"]
["Prevention: Blood safety and universal precaution",null,null,"% of orphaned children compared to non-orphaned children aged 10-14 who are currently attending school ","Serological surveys"]
["Treatment: Antiretroviral treatment (ARV) and monitoring",null,null,"% of young people aged 15-24 reporting the use of a condom the last time they had sex with a non-regular sexual partner ","Prevalence surveys"]
["Treatment: Prophylaxis and treatment for opportunistic infections",null,null,"% of people expressing accepting attitudes towards PLWHA, of all people surveyed aged 15-49 ","Facility-based survey "]
["Care and support: Care and support for the chronically ill",null,null,"% of female sex workers reporting the use of a condom with every client in the last month ","Key informant survey"]
["Care and support: Support for orphans and vulnerable children",null,null,"% of men who have had sex with a female sex worker in the last year ","Specific surveys (to be defined)"]
["TB/HIV collaborative activities: HIV care and support for HIV-positive TB patients ","TB/HIV collaborative activities: Intensified case-finding among PLWHA",null,"% of men reporting the use of condom the last time they had anal sex with a male partner in the last 6 months ","Civil registration systems (vital/disease specific registration) "]
["Supportive environment: Policy development including workplace policy","TB/HIV collaborative activities: Prevention of TB disease in PLWHA",null,null,"Census"]
["Supportive environment: Strengthening of civil society and institutional capacity building ","TB/HIV collaborative activities: Prevention of HIV in TB patients",null,null,"Health service statistics"]
["Supportive environment: Stigma reduction in all settings","TB/HIV collaborative activities: Prevention of opportunistic infections in PLWHA with TB",null,null,"Patient register"]
["Supportive environment: Program management and administration",null,null,null,"Clinical cohort follow-up studies "]
["HSS: Service delivery","TB/HIV collaborative activities: Provision of antiretroviral treatment for TB patients during TB treatment",null,null,"Community services assessment"]
["HSS: Human resources","HSS: PAL (Practical Approach to Lung Health)",null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
["HSS: Community Systems Strengthening",null,null,null,"Operational research"]
["HSS: Information system & Operational research"]
["HSS: Infrastructure"]
["HSS: Procurement and Supply management"]
["HSS: Other, specify"]

{"sheet":"Memo TB","index":29,"n_rows":27,"n_cols":5,"rows_kept":27,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["please select…","please select…","please select…","please select…","please select…"]
["Improving diagnosis","TB prevalence rate","impact","Case detection","National Health Accounts"]
["Standardized treatment, patient support and patient charter","TB incidence rate","outcome","Treatment success rate","DHS/DHS+ (Demographic and Health Survey)"]
["Procurement and supply management","TB mortality rate",null,"Smear conversion rate","MICS (Multiple Indicator Cluster Survey)"]
["M&E",null,null,null,"AIS (AIDS Indicator Survey)"]
["TB/HIV",null,null,null,"SAMS (Service Availibility Mapping Survey)"]
["MDR-TB",null,null,null,"BSS (Behavioral and Surveillance Survey)"]
["High-risk groups ",null,null,null,"Sentinel surveillance"]
["HSS (beyond TB)",null,null,null,"Serological surveys"]
["PAL (Practical Approach to Lung Health)",null,null,null,"Prevalence surveys"]
["PPM / ISTC (Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)",null,null,null,"Facility-based survey "]
["ACSM (Advocacy, communication and social mobilization) ",null,null,null,"Key informant survey"]
["Community TB care",null,null,null,"Specific surveys (to be defined)"]
["Programme-based operational research"]
["Other:Specify"]
["Supportive environment: Program management and administration",null,null,null,"Civil registration systems (vital/disease specific registration) "]
[null,null,null,null,"Census"]
[null,null,null,null,"Health service statistics"]
[null,null,null,null,"Patient register"]
[null,null,null,null,"Clinical cohort follow-up studies "]
[null,null,null,null,"Community services assessment"]
[null,null,null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
[null,null,null,null,"Operational research"]
[null,null,null,null,"R&R TB system, quarterly report"]
[null,null,null,null,"R&R TB system, yearly management report "]
[null,null,null,null,"Other Surveillance reports, specify"]

{"sheet":"Memo Malaria","index":30,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["please select…","please select…","please select…","please select…","please select…"]
["Prevention:  Behavioral Change Communication - Mass media","Death rates associated with Malaria: all-cause under-5 mortality rate in highly endemic areas ","impact","% of U5 children (and other target groups) with malaria/fever receiving appropriate treatment within 24 hours (community/health facility)","National Health Accounts"]
["Prevention:  Behavioral Change Communication - community outreach","Incidence of clinical malaria cases (estimated and/or reported) ","outcome","% of U5 children (and other target group) with uncomplicated malaria correctly managed at health facilities","DHS/DHS+ (Demographic and Health Survey)"]
["Prevention: Insecticide-treated nets (ITNs)","Anaemia prevalence in children under 5 years of age",null,"% of U5 children (and other target groups) admitted with severe malaria and correctly managed at health facilities","MICS (Multiple Indicator Cluster Survey)"]
["Prevention: Malaria prevention during pregnancy","Prevalence of malaria parasite infection ",null,"% of children U5 sleeping under an ITN the previous night","MIS (Malaria Indicator Survey)"]
["Prevention: Vector control (other than ITNs)","Laboratory-confirmed malaria cases seen in heath facilities",null,"% of households with at least one ITN","SAMS (Service Availibility Mapping Survey)"]
["Prevention: other - specify","Laboratory-confirmed malaria deaths seen in health facilities",null,"% of pregnant women (and other target groups) sleeping under an ITN the previous night","BSS (Behavioral and Surveillance Survey)"]
["Treatment: Prompt, effective anti-malarial treatment","Malaria-attributed deaths in sentinel demographic surveillance sites",null,"% of pregnant women on Intermittent preventive treatment (IPT) according to national policy (specific to Sub-Saharian Africa)","Sentinel surveillance"]
["Treatment: Home based management of malaria","API (Annual Parasite Index) (specific to Latin America and Asia)",null,"% of households in malaria areas protected by IRS","MOH (routine HIS or HMIS)"]
["Treatment: Diagnosis",null,null,null,"RBM (Roll Back Malaria)"]
["Treatment: other - specify",null,null,null,"Serological surveys"]
["Supportive environment: Monitoring drug resistance",null,null,null,"Prevalence surveys"]
["Supportive environment: Monitoring insecticide resistance",null,null,null,"Facility-based survey "]
["Supportive environment: Coordination and partnership development (national, community, public-private)",null,null,null,"Key informant survey"]
["Supportive environment: other - specify",null,null,null,"Specific surveys (to be defined)"]
["Supportive environment: Program management and administration",null,null,null,"Civil registration systems (vital/disease specific registration) "]
["HSS: Service delivery",null,null,null,"Census"]
["HSS: Human resources",null,null,null,"Health service statistics"]
["HSS: Community Systems Strengthening",null,null,null,"Patient register"]
["HSS: Information system & Operational research",null,null,null,"Clinical cohort follow-up studies "]
["HSS: Infrastructure",null,null,null,"Community services assessment"]
["HSS: Procurement and Supply management",null,null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
["HSS: other - specify",null,null,null,"Operational research"]
[null,null,null,null,"Questionnaire"]